annual reportmarch dear shareholder year achievement evolution johnson johnson deliver solid financial performance enhance value shareholder progress significant undertaking prepare johnson johnson operate fast focus sector company initiate separation consumer health business kenvue year industry feel effect high inflation geopolitical tension continue supply chain disruption joaquin duato chairman ceo times like remind privileged lead johnson johnson eighth chairman ceo history company navigate total shareholder return tsr economic cycle address outperform competitor composite healthcare important unmet need contribute tsr nearly year time learn compound annual growth rate decision longterm year significant value creation possible longterm strategic focus deep commitment credo value outstanding execution team determination use size good segment business long global leader health focus patient customer need reinforce sense medtech purpose urgency thank perform line ahead competitive employee embody idealsand composite past year growth drive breadth diversification business focus commercial strategy successful successful year launch differentiate product improvement global procedure recovery performance priority deliver innovation agenda achieve fullyear operational sale accelerate cadence new product growth adjust net earning significantly enhance medtech pipeline billion adjust diluted net earning include program share represent increase million net present value potential respectively compare medtech deliver operational sale growth operational basis adjust diluted net earning business orthopaedic surgery share increase interventional solution vision invest nearly billion deploy acquisition abiome position global billion acquisition increase leader heart recovery immediately enhance dividend consecutive year medtech revenue growth diversifie return capital shareholder share portfolio include priority platform repurchase program billion annual revenue chairman letter pharmaceutical strengthen position lead deliver world pharmaceutical company deliver consecutive year abovemarket adjust operational sale growth exclude covid vaccine rank million access commit program growth drive oncology medicine index focus close immunology medicine include darzalex reflect decade racial health gap erleada stelara tremfya long strategy race continue investigate new indication maximize access health equity initiative transformative regimen reach innovative medicine investment technology community health patient include darzalex frontline multiple center health myeloma erleada earlystage prostate cancer literacy education tremfya crohns disease ulcerative colitis increase racial rybrevant combination lazertinib frontline billion diversity nonsmallcell lung cancer egfr mutation global impact spend healthcare talent investment pipeline strengthen small pipeline workforce portfolio multiple myeloma medicine addition diverse supplier launch carvykti cell therapy tecvayli firstinclass bispecific antibody african submit bla talquetamab investigational consecutive country offtheshelf bispecific antibody year million recognition commitment consumer health cdp alist rating johnson johnson significant stride separation leadership foundation africa business independent company climate action frontline catalytic deliver solid performance year fund provide support community roll kenvue brand reflective health worker week johnson johnsons story history kenvue bright future standalone organization pay parental leave qualified johnson billion appoint leadership include thibaut mongon johnson employees ceo designate paul ruh cfo designate larry world dose vermox merlo chairman ceo cvs non donate executive chair designate kenvue facilitate treatment intestinal worm start begin operate consumer business company company early renewable year kenvue file form sec give electricity option pursue ipo potential step separation remain track complete secure process operation brazil direct know great impact patient power purchase continue prioritize promise agreement opportunity ongoing emphasis building start digital capability include datum science intelligent automation fuel wave innovation intersection science technology chairman letterdelivere investor straight year billion rank increase dividend invest merger onfortune admire acquisition company list pharmaceutical industry number company brand platform world aaa credit rating include billion year free cash flow johnson johnson sale return shareholder cash flow operating activity addition property plant equipment billion invest opportunity responsibility lead world evolve johnson johnson evolve ahead know meet customer partner government official time put patient employee world year center keep look forward ceo constantly remind world open opportunity expect partner choice people depend deliver want succeed achieve success century johnson johnson hold high regard stay true mission serve patient hold high standardsas family doctor nurse employee affirm purpose motivate day communitie depend world standard set small time waste predecessor alex gorsky deeply honor serve chairman ceo follow retirement alex lay strong foundation future anchor sincerely people johnson johnson great strength commitment credo fill confidence inspiration day joaquin duato chairman ceo important year historya new chapter lead global company johnson johnson uniquely position lead industry fastmove healthcare landscape nongaap measure operational sale growth exclude effect translational currency adjust net earning adjust net earning share exclude special item intangible asset amortization expense adjust operational net earning share exclude special item intangible asset amortization expense effect translational currency nongaap reconciliation annual report chairman letter united states securities exchange commission washington annual report pursuant section security exchange act forthefiscalyearendedjanuary transition report pursuant section security exchange act transition period commissionfilenumber johnson johnson exactnameofregistrantasspecifiedinitscharter newjersey stateofincorporation irsemployeridentificationno onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffice zipcode onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffices registrantstelephonenumberincludingareacode securitiesregisteredpursuanttosectionboftheact titleofeachclass tradingsymbol nameofeachexchangeonwhichregistered commonstockparvalue jnj newyorkstockexchange notesduemay jnjc newyorkstockexchange notesduenovember jnjbp newyorkstockexchange notesduenovember jnj newyorkstockexchange notesduemay jnj newyorkstockexchange indicatebycheckmarkiftheregistrantisawellknownseasonedissuerasdefinedinruleofthesecurities act yes indicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttosectionorsectiondoftheexchange act yes indicatebycheckmarkwhethertheregistranthasfiledallreportsrequiredtobefiledbysectionordofthe exchangeactduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwasrequiredtofilesuch reportsandhasbeensubjecttosuchfilingrequirementsforthepastday yes indicatebycheckmarkwhethertheregistranthassubmittedelectronicallyeveryinteractivedatafilerequiredtobesubmitte pursuanttoruleofregulationstduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwas requiredtosubmitsuchfile yes indicatebycheckmarkwhethertheregistrantisalargeacceleratedfileranacceleratedfileranonacceleratedfilerasmaller reportingcompanyoremerginggrowthcompanyseethedefinitionsoflargeacceleratedfileracceleratedfilersmaller reportingcompanyandemerginggrowthcompanyinruleboftheexchangeact largeacceleratedfiler acceleratedfiler nonacceleratedfiler smallerreportingcompany emerginggrowthcompany ifanemerginggrowthcompanyindicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiod forcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttosectionaoftheexchange act indicatebycheckmarkwhethertheregistranthasfiledareportonandattestationtoitsmanagementsassessmentofthe effectivenessofitsinternalcontroloverfinancialreportingundersectionbofthesarbanesoxleyactusc bbytheregisteredpublicaccountingfirmthatpreparedorissueditsauditreport yes ifsecuritiesareregisteredpursuanttosectionboftheactindicatebycheckmarkwhetherthefinancialstatementsof theregistrantincludedinthefilingreflectthecorrectionofanerrortopreviouslyissuedfinancialstatement indicatebycheckmarkwhetheranyofthoseerrorcorrectionsarerestatementsthatrequiredarecoveryanalysisofincentive basedcompensationreceivedbyanyoftheregistrantsexecutiveofficersduringtherelevantrecoveryperiodpursuantto indicatebycheckmarkwhethertheregistrantisashellcompanyasdefinedinruleboftheexchange act yes theaggregatemarketvalueofthecommonstockheldbynonaffiliatescomputedbyreferencetothepriceatwhichthe commonstockwaslastsoldasofthelastbusinessdayoftheregistrantsmostrecentlycompletedsecondfiscalquarter wasapproximatelybillion onfebruarythereweresharesofcommonstockoutstanding documentsincorporatedbyreference partsiandiii portionsofregistrantsproxystatementforitsannualmeetingofshareholdersfiledwithin daysafterthecloseoftheregistrantsfiscalyeartheproxystatementareincorporatedby referencetothisreportonformkthisreportitem parti business general segmentsofbusiness geographicareas rawmaterial patent trademark seasonality competition environment regulation employeesandhumancapitalmanagement availableinformation riskfactor unresolvedstaffcomment property legalproceeding minesafetydisclosure executiveofficersoftheregistrant partii marketforregistrantscommonequityrelatedstockholdermattersandissuerpurchasesof equitysecuritie reserve managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition quantitativeandqualitativedisclosuresaboutmarketrisk financialstatementsandsupplementarydata changesinanddisagreementswithaccountantsonaccountingandfinancialdisclosure controlsandprocedures otherinformation disclosuresregardingforeignjurisdictionsthatpreventinspection partiii directorsexecutiveofficersandcorporategovernance executivecompensation securityownershipofcertainbeneficialownersandmanagementandrelatedstockholder matter certainrelationshipsandrelatedtransactionsanddirectorindependence principalaccountantfeesandservice partiv exhibitsandfinancialstatementschedule formksummary signature exhibitindex cautionary note forwardlooke statement thisannualreportonformkandjohnsonjohnsonsotherpubliclyavailabledocumentscontainforwardlooke statementswithinthemeaningofthesafeharborprovisionsoftheunitedstatesprivatesecuritieslitigationreformact ofmanagementandrepresentativesofjohnsonjohnsonanditssubsidiariesthecompanyalsomayfromtimeto timemakeforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsand reflectmanagementsassumptionsviewsplansobjectivesandprojectionsaboutthefutureforwardlookingstatement maybeidentifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandotherwordsof similarmeaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsexpectedoperatingresultsand financialperformanceimpactofplannedacquisitionsanddispositionsimpactandtimingofrestructuringinitiatives includingassociatedcostsavingsandotherbenefitstheplannedseparationofthecompanysconsumerhealth businessthecompanysstrategyforgrowthproductdevelopmentactivitiesregulatoryapprovalsmarketpositionand expenditure becauseforwardlookingstatementsarebasedoncurrentbeliefsexpectationsandassumptionsregardingfutureevent theyaresubjecttouncertaintiesrisksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorknownorunknownrisksor uncertaintiesmaterializethecompanysactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand projectionsexpressedorimpliedinitsforwardlookingstatementsinvestorsarethereforecautionednottorelyonthese forwardlookingstatementsrisksanduncertaintiesincludebutarenotlimitedto risksrelatedtoproductdevelopmentmarketsuccessandcompetition challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologie onwhichthecompanyscontinuedgrowthandsuccessdependincludinguncertaintyofclinicaloutcomesadditional analysisofexistingclinicaldataobtainingregulatoryapprovalshealthplancoverageandcustomeraccessandinitial andcontinuedcommercialsuccess challengestothecompanysabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew andexistingproductsandtechnologiesintheunitedstatesandotherimportantmarket theimpactofpatentexpirationstypicallyfollowedbytheintroductionofcompetinggenericbiosimilarorotherproduct andresultingrevenueandmarketsharelosse increasinglyaggressiveandfrequentchallengestothecompanyspatentsbycompetitorsandothersseekingtolaunch competinggenericbiosimilarorotherproductsandincreasedreceptivityofcourtstheunitedstatespatentand trademarkofficeandotherdecisionmakerstosuchchallengespotentiallyresultinginlossofmarketexclusivityand rapiddeclineinsalesfortherelevantproductsoonerthanexpecte competitioninresearchanddevelopmentofnewandimprovedproductsprocessesandtechnologieswhichcanresult inproductandprocessobsolescence competitiontoreachagreementwiththirdpartiesforcollaborationlicensingdevelopmentandmarketingagreement forproductsandtechnologie competitionbasedoncosteffectivenessproductperformancetechnologicaladvancesandpatentsattainedby competitorsand allegationsthatthecompanysproductsinfringethepatentsandotherintellectualpropertyrightsofthirdpartieswhich couldadverselyaffectthecompanysabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamage andfutureroyaltie risksrelatedtoproductliabilitylitigationandregulatoryactivity productefficacyorsafetyconcernswhetherornotbasedonscientificevidencepotentiallyresultinginproduct withdrawalsrecallsregulatoryactiononthepartoftheunitedstatesfoodanddrugadministrationorinternational counterpartsdecliningsalesreputationaldamageincreasedlitigationexpenseandsharepriceimpact theimpactincludingdecliningsalesandreputationaldamageofsignificantlitigationorgovernmentactionadverseto thecompanyincludingproductliabilityclaimsandallegationsrelatedtopharmaceuticalmarketingpracticesand contractingstrategie theimpactofanadversejudgmentorsettlementandtheadequacyofreservesrelatedtolegalproceedingsinclude patentlitigationproductliabilitypersonalinjuryclaimssecuritiesclassactionsgovernmentinvestigationsemployment andotherlegalproceeding johnsonjohnsonannualreport increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin investigationsandprosecutionswhichcarrytheriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimite todebarmentfromgovernmentbusiness failuretomeetcomplianceobligationsincomplianceagreementswithgovernmentsorgovernmentagencieswhich couldresultinsignificantsanction potentialchangestoapplicablelawsandregulationsaffectingunitedstatesandinternationaloperationsinclude relatingtoapprovalofnewproductslicensingandpatentrightssalesandpromotionofhealthcareproductsaccess toandreimbursementandpricingforhealthcareproductsandservicesenvironmentalprotectionandsourcingofraw material compliancewithlocalregulationsandlawsthatmayrestrictthecompanysabilitytomanufactureorsellitsproductsin relevantmarketsincludingrequirementstocomplywithmedicaldevicereportingregulationsandotherrequirement suchastheeuropeanunionsmedicaldevicesregulation changesindomesticandinternationaltaxlawsandregulationsincreasingauditscrutinybytaxauthoritiesaroundthe worldandexposurestoadditionaltaxliabilitiespotentiallyinexcessofexistingreservesand theissuanceofneworrevisedaccountingstandardsbythefinancialaccountingstandardsboardandregulationsby thesecuritiesandexchangecommission risksrelatedtothecompanysstrategicinitiativeshealthcaremarkettrendsandtheplanne separationofthecompanysconsumerhealthbusiness pricingpressuresresultingfromtrendstowardhealthcarecostcontainmentincludingthecontinuedconsolidation amonghealthcareprovidersandothermarketparticipantstrendstowardmanagedcaretheshifttowardgovernment increasinglybecomingtheprimarypayersofhealthcareexpensessignificantnewentrantstothehealthcaremarket seekingtoreducecostsandgovernmentpressureoncompaniestovoluntarilyreducecostsandpriceincrease restrictedspendingpatternsofindividualinstitutionalandgovernmentalpurchasersofhealthcareproductsand servicesduetoeconomichardshipandbudgetaryconstraint challengestothecompanysabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovation suchasdevelopmentcollaborationsstrategicacquisitionslicensingandmarketingagreementsandthepotential heightenedcostsofanysuchexternalarrangementsduetocompetitivepressure thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor divestiturebythecompanymaynotberealizedormaytakelongertorealizethanexpecte thepotentialthattheexpectedbenefitsandopportunitiesrelatedtopastandongoingrestructuringactionsmaynotbe realizedormaytakelongertorealizethanexpecte thecompanysabilitytoconsummatetheplannedseparationofthecompanysconsumerhealthbusinessonatimely basisoratall thecompanysabilitytosuccessfullyseparatethecompanysconsumerhealthbusinessandrealizetheanticipate benefitsfromtheplannedseparationand thenewconsumerhealthcompanysabilitytosucceedasastandalonepubliclytradedcompany risksrelatedtoeconomicconditionsfinancialmarketsandoperatinginternationally therisksassociatedwithglobaloperationsonthecompanyanditscustomersandsuppliersincludingforeign governmentsincountriesinwhichthecompanyoperate theimpactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch fluctuationsonrevenuesexpensesandresultingmargin potentialchangesinexportimportandtradelawsregulationsandpoliciesoftheunitedstatesandothercountrie includinganyincreasedtraderestrictionsortariffsandpotentialdrugreimportationlegislation theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomiessovereignriskpossible impositionofgovernmentalcontrolsandrestrictiveeconomicpoliciesandunstableinternationalgovernmentsandlegal system theimpactofglobalpublichealthcrisesandpandemicsincludingthenovelcoronaviruscovidpandemic changestoglobalclimateextremeweatherandnaturaldisastersthatcouldaffectdemandforthecompanysproduct andservicescausedisruptionsinmanufacturinganddistributionnetworksaltertheavailabilityofgoodsandservice withinthesupplychainandaffecttheoveralldesignandintegrityofthecompanysproductsandoperationsand theimpactofarmedconflictsandterroristattacksintheunitedstatesandotherpartsoftheworldincludingsocialand economicdisruptionsandinstabilityoffinancialandothermarket johnsonjohnsonannualreportrisksrelatedtosupplychainandoperation difficultiesanddelaysinmanufacturinginternallythroughthirdpartyprovidersorotherwisewithinthesupplychainthat mayleadtovoluntaryorinvoluntarybusinessinterruptionsorshutdownsproductshortageswithdrawalsor suspensionsofproductsfromthemarketandpotentialregulatoryaction interruptionsandbreachesofthecompanysinformationtechnologysystemsorthoseofthecompanysvendor whichcouldresultinreputationalcompetitiveoperationalorotherbusinessharmaswellasfinancialcostsand regulatoryaction relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing regulatoryrequirementsthatmayadverselyaffectsupplysourcingandpricingofmaterialsusedinthecompanys productsand thepotentialthattheexpectedbenefitsandopportunitiesrelatedtorestructuringactionscontemplatedfortheglobal supplychainmaynotberealizedormaytakelongertorealizethanexpectedincludingduetoanyrequiredapproval fromapplicableregulatoryauthoritie investorsalsoshouldcarefullyreadtheriskfactorsdescribedinitemaofthisannualreportonformkfora descriptionofcertainrisksthatcouldamongotherthingscausethecompanysactualresultstodiffermateriallyfrom thoseexpressedinitsforwardlookingstatementsinvestorsshouldunderstandthatitisnotpossibletopredictoridentify allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinitematobeacompletestatementofall potentialrisksanduncertaintiesthecompanydoesnotundertaketopubliclyupdateanyforwardlookingstatementthat maybemadefromtimetotimewhetherasaresultofnewinformationorfutureeventsordevelopment johnsonjohnsonannualreport thispageintentionallyleftblankpart item business general johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldjohnsonjohnson isaholdingcompanywithoperatingcompaniesconductingbusinessinvirtuallyallcountriesoftheworldthecompanys primaryfocusisproductsrelatedtohumanhealthandwellbeingjohnsonjohnsonwasincorporatedinthestateof newjerseyin theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe companysthreebusinesssegmentsconsumerhealthpharmaceuticalandmedtechpreviouslyreferredtoasmedical deviceswithinthestrategicparametersprovidedbythecommitteeseniormanagementgroupsatusandinternational operatingcompaniesareeachresponsiblefortheirownstrategicplansandthedaytodayoperationsofthose companieseachsubsidiarywithinthebusinesssegmentsiswithlimitedexceptionsmanagedbyresidentsofthecountry wherelocate segment business thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpharmaceuticalandmedtechadditional informationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsofsegments andoperatingresultsunderitemmanagementsdiscussionandanalysisofresultsofoperationsandfinancial conditionofthisreportandnotesegmentsofbusinessandgeographicareasofthenotestoconsolidate financialstatementsincludedinitemofthisreport consumerhealth theconsumerhealthsegmentincludesabroadrangeofproductsfocusedonpersonalhealthcareusedintheskin healthbeautyoverthecountermedicinesbabycareoralcarewomenshealthandwoundcaremarketsmajor brandsinskinhealthbeautyincludetheaveenocleancleardrcilaboneutrogenaandogxproduct linesoverthecounterotcmedicinesincludethebroadfamilyoftylenolacetaminophenproductssudafe coldfluandallergyproductsbenadrylandzyrtecallergyproductsmotrinibibuprofenproductsnicorette smokingcessationproductsoutsidetheuszarbeesproductsinspiredbynatureandthepepcidlineofacidreflux productsbabycareincludesthejohnsonsandaveenobabylineofproductsoralcareincludesthelisterine productlinemajorbrandsinwomenshealthoutsideofnorthamericaarestayfreeandcarefreesanitarypad andobtamponbrandswoundcarebrandsincludethebandaidbrandadhesivebandagesandneosporinfirst aidproductlinestheseproductsaremarketedtothegeneralpublicandsoldonlineecommerceandtoretailoutlet anddistributorsthroughouttheworld innovemberthecompanyannounceditsintentiontoseparatethecompanysconsumerhealthbusinesskenvue asthenamefortheplannednewconsumerhealthcompanywiththeintentiontocreateanewpubliclytraded companybytheendofthefiscalyear pharmaceutical thepharmaceuticalsegmentisfocusedonthefollowingtherapeuticareasimmunologyegrheumatoidarthritis psoriaticarthritisinflammatoryboweldiseaseandpsoriasisinfectiousdiseaseseghivaidsneuroscienceeg mooddisordersneurodegenerativedisordersandschizophreniaoncologyegprostatecancerhematologic malignancieslungcancerandbladdercancercardiovascularandmetabolismegthrombosisdiabetesandmacular degenerationandpulmonaryhypertensionegpulmonaryarterialhypertensionmedicinesinthissegmentare distributeddirectlytoretailerswholesalersdistributorshospitalsandhealthcareprofessionalsforprescriptionusekey productsinthepharmaceuticalsegmentincluderemicadeinfliximabatreatmentforanumberofimmunemediate inflammatorydiseasessimponigolimumabasubcutaneoustreatmentforadultswithmoderatetosevererheumatoid johnsonjohnsonannualreport arthritisactivepsoriaticarthritisactiveankylosingspondylitisandmoderatelyactivetoseverelyactiveulcerativecolitis simponiariagolimumabanintravenoustreatmentforadultswithmoderatetosevererheumatoidarthritisactive psoriaticarthritisandactiveankylosingspondylitisandactivepolyarticularjuvenileidiopathicarthritispjiainpeople yearsofageandolderstelaraustekinumabatreatmentforadultsandchildrenwithmoderatetosevereplaque psoriasisforadultswithactivepsoriaticarthritisforadultswithmoderatelytoseverelyactivecrohnsdiseaseand treatmentofmoderatelytoseverelyactiveulcerativecolitistremfyaguselkumabatreatmentforadultswithmoderate tosevereplaquepsoriasisandactivepsoriaticarthritisedurantrilpivirineprezistadarunavirandprezcobix rezolstadarunavircobicistatantiretroviralmedicinesforthetreatmentofhumanimmunodeficiencyvirushivin combinationwithotherantiretroviralproductsandsymtuzadarunavircobicistatemtricitabinetenofoviralafenamidea oncedailysingletabletregimenforthetreatmentofhivconcertamethylphenidatehclextendedreleasetablet ciiatreatmentforattentiondeficithyperactivitydisorderinvegasustennaxeplionpaliperidonepalmitateforthe treatmentofschizophreniaandschizoaffectivedisorderinadultsinvegatrinzatrevictapaliperidonepalmitatefor thetreatmentofschizophreniainpatientsaftertheyhavebeenadequatelytreatedwithinvegasustennaforatleast fourmonthsrisperdalconstarisperidonelongactinginjectionforthetreatmentofschizophreniaandthe maintenancetreatmentofbipolardisorderinadultszytigaabirateroneacetateatreatmentforpatientswithprostate cancererleadaapalutamideanextgenerationandrogenreceptorinhibitorforthetreatmentofpatientswithprostate cancerimbruvicaibrutinibatreatmentforcertainbcellmalignanciesorbloodcancersandchronicgraftversushost diseasedarzalexdaratumumabatreatmentformultiplemyelomadarzalexfasprodaratumumaband hyaluronidasefihjatreatmentformultiplemyelomaandlightchainalamyloidosisxareltorivaroxabananoral anticoagulantforthepreventionofdeepveinthrombosisdvtwhichmayleadtopulmonaryembolismpeinpatient undergoinghiporkneereplacementsurgerytoreducetheriskofstrokeandsystemicembolisminpatientswith nonvalvularatrialfibrillationandforthetreatmentandreductionofriskofrecurrenceofdvtandpetoreducetheriskof majorcardiovasculareventsinpatientswithcoronaryarterydiseasecadandperipheralarterydiseasepadforthe treatmentandsecondarypreventionofthromboembolisminpediatricpatientsandforthromboprophylaxisinpediatric patientsfollowingthefontanprocedureinvokanacanagliflozinforthetreatmentofadultswithtypediabetes invokametvokanametcanagliflozinmetforminhclacombinationtherapyoffixeddosesofcanagliflozinand metforminhydrochlorideforthetreatmentofadultswithtypediabetesandinvokametxrcanagliflozinmetformin hydrochlorideextendedreleaseaoncedailyfixeddosecombinationtherapyofcanagliflozinandmetformin hydrochlorideextendedreleaseforthetreatmentofadultswithtypediabetesopsumitmacitentanasmonotherapy orincombinationindicatedforthelongtermtreatmentofpulmonaryarterialhypertensionpahuptraviselexipag theonlyapprovedoralandintravenousselectiveipreceptoragonisttargetingaprostacyclinpathwayinpahmanyof thesemedicinesweredevelopedincollaborationwithstrategicpartnersorarelicensedfromothercompaniesand maintainactivelifecycledevelopmentprograms medtech themedtechpreviouslyreferredtoasmedicaldevicessegmentincludesabroadportfolioofproductsusedinthe interventionalsolutionsorthopaedicssurgeryandvisioncategoriesinterventionalsolutionsincludeelectrophysiology productsbiosensewebstertotreatcardiovasculardiseasesneurovascularcarecerenovusthattreatshemorrhagicand ischemicstrokeandtheheartrecoveryportfolioabiomedwhichincludestechnologiestotreatseverecoronaryartery diseaserequiringhighriskpcioramicardiogenicshocktheorthopaedicsportfoliodepuysynthescomprisesproduct insupportofhipskneestraumaandspinesportsotherthesurgeryportfoliosincludeadvancedandgeneralsurgery offeringsethiconsolutionsthatfocusonbreastaestheticsmentorandearnoseandthroatacclarentprocedure johnsonjohnsonvisionproductsincludeacuvuebrandcontactlensesandophthalmictechnologiesrelatedtocataract andlaserrefractivesurgerytheseproductsaredistributedtowholesalershospitalsandretailersandusedpredominantly intheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinic geographic area johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbee theproductsmadeandsoldintheinternationalbusinessincludemanyofthosedescribedaboveundersegmentsof businessconsumerhealthpharmaceuticalandmedtechhowevertheprincipalmarketsproductsand methodsofdistributionintheinternationalbusinessvarywiththecountryandtheculturetheproductssoldin internationalbusinessincludethosedevelopedintheusandbysubsidiariesabroad johnsonjohnsonannualreportinvestmentsandactivitiesinsomecountriesoutsidetheusaresubjecttohigherrisksthancomparableusactivitie becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomie restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertaintie raw material rawmaterialsessentialtothecompanysbusinessaregenerallyreadilyavailablefrommultiplesourceswherethereare exceptionsthetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe financialresultsofthecompany patent thecompanyssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere possibletheyownorarelicensedunderasignificantnumberofpatentsintheusandothercountriesrelatingtotheir productsproductusesformulationsandmanufacturingprocesseswhichintheaggregatearebelievedtobeofmaterial importancetothecompanyintheoperationofitsbusinessesthecompanyssubsidiariesfacepatentchallengesfrom thirdpartiesincludingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsofthecompanys keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductssignificantlegal proceedingsandclaimsinvolvingthecompanyspatentandotherintellectualpropertyaredescribedinnotelegal proceedingsintellectualpropertyofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport salesofthecompanyslargestproductstelaraustekinumabaccountedforapproximatelyofthecompany totalrevenuesforfiscalaccordinglythepatentsrelatedtothisproductarebelievedtobematerialtothecompany janssenbiotechincawhollyownedsubsidiaryofjohnsonjohnsonownspatentsspecificallyrelatedtostelara thelatestexpiringunitedstatescompositionofmatterpatentexpiresinthelatestexpiringeuropeancomposition ofmatterpatentexpiresin salesofthecompanyssecondlargestproductcollectivelydarzalexdaratumumabanddarzalexfaspro daratumumabandhyaluronidasefihjaccountedforapproximatelyofthecompanystotalrevenuesforfiscal accordinglythepatentsrelatedtothisproductarebelievedtobematerialtothecompanygenmabasownstwo patentfamiliesrelatedtodarzalexandjanssenbiotechinchasanexclusivelicensetothosepatentfamiliesthetwo patentfamiliesbothexpireintheunitedstatesinthelatestexpiringlicensedeuropeanpatentexpiresin janssenbiotechincownsaseparatepatentportfoliorelatedtodarzalexfaspro trademark thecompanyssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection forthesetrademarksbyallavailablemeansthesetrademarksareprotectedbyregistrationintheusandothercountrie wheresuchproductsaremarketedthecompanyconsidersthesetrademarksintheaggregatetobeofmaterial importanceintheoperationofitsbusinesse seasonality worldwidesalesdonotreflectanysignificantdegreeofseasonalityhoweverspendinghastypicallybeenheavierinthe fourthquarterofeachyearthaninotherquartersthisreflectsincreasedspendingdecisionsprincipallyforadvertise andresearchanddevelopmentactivity competition inalloftheirproductlinesthecompanyssubsidiariescompetewithcompaniesbothlocallyandgloballycompetition existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolvedcompetitionin researchbothinternallyandexternallysourcedinvolvingthedevelopmentandtheimprovementofnewandexiste productsandprocessesisparticularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotecting theunderlyingintellectualpropertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallarea ofitsbusinessthecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthe developmentandmaintenanceofcustomerdemandforthecompanysconsumerproductsinvolvesignificant expendituresforadvertisingandpromotion johnsonjohnsonannualreport environment thecompanyissubjecttoavarietyofusandinternationalenvironmentalprotectionmeasuresthecompanybelieve thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulationsthecompanys compliancewiththeserequirementsisnotexpectedtohaveamaterialeffectuponitscapitalexpenditurescashflow earningsorcompetitiveposition regulation thecompanysbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperation areconductedandthegeneraltrendistowardincreasinglystringentregulationandenforcementthecompanyissubject tocostlyandcomplexusandforeignlawsandgovernmentalregulationsandanyadverseregulatoryactionmay materiallyadverselyaffectthecompanysfinancialconditionandbusinessoperationsintheusthedrugdeviceand cosmeticindustrieshavelongbeensubjecttoregulationbyvariousfederalandstateagenciesprimarilyastoproduct safetyefficacymanufacturingadvertisinglabelingandsafetyreportingtheexerciseofbroadregulatorypowersbythe usfoodanddrugadministrationtheusfdacontinuestoresultinincreasesintheamountsoftestingand documentationrequiredforusfdaapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseof productintroductionsimilartrendsarealsoevidentinmajormarketsoutsideoftheusthenewmedicaldevice regulatoryframeworkandtheevolvingprivacydatalocalizationandemergingcybersecuritylawsandregulationsaround theworldareexamplesofsuchincreasedregulationfiveusstatescaliforniaconnecticutcoloradoutahand virginianowhavecomprehensiveprivacylawsinplaceandchinaintroducedbroadpersonalinformationprotectionand datasecurityregulationsinwithotherjurisdictionsenactingsimilarprivacylawslocaldataprotectionauthoritie willforcegreateraccountabilityonthecollectionaccessanduseofpersonaldatainthehealthcareindustry theregulatoryagenciesunderwhosepurviewthecompanyoperateshaveadministrativepowersthatmaysubjectittoaction suchasproductwithdrawalsrecallsseizureofproductsandothercivilandcriminalsanctionsinsomecasesthecompany subsidiariesmaydeemitadvisabletoinitiateproductrecallsregardlessofwhetherithasbeenrequiredordirectedto theusfdaandregulatoryagenciesaroundtheglobearealsoincreasingtheirenforcementactivitiesiftheusfda weretoconcludethatwearenotincompliancewithapplicablelawsorregulationsorthatanyofourdrugsormedical devicesareineffectiveorposeanunreasonablehealthrisktheusfdacouldbansuchproductsdetainorseize adulteratedormisbrandedproductsorderarecallrepairreplacementorrefundofsuchproductsrefusetogrant pendingapplicationsformarketingauthorizationorrequirecertificatesofforeigngovernmentsforexportsandorrequire ustonotifyhealthprofessionalsandothersthattheproductspresentunreasonablerisksofsubstantialharmtothepublic healththeusfdamayalsoassesscivilorcriminalpenaltiesagainstusourofficersoremployeesandimpose operatingrestrictionsonacompanywidebasisorenjoinandorrestraincertainconductresultinginviolationsof applicablelawtheusfdamayalsorecommendprosecutiontotheusdepartmentofjusticeanyadverseregulatory actiondependingonitsmagnitudemayrestrictusfromeffectivelymarketingandsellingourproductsandlimitourability toobtainfutureclearancesorapprovalsandcouldresultinasubstantialmodificationtoourbusinesspracticesand operationsequivalentenforcementmechanismsexistindifferentcountriesinwhichweconductbusiness thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudyinvestigationandregulationby governmentalagenciesandlegislativebodiesaroundtheworldintheusattentionhasbeenfocusedbystate regulatoryagenciesandcongressonpricesprofitsoverutilizationandthequalityandcostsofhealthcaregenerallylaw andregulationshavebeenenactedtorequireadherencetostrictcompliancestandardsandpreventfraudandabusein thehealthcareindustrythereisincreasedfocusoninteractionsandfinancialrelationshipsbetweenhealthcarecompanie andhealthcareprovidersvarioustransparencylawsandregulationsrequiredisclosuresofpaymentsandothertransfer ofvaluemadetophysiciansandteachinghospitalsandbeginningwithdisclosuresintocertainnonphysician practitionersfederalandforeignlawsgoverninginternationalbusinesspracticesrequirestrictcompliancewithanti briberystandardsandcertainprohibitionswithrespecttopaymentstoanyforeigngovernmentofficialpayersand pharmacybenefitmanagerspbmshavebecomeamorepotentforceinthemarketplaceandincreasedattentionis beingpaidtodrugpricingandappropriatedrugandmedicaldeviceutilization ourbusinesshasbeenandcontinuestobeaffectedbyfederalandstatelegislationthataltersthepricingcoverageand reimbursementlandscapeatthefederallevelinaugustpresidentbidensignedintolawtheinflationreductionactira whichincludesprovisionsthateffectivelyauthorizethegovernmenttoestablishpricesforcertainhighspendsinglesourcedrug andbiologicsreimbursedbythemedicareprogramstartinginformedicarepartddrugsandformedicarepartb drugsitisnotyetcertainwhichproductsthefederalgovernmentwillselectandsubjecttogovernmentestablishedpricesorhow thefederalgovernmentwillestablishpricesforselectedproductsastheiraspecifiesaceilingpricebutnotaminimumpriceone ormoreofourproductscouldbeselectedandsubjecttothegovernmentestablishedprice johnsonjohnsonannualreporttheiraalsocontainsprovisionsthatimposerebatesifcertainpricesincreaseataratethatoutpacestherateofinflation beginningoctoberformedicarepartddrugsandjanuaryformedicarepartbdrugsseparateira provisionsredesignthemedicarepartdbenefitinvariouswaysincludingbyshiftingagreaterportionofcoststo manufacturerswithincertaincoveragephasesandreplacingthepartdcoveragegapdiscountprogramwithanew manufacturerdiscountingprogramfailuretocomplywithiraprovisionsmaysubjectmanufacturerstovariouspenalties includingcivilmonetarypenaltiestheimpactoftheiraonourbusinessandthebroaderpharmaceuticalindustryremain uncertainasthefederalgovernmenthasyettomakevariousiraimplementationdecision additionallyweexpectcontinuedscrutinyondrugpricingandgovernmentpricereportingfromcongressagenciesand otherbodiesatthefederalandstatelevel thereareanumberofadditionalbillspendingincongressandhealthcarereformproposalsatthestatelevelthatwould affectdrugpricingincludinginthemedicareandmedicaidprogramsthischanginglegallandscapehasbothpositiveand negativeimpactsontheushealthcareindustrywithmuchremaininguncertainastohowvariousprovisionsoffederal andstatelawandpotentialmodificationorrepealoftheselawswillultimatelyaffecttheindustrytheiraandanyother federalorstatelegislativechangecouldaffectthepricingandmarketconditionsforourproduct inadditionbusinesspracticesinthehealthcareindustryhavecomeunderincreasedscrutinyparticularlyintheusby governmentagenciesandstateattorneysgeneralandresultinginvestigationsandprosecutionscarrytheriskofsignificant civilandcriminalpenaltiesofnoteistheincreasedenforcementactivitybydataprotectionauthoritiesinvarious jurisdictionsparticularlyintheeuropeanunionwheresignificantfineshavebeenleviedoncompaniesfordatabreaches violationsofprivacyrequirementsandunlawfulcrossborderdatatransfersintheusthefederaltradecommission hassteppedupenforcementofdataprivacywithseveralsignificantsettlementsandtherehavebeenamaterialincreasein classactionlawsuitslinkedtothecollectionanduseofbiometricdata furtherthecompanyreliesonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexare subjecttoincreasingregulatoryrequirementsandmaybefacedwithunexpectedchangessuchasthoseresultingfrom thecovidpandemicandbrexitthatmayaffectsourcingsupplyandpricingofmaterialsusedinthecompanys productstheseprocessesalsoaresubjecttocomplexandlengthyregulatoryapproval employee human capital management asofjanuaryandjanuarythenumberofemployeeswereapproximately employee fulltimeequivalentfteposition employeeisdefinedasanindividualworkingfulltimeorparttimeexcludingfixedtermemployeesinternsandcoopemployee employeedatamaynotincludefullpopulationfrommorerecentlyacquiredcompaniesandindividualsonlongtermdisabilityareexclude contingentworkerscontractorsandsubcontractorsarealsoexcludedabiomedheadcounthasbeenincludedintheabovetable fterepresentsthetotalnumberoffulltimeequivalentpositionsanddoesnotreflectthetotalnumberofindividualemployeesa someworkparttime employee region percentage asia pacific emea latin america north america johnsonjohnsonannualreport strategy thecompanybelievesthatitsemployeesarecriticaltoitscontinuedsuccessandareanessentialelementofitslong termstrategymanagementisresponsibleforensuringthatitspoliciesandprocessesreflectandreinforcethecompanys desiredcorporatecultureincludingpoliciesandprocessesrelatedtostrategyriskmanagementandethicsand compliancethecompanyshumancapitalmanagementstrategyisbuiltonthreefundamentalfocusarea attractingandrecruitingthebesttalent developingandretainingtalent empoweringandinspiringtalent underpinningthesefocusareasareongoingeffortstocultivateandfosteraculturebuiltondiversityequityandinclusion deiinnovationhealthwellbeingandsafetywherethecompanysemployeesareencouragedtosucceedboth professionallyandpersonallywhilehelpingthecompanyachieveitsbusinessgoal cultureandemployeeengagement atthecompanyemployeesareguidedbyourcredowhichsetsforththecompanysresponsibilitiestopatient consumerscustomershealthcareprofessionalsemployeescommunitiesandshareholdersemployeesworldwidemust adheretothecompanyscodeofbusinessconductwhichsetsbasicrequirementsandservesasafoundationforthe companypoliciesproceduresandguidelinesallofwhichprovideadditionalguidanceonexpectedemployeebehaviorsin everymarketwhereitoperatesthecompanyconductsglobalsurveysthatofferitsemployeestheabilitytoprovide feedbackandvaluableinsighttohelpaddresspotentialhumanresourcesrisksandidentifyopportunitiestoimprovein ofglobalemployeesacrosscountriesparticipatedinourcredosurveywhichwasofferedin language growthanddevelopment tocontinuetoleadinthechanginghealthcarelandscapeitiscrucialthatthecompanycontinuetoattractandretaintop talentthecompanybelievesthatitsemployeesmustbeequippedwiththerightknowledgeandskillsandbeprovided withopportunitiestogrowanddevelopintheircareersaccordinglyprofessionaldevelopmentprogramsandeducational resourcesareavailabletoallemployeesthecompanysobjectiveistofosteralearningculturethathelpsshapeeach personsuniquecareerpathwhilecreatingarobustpipelineoftalenttodeliveronthecompanyslongtermstrategiesin furtheranceofthisobjectivethecompanydeploysaglobalapproachtoensuredevelopmentisforeveryoneregardlessof wheretheyareontheircareerjourneyinofemployeesinmanagerandabovejobcategorieswhohad movementsincludingupwardpromotionsorlateraltransferstookadvantageofcareeropportunitiesbymovingacross functionscountryorbusinesssegmentlinesexcludingemployeesintheresearchanddevelopmentorganizationsthe companysvoluntaryturnoverratewas diversityequityandinclusiondei thecompanyiscommittedtoworkplacediversityandtocultivatingfosteringandadvancingacultureofequityand inclusioninjohnsonjohnsonintroducedthecompanysevolvedenterprisediversityequityandinclusion strategywhichrecognizeshowdeiacceleratesthecompanysabilitytomeetthechangingneedsofthecommunitiesthe companyservestodeliverourpurposetoprofoundlychangethetrajectoryofhealthforhumanitythecompanysdei visionisbeyourselfchangetheworldthecompanysdeimissionismakediversityequityandinclusionhowwework everydayourevolvedenterprisedeistrategyisalignedtoourdeivisionandmissionandrestsonfourcorepillar accelerateourglobalcultureofinclusionwhereeveryindividualbelong buildaworkforcethatreflectsthediversityofourcommunitie transformtalentandbusinessprocessestoachieveequitableaccessandoutcomesforall driveinnovationandgrowthwithourbusinesstoservediversemarketsaroundtheworld thecompanysdeistrategyisguidedbyinternalandexternalinsightsglobalbestpracticesandcontinualemployee feedbackwhichremindthecompanythatwhilediversitychangesbylocationinclusionisthesameeverywhere johnsonjohnsonannualreportcompensationandbenefit aspartofthecompanystotalrewardsphilosophythecompanyofferscompetitivecompensationandbenefitstoattract andretaintoptalentthecompanyiscommittedtofairnessandequitabletreatmentinitscompensationandbenefitsfor employeesatalllevelsthecompanyobserveslegalminimumwageprovisionsandexceedsthemwherepossiblethe companystotalrewardsofferingsincludeanarrayofprogramstosupportitsemployeeswellbeingincludingannual performanceincentiveopportunitiespensionandretirementsavingsprogramshealthandwelfarebenefitspaidtimeoff leaveprogramsflexibleworkschedulesandemployeeassistanceprogramsinrecognitionofthecompanyscommitment tohelpemployeesbalancetheirpersonalandprofessionalresponsibilitiesthecompanyextendeditspaidparentalleave benefitgloballyfromtoweeksforalleligibleemployeesintheusthebenefitwaseffectiveonjanuary withretroactivecoveragefornewfamilyadditionsasofjuly healthwellnessandsafety thecompanysinvestmentinemployeehealthwellbeingandsafetyisbuiltonitsconvictionthatadvancinghealthfor humanitystartswithadvancingthehealthofitsemployeeswiththerightawarenessfocuspracticesandtoolsthe companyensuresthatallitsemployeesaroundtheworldaswellastemporarycontractorsandvisitorstothecompany sitescanworksafelythecompanyhascontinuouslyexpandedhealthandwellbeingprogramsthroughoutthecompany andacrosstheglobeincorporatingnewthinkingandtechnologiestokeepitsofferingsbestinclassandtohelpemployee achievetheirpersonalhealthgoalstheprogramsandpracticesthecompanyadvancesfortotalhealthphysicalmental emotionalandfinancialensureemployeehealthprotectionforemerginghealthrisksprotectingandsupportingour employeesasthecovidpandemichasevolvedcontinuestobeatoppriorityandthecompanysapproachinclude ensuringthehealthandsafetyofouremployeesintheworkplacethroughrobustlayersofprotectionenhancedcleane andaccesstocleaningsuppliesandpersonalprotectiveequipmentsupportingemployeeswithbenefitsandwellbee toolsthecompanycontinuestoaddressouremployeesneedsthroughjjflexahybridmodelthatempowersthe companysofficebasedemployeestofindtherightproductivityandbalanceofinpersonandremotework available information thecompanysmaincorporatewebsiteaddressiswwwjnjcomallofthecompanyssecfilingsarealsoavailableonthe companyswebsiteatwwwinvestorjnjcomseccfmassoonasreasonablypracticableafterhavingbeenelectronically filedorfurnishedtothesecallsecfilingsarealsoavailableatthesecswebsiteatwwwsecgov investorsandthepublicshouldnotethatthecompanyalsoannouncesinformationat wwwfactsaboutourprescriptionopioidscomwwwfactsabouttalccomandwwwltlmanagementinformationcom weusethesewebsitestocommunicatewithinvestorsandthepublicaboutourproductslitigationandothermattersitis possiblethattheinformationweposttothesewebsitescouldbedeemedtobematerialinformationthereforewe encourageinvestorsandothersinterestedinthecompanytoreviewtheinformationpostedtothesewebsitesin conjunctionwithwwwjnjcomthecompanyssecfilingspressreleasespublicconferencecallsandwebcast inadditiontheamendedandrestatedcertificateofincorporationbylawsthewrittenchartersoftheauditcommittee thecompensationbenefitscommitteethenominatingcorporategovernancecommitteetheregulatory compliancesustainabilitycommitteethesciencetechnologycommitteeandanyspecialcommitteeoftheboardof directorsandthecompanysprinciplesofcorporategovernancecodeofbusinessconductforemployeescodeof businessconductethicsformembersoftheboardofdirectorsandexecutiveofficersandothercorporate governancematerialsareavailableatwwwinvestorjnjcomgovcfmonthecompanyswebsiteandwillbeprovide withoutchargetoanyshareholdersubmittingawrittenrequestasprovidedabovetheinformationonwwwjnjcom wwwfactsaboutourprescriptionopioidscomwwwfactsabouttalccomandwwwltlmanagementinformationcomisnotand willnotbedeemedapartofthisreportorincorporatedintoanyotherfilingsthecompanymakeswiththesec johnsonjohnsonannualreport itema risk factor aninvestmentinthecompanyscommonstockordebtsecuritiesinvolvesrisksanduncertaintiesthecompanyseeksto identifymanageandmitigateriskstoourbusinessbutuncertaintiesandrisksaredifficulttopredictandmanyareoutside ofthecompanyscontrolandcannotthereforebeeliminatedinadditiontotheotherinformationinthisreportandthe companysotherfilingswiththesecinvestorsshouldconsidercarefullythefactorssetforthbelowinvestorsshouldbe awarethatitisnotpossibletopredictoridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacomplete discussionofallpotentialrisksoruncertaintiesifknownorunknownrisksoruncertaintiesmaterializethecompany businessresultsofoperationsorfinancialconditioncouldbeadverselyaffectedpotentiallyinamaterialway risk relate business industry operation thecompanysbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould adverselyaffectthecompanysearning thecompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarketsthecompanys businessescompetewithcompaniesofallsizesonthebasisofcosteffectivenesstechnologicalinnovationsintellectual propertyrightsproductperformancerealorperceivedproductadvantagespricingandavailabilityandrateof reimbursementthecompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisition collaborationsandlicensingagreementswiththirdpartiescompetitionforrightstoproductcandidatesandtechnologie mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsforthecompanycompetitor developmentofmoreeffectiveorlesscostlyproductsandortheirabilitytosecurepatentandotherintellectualproperty rightsandsuccessfullymarketproductsaheadofthecompanycouldnegativelyimpactsalesofthecompanysexisting productsaswellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproduct development forthecompanyspharmaceuticalbusinesseslossofpatentexclusivityforaproductoftenisfollowedbyasubstantial reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproductforthecompanysmedtech businessestechnologicalinnovationproductqualityreputationandcustomerserviceareespeciallyimportantto competitivenessdevelopmentbyothercompaniesofneworimprovedproductsprocessesandtechnologiescould threatentomakethecompanysproductsortechnologieslessdesirablelesseconomicalorobsoletethecompanys consumerhealthbusinessesfaceintensecompetitionfromotherbrandedproductsandretailersprivatelabelbrandsif thecompanyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproductsthiscouldadverselyaffect revenuesandprofitabilityofthoseproduct interruptionsanddelaysinmanufacturingoperationscouldadverselyaffectthecompanysbusinesssale andreputation thecompanysmanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplexhighquality componentsandmaterialsthecompanyssubsidiariesoperatemanufacturingfacilitiesaswellassourcingfrom thousandsofsuppliersaroundtheworldthecompanyhasinthepastandmayinthefuturefaceunanticipate interruptionsanddelaysinmanufacturingthroughitsinternalorexternalsupplychainmanufacturingdisruptionscanoccur formanyreasonsincludingregulatoryactionproductionqualitydeviationsorsafetyissueslabordisputeslabor shortagessitespecificincidentssuchasfiresnaturaldisasterssuchashurricanesandothersevereweatherevent rawmaterialshortagespoliticalunrestterroristattacksandepidemicsorpandemicssuchdelaysanddifficultiesin manufacturingcanresultinproductshortagesdeclinesinsalesandreputationalimpactaswellassignificantremediation andrelatedcostsassociatedwithaddressingtheshortage thecompanyreliesonthirdpartiestomanufacturecertainofourproductsanyfailurebyorlossofathird partymanufacturercouldresultindelaysandincreasedcostswhichmayadverselyaffectourbusiness thecompanyreliesonthirdpartiestomanufacturecertainofourproductswedependonthesethirdparty manufacturerstoallocatetousaportionoftheirmanufacturingcapacitysufficienttomeetourneedstoproduceproduct ofacceptablequalityandatacceptablemanufacturingyieldsandtodeliverthoseproductstousonatimelybasisandat acceptablepriceshoweverwecannotguaranteethatthesethirdpartymanufacturerswillbeabletomeetournearterm orlongtermmanufacturingrequirementswhichcouldresultinlostsalesandhaveanadverseeffectonourbusiness otherrisksassociatedwithourrelianceonthirdpartiestomanufacturetheseproductsincluderelianceonthethirdparty forregulatorycomplianceandqualityassurancemisappropriationofthecompanysintellectualpropertylimitedabilityto johnsonjohnsonannualreportmanageourinventorypossiblebreachofthemanufacturingagreementbythethirdpartyandthepossibleterminationor nonrenewalofthemanufacturingagreementbythethirdpartyatatimethatiscostlyorinconvenientforusmoreoverif anyofourthirdpartymanufacturerssuffersanydamagetofacilitieslosesbenefitsundermaterialagreement experiencespoweroutagesencountersfinancialdifficultiesisunabletosecurenecessaryrawmaterialsfromitssupplier orsuffersanyotherreductioninefficiencythecompanymayexperiencesignificantbusinessdisruptionintheeventof anysuchdisruptionthecompanywouldneedtoseekandsourceotherqualifiedthirdpartymanufacturerslikelyresulte infurtherdelaysandincreasedcostswhichcouldaffectourbusinessadversely counterfeitversionsofourproductscouldharmourpatientsandhaveanegativeimpactonourrevenue earningsreputationandbusiness ourindustrycontinuestobechallengedbythevulnerabilityofdistributionchannelstoillegalcounterfeitingandthe presenceofcounterfeitproductsinagrowingnumberofmarketsandovertheinternetthirdpartiesmayillegallydistribute andsellcounterfeitversionsofourproductswhichdonotmeetourrigorousmanufacturingandtestingstandardsto distributorsandpatientscounterfeitproductsmaybevisuallyindistinguishablefromtheauthenticversioncounterfeit medicinesposearisktopatienthealthandsafetybecauseoftheconditionsunderwhichtheyaremanufacturedoftenin unregulatedunlicenseduninspectedandunsanitarysitesaswellasthelackofregulationoftheircontent theindustrysfailuretomitigatethethreatofcounterfeitmedicinescouldadverselyimpactourbusinessandreputationby impactingpatientconfidenceinourauthenticproductspotentiallyresultinginlostsalesproductrecallsandanincrease threatoflitigationinadditiondiversionofourproductsfromtheirauthorizedmarketintootherchannelsmayresultin reducedrevenuesandnegativelyaffectourprofitability globalhealthcrisespandemicsepidemicsorotheroutbreakscouldadverselydisruptorimpactcertain aspectsofthecompanysbusinessresultsofoperationsandfinancialcondition wearesubjecttorisksassociatedwithglobalhealthcrisesepidemicspandemicsandotheroutbreakssuchincident ahealthcrisisorhealthcrisesincludingtheglobaloutbreakofcoronavirusanditsvariantscovidthecovid pandemichasadverselyimpactedandmaycontinuetoadverselyimpactcertainaspectsofthecompanysbusiness resultsofoperationsandfinancialconditionincludinglowersalesandreducedcustomerdemandandusageofcertainof ourproductsthecontinuedspreadofcovidorotherhealthcrisesmaycausethecompanytomodifyitsbusiness practicesandtakefurtheractionsasmayberequiredbygovernmentauthoritiesorasthecompanydeterminesareinthe bestinterestsofourpatientscustomersemployeesandbusinesspartnerswhilethecompanyhasrobustbusiness continuityplansinplaceacrossourglobalsupplychainnetworktohelpmitigatetheimpactofhealthcrisestheseeffort maynotcompletelypreventourbusinessfrombeingadverselyaffectedandfutureimpactsremainuncertain whiletheusandothercountrieshavesubstantiallyreopenedtheireconomiestheextenttowhichcovidorother healthcrisescouldimpactthecompanysfutureoperationswilldependonmanyfactorswhichcannotbepredictedwith confidenceincludingthedurationofanoutbreakandimpactofvariantsasurgeincovidorotherhealthcrisescould resultintheimpositionofnewmandatesandprolongedrestrictivemeasuresimplementedinordertocontrolthespreadof diseasetheglobalspreadofcovidorotherhealthcrisescouldadverselyimpactthecompanysoperation includingamongotherthingsourmanufacturingoperationssupplychainthirdpartysupplierssalesandmarketingand clinicaltrialoperationsanyofthesefactorscouldadverselyaffectthecompanysbusinessfinancialresultsandglobal economicconditionsgenerally wealsofaceuncertaintiesrelatedtoourvaccinedevelopmentprogramsincludinguncertaintiesrelatedtotheriskthatour continueddevelopmentprogramsmaynotbesuccessfulcommerciallyviableorreceiveapprovalfromregulatory authoritiesrisksassociatedwithclinicaltrialandrealworlddataincludingfurtheranalysesofitsefficacysafetyand durabilitytheriskthatcontinuedevolutionandmutationofdiseaseandthedurationofaparticularoutbreakmayimpedeour abilitytoconducttrialswithinaspecifiedtimeframetheriskthatdataaresubjecttodifferinginterpretationsand assessmentsincludingduringthepeerreviewpublicationprocessinthescientificcommunitygenerallyandbynational immunizationtechnicaladvisorygroupsnitagsandregulatoryauthoritiesdisruptionsintherelationshipsbetweenusour thirdpartysuppliersexternalmanufacturersandotherthirdpartieswithwhomweengagetheriskthatothercompanie mayproducesuperiororcompetitiveproductstheriskthatdemandforanyproductswemaydevelopmaynolongerexist risksrelatedtotheavailabilityofrawmaterialstomanufactureanysuchproductstheriskthatwemaynotbeabletorecoup costsassociatedwithourrdandmanufacturingeffortsandrisksassociatedwithanychangesinthewayweapproachor provideadditionalresearchfundingforpotentialdrugdevelopmenttheriskthatwemaynotbeabletocreateorscaleup manufacturingcapacityonatimelybasisthatwemaycontinuetoexperiencemanufacturingdelaysonceamanufacturing siteisactivatedorhaveaccesstologisticsorsupplychannelscommensuratewithglobaldemandforanypotential approvedvaccineorproductcandidatewhichwouldnegativelyimpactourabilitytosupplytheestimatednumbersofdose johnsonjohnsonannualreport ofourvaccinewithintheprojectedtimeperiodsindicatedandotherchallengesandrisksassociatedwiththepaceofour vaccinedevelopmentprogramandpricingandaccesschallengesforsuchproductsincludingintheus risk related government regulation legal proceeding globalsalesinthecompanyspharmaceuticalandmedtechsegmentsmaybenegativelyimpactedby healthcarereformsandincreasingpricingpressure salesofthecompanyspharmaceuticalandmedtechproductsaresignificantlyaffectedbyreimbursementsbythirdparty payerssuchasgovernmenthealthcareprogramsprivateinsuranceplansandmanagedcareorganizationsaspartof variouseffortstocontainhealthcarecoststhesepayersareputtingdownwardpressureonpricesatwhichproductswill bereimbursedintheusincreasedpurchasingpowerofentitiesthatnegotiateonbehalfofmedicaremedicaidand privatesectorbeneficiariesinpartduetocontinuedconsolidationamonghealthcareproviderscouldresultinfurther pricingpressuresinadditionrecentlegislationandongoingpoliticalscrutinyorpricingcoverageandreimbursement couldresultinadditionalpricingpressuresspecificallytheinflationreductionactofiramaysubjectcertain productstogovernmentestablishedpricingpotentiallyimposerebatesandsubjectmanufacturerswhofailtoadhereto thegovernmentsinterpretationsofthelawtopenaltiesoutsidetheusnumerousmajormarketsincludingtheeu unitedkingdomjapanandchinahavepervasivegovernmentinvolvementinfundinghealthcareandinthatregard directlyorindirectlyimposepricecontrolslimitaccesstoorreimbursementforthecompanysproductsorreducethe valueofitsintellectualpropertyprotection thecompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpensesfinesand reputationaldamage intheordinarycourseofbusinessjohnsonjohnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuit involvingvariousissuessuchasproductliabilitypatentdisputesandclaimsthattheirproductsalesmarketingandprice practicesviolatevariousantitrustunfairtradepracticesandorconsumerprotectionlawsthecompanysmoresignificant legalproceedingsaredescribedinnotelegalproceedingsundernotestotheconsolidatedfinancialstatement includedinitemofthisreportlitigationingeneralandsecuritiesderivativeactionclassactionandmultidistrict litigationinparticularcanbeexpensiveanddisruptivesomeofthesemattersmayincludethousandsofplaintiffsmay involvepartiesseekinglargeandorindeterminateamountsincludingpunitiveorexemplarydamagesandmayremain unresolvedforseveralyearsforexamplethecompanyisadefendantinnumerouslawsuitsarisingoutoftheuseofbody powderscontainingtalcprimarilyjohnsonsbabypowderandthecompanyssalemanufacturingandmarketingof opioidswhilethecompanybelievesithassubstantialdefensesinthesemattersitisnotfeasibletopredicttheultimate outcomeoflitigationthecompanycouldinthefutureberequiredtopaysignificantamountsasaresultofsettlementsor judgmentsinthesematterspotentiallyinexcessofaccrualsincludingmatterswherethecompanycouldbeheldjointly andseverallyliableamongotherdefendantstheresolutionoforincreaseinaccrualsforoneormoreofthesemattersin anyreportingperiodcouldhaveamaterialadverseeffectonthecompanysresultsofoperationsandcashflowsforthat periodthecompanydoesnotpurchasethirdpartyproductliabilityinsurancehoweverthecompanyutilizesawholly ownedcaptiveinsurancecompanysubjecttocertainlimit productreliabilitysafetyandeffectivenessconcernscanhavesignificantnegativeimpactsonsalesand resultsofoperationsleadtolitigationandcausereputationaldamage concernsaboutproductsafetywhetherraisedinternallyorbylitigantsregulatorsorconsumeradvocatesandwhetheror notbasedonscientificevidencecanresultinsafetyalertsproductrecallsgovernmentalinvestigationsregulatoryaction onthepartoftheusfoodanddrugadministrationoritscounterpartinothercountriesprivateclaimsandlawsuit paymentoffinesandsettlementsdecliningsalesandreputationaldamagethesecircumstancescanalsoresultin damagetobrandimagebrandequityandconsumertrustinthecompanysproductsproductrecallshaveinthepast andcouldinthefuturepromptgovernmentinvestigationsandinspectionstheshutdownofmanufacturingfacilities continuedproductshortagesandrelatedsalesdeclinessignificantremediationcostsreputationaldamagepossiblecivil penaltiesandcriminalprosecution thecompanyfacessignificantregulatoryscrutinywhichimposessignificantcompliancecostsand exposesthecompanytogovernmentinvestigationslegalactionsandpenaltie likeothercompaniesinthehealthcareindustrythecompanyissubjecttoextensiveregulationinvestigationsandlegal actionbynationalstateandlocalgovernmentagenciesintheusandothercountriesinwhichitoperatesregulatory issuesregardingcompliancewithcurrentgoodmanufacturingpracticescgmpandcomparablequalityregulationsin foreigncountriesbymanufacturersofdrugsdevicesandconsumerproductscanleadtofinesandpenaltiesproduct johnsonjohnsonannualreportrecallsproductshortagesinterruptionsinproductiondelaysinnewproductapprovalsandlitigationinadditionthe marketingpricingandsaleofthecompanysproductsaresubjecttoregulationinvestigationsandlegalactionsincluding underthefederalfooddrugandcosmeticactthemedicaidrebateprogramfederalandstatefalseclaimsactsstate unfairtradepracticesactsandconsumerprotectionlawsscrutinyofhealthcareindustrybusinesspracticesby governmentagenciesandstateattorneysgeneralintheusandanyresultinginvestigationsandprosecutionscarryrisk ofsignificantcivilandcriminalpenaltiesincludingbutnotlimitedtodebarmentfromparticipationingovernment healthcareprogramsanysuchdebarmentcouldhaveamaterialadverseeffectonthecompanysbusinessandresultsof operationsthemostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesaredescribedin notelegalproceedingsgovernmentproceedingsundernotestotheconsolidatedfinancialstatementsinclude initemofthisreport changesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpactthecompany operatingresult changesintaxlawsorregulationsaroundtheworldincludingintheusandasledbytheorganizationforeconomic cooperationanddevelopmentsuchastherecentadoptionbytheeuenactmentbysouthkoreaandtheanticipate enactmentbyadditionalcountriesofaglobalminimumtaxcouldnegativelyimpactthecompanyseffectivetaxrateand resultsofoperationsachangeinstatutorytaxrateorcertaininternationaltaxprovisionsinanycountrywouldresultinthe revaluationofthecompanysdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhich thenewtaxlawisenactedthischangewouldresultinanexpenseorbenefitrecordedtothecompanysconsolidate statementofearningsthecompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperate changestotaxlawsorregulationsmayoccuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialto thefiscalquarterandyearinwhichthelawchangeisenacte seenoteincometaxesundernotestotheconsolidatedfinancialstatementsincludedinitemofthisreportfor additionalinformation thecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandisaddressingtaxauditsanddispute withmanytaxauthoritiesinconnectionwithvariousgovernmentinitiativescompaniesarerequiredtodisclosemore informationtotaxauthoritiesonoperationsaroundtheworldwhichmayleadtogreaterauditscrutinyofprofitsearnedin othercountriesthecompanyregularlyassessesthelikelyoutcomesofitstaxauditsanddisputestodeterminethe appropriatenessofitstaxreserveshoweveranytaxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytothe companysexpectationswhichcouldresultintaxliabilitiesinexcessofreserve risk relate intellectual property thecompanyfacesincreasedchallengestointellectualpropertyrightscentraltoitsbusiness thecompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrightsrelatingtoitsproductsand manufacturingprocessestheserightsareessentialtothecompanysbusinessesandmateriallyimportanttothe companysresultsofoperationspublicpolicybothwithinandoutsidetheushasbecomeincreasinglyunfavorable towardintellectualpropertyrightsthecompanycannotbecertainthatitwillobtainadequatepatentprotectionfornew productsandtechnologiesintheunitedstatesandotherimportantmarketsorthatsuchprotectionsoncegrantedwill lastaslongasoriginallyanticipate competitorsroutinelychallengethevalidityorextentofthecompanysownedorlicensedpatentsandproprietaryright throughlitigationinterferencesoppositionsandotherproceedingssuchasinterpartesreviewiprproceedingsbefore theunitedstatespatenttrademarkofficeusptotheseproceedingsabsorbresourcesandcanbeprotractedas wellasunpredictableinadditionchallengesthatthecompanysproductsinfringethepatentsofthirdpartiescouldresult inaninjunctionandortheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionand salesoftheproductsinquestion thecompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand biosimilarversionsofthecompanyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering thoseproductsintheusmanufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay challengethevalidityorclaimnoninfringementofinnovatorproductsthroughtheabbreviatednewdrugapplicationor andaprocesswiththeusfdaandrelatedandalitigationthebiologicspricecompetitionandinnovationact bpciaenactedinwhichcreatedanewregulatorypathwayfortheapprovalbytheusfdaofbiosimilar alternativestoinnovatordevelopedbiologicalproductsalsocreatedmechanismsforbiosimilarapplicantstochallengethe patentsontheinnovatorbiologicstheiprprocesswiththeusptoisalsobeingusedbycompetitorstochallenge patentsassertedinlitigation johnsonjohnsonannualreport intheeventthecompanyisnotsuccessfulindefendingitspatentsagainstsuchchallengesorupontheatrisklaunch bythegenericorbiosimilarfirmofitsproductthecompanycanloseamajorportionofrevenuesforthereference productinaveryshortperiodoftimecurrentlegalproceedingsinvolvingthecompanyspatentsandotherintellectual propertyrightsaredescribedinnotelegalproceedingsintellectualpropertyundernotestotheconsolidate financialstatementsincludedinitemofthisreport risksrelatedtoproductdevelopmentregulatoryapprovalandcommercialization significantchallengesordelaysinthecompanysinnovationanddevelopmentofnewproduct technologiesandindicationscouldhaveanadverseimpactonthecompanyslongtermsuccess thecompanyscontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiate productsandservicesthataddresstheevolvinghealthcareneedsofpatientsprovidersandconsumersdevelopmentof successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhenthecompanysexistingproduct losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivitynewproductsintroduce withinthepastfiveyearsaccountedforapproximatelyofsalesthecompanycannotbecertainwhenor whetheritwillbeabletodeveloplicenseorotherwiseacquirecompaniesproductsandtechnologieswhetherparticular productcandidateswillbegrantedregulatoryapprovalandifapprovedwhethertheproductswillbecommercially successful thecompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaboration acquisitionsjointventuresandlicensingorotherarrangementswiththirdpartiesinallofthesecontextsdevelopingnew productsparticularlypharmaceuticalandbiotechnologyproductsandmedicaldevicesrequiressignificantinvestmentof resourcesovermanyyearsonlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially viableproductstheprocessdependsonmanyfactorsincludingtheabilitytodiscernpatientsandhealthcareproviders futureneedsdeveloppromisingnewcompoundsstrategiesandtechnologiesachievesuccessfulclinicaltrialresults secureeffectiveintellectualpropertyprotectionobtainregulatoryapprovalsonatimelybasisandifandwhentheyreach themarketsuccessfullydifferentiatethecompanysproductsfromcompetingproductsandapproachestotreatment newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue toproductandpricecompetitionchangesincustomerpreferencesorhealthcarepurchasingpatternsresistanceby healthcareprovidersoruncertaintyoverthirdpartyreimbursementevenfollowinginitialregulatoryapprovalthesuccess ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerrealworldpatientpopulationsaswellas marketentryofcompetitiveproduct risk relate financial economic market condition thecompanyfacesavarietyoffinancialeconomiclegalsocialandpoliticalrisksassociatedwith conductingbusinessinternationally thecompanysextensiveoperationsandbusinessactivitythroughouttheworldareaccompaniedbycertainfinancial economiclegalsocialandpoliticalrisksincludingthoselistedbelow foreigncurrencyexchangeinfiscalapproximatelyofthecompanyssalesoccurredoutsideoftheuswith approximatelyineuropeinthewesternhemisphereexcludingtheusandintheasiapacificandafrica regionchangesinnonuscurrenciesrelativetotheusdollarimpactthecompanysrevenuesandexpenseswhile thecompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflow unhedgedexposurescontinuetobesubjecttocurrencyfluctuationsinadditiontheweakeningorstrengtheningofthe usdollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe companysnonusbusinessactivityaretranslatedintousdollar inflationandcurrencydevaluationrisksthecompanyfaceschallengesinmaintainingprofitabilityofoperationsin economiesexperiencinghighinflationratesspecificallythecompanyhasaccountedforoperationsinargentinaturkey andvenezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassedwhilethecompany strivestomaintainprofitmarginsintheseareasthroughcostreductionprogramsproductivityimprovementsandperiodic priceincreasesitmightexperienceoperatinglossesasaresultofcontinuedinflationinadditiontheimpactofcurrency devaluationsincountriesexperiencinghighinflationratesorsignificantcurrencyexchangefluctuationscouldnegatively impactthecompanysoperatingresult illegalimportationofpharmaceuticalproductstheillegalimportationofpharmaceuticalproductsfromcountrieswhere governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffectthecompanyssalesand johnsonjohnsonannualreportprofitabilityintheusandothercountriesinwhichthecompanyoperateswiththeexceptionoflimitedquantitiesof prescriptiondrugsforpersonaluseforeignimportsofpharmaceuticalproductsareillegalundercurrentuslaw howeverthevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower pricedimportshasgrownsignificantly antibriberyandotherregulationsthecompanyissubjecttovariousfederalandforeignlawsthatgovernitsinternational businesspracticeswithrespecttopaymentstogovernmentofficialsthoselawsincludetheusforeigncorrupt practicesactfcpawhichprohibitsuspubliclytradedcompaniesfrompromisingofferingorgivinganythingofvalue toforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingthecompanyobtain orretainbusinessorgainanyimproperadvantagethecompanysbusinessisheavilyregulatedandthereforeinvolve significantinteractionwithforeignofficialsalsoinmanycountriesoutsidetheusthehealthcareproviderswho prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare governmententitiesthereforethecompanysinteractionswiththeseprescribersandpurchasersaresubjecttoregulation underthefcpainadditiontotheusapplicationandenforcementofthefcpavariousjurisdictionsinwhichthe companyoperateshavelawsandregulationsincludingtheukbriberyactaimedatpreventingandpenalize corruptandanticompetitivebehaviorenforcementactivitiesundertheselawscouldsubjectthecompanytoadditional administrativeandlegalproceedingsandactionswhichcouldincludeclaimsforcivilpenaltiescriminalsanctionsand administrativeremediesincludingexclusionfromhealthcareprogram otherfinancialeconomiclegalsocialandpoliticalrisksotherrisksinherentinconductingbusinessgloballyinclude localandregionaleconomicenvironmentsandpoliciesinthemarketsthatweserveincludinginterestratesmonetary policyinflationeconomicgrowthrecessioncommoditypricesandcurrencycontrolsorotherlimitationsontheability toexpatriatecash protectiveeconomicpoliciestakenbygovernmentssuchastradeprotectionmeasuresandimportexportlicensing requirement compliancewithlocalregulationsandlawsincludinginsomecountriesregulatoryrequirementsrestrictingthe companysabilitytomanufactureorsellitsproductsintherelevantmarket diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdiction potentialnationalizationorexpropriationofthecompanysforeignasset politicalorsocialupheavalseconomicinstabilityrepressionorhumanrightsissuesand geopoliticaleventsincludingnaturaldisastersdisruptionstomarketsduetowararmedconflictterrorismepidemicsor pandemic failuretomaintainasatisfactorycreditratingcouldadverselyaffectourliquiditycapitalposition borrowingcostsandaccesstocapitalmarket wecurrentlymaintaininvestmentgradecreditratingswithmoodysinvestorsserviceandstandardpoorsrating servicesratingagenciesroutinelyevaluateusandtheirratingsofourlongtermandshorttermdebtarebasedona numberoffactorsanydowngradeofourcreditratingsbyacreditratingagencywhetherasaresultofouractionsor factorswhicharebeyondourcontrolcanincreasethecostofborrowingunderanyindebtednesswemayincurreduce marketcapacityforourcommercialpaperorrequirethepostingofadditionalcollateralunderourderivativecontract therecanbenoassurancethatwewillbeabletomaintainourcreditratingsandanyadditionalactualoranticipate changesordowngradesinourcreditratingsincludinganyannouncementthatourratingsareunderreviewfora downgrademayhaveanegativeimpactonourliquiditycapitalpositionandaccesstocapitalmarket therussiaukrainewarandactionstakeninresponsetotherussiaukrainewarcouldadverselyaffect ourbusinessresultsofoperationsorfinancialcondition infebruaryrussialaunchedamilitaryinvasionofukrainetheongoingrussiaukrainewarhasprovokedstrong reactionsfromtheunitedstatestheunitedkingdomtheeuropeanunionandvariousothercountriesandeconomicand politicalorganizationsaroundtheworldwehavebeenmonitoringthegeopoliticalsituationinrussiasincethestartofthe russiaukrainewarandhavesuspendedadditionalinvestmentenrollmentofclinicaltrialsandsupplyofourpersonal careproductsinrussiawecontinuetomonitortheneedforhumanitarianreliefintheregionandcontinuetosupplyour medicinesmedicaldevicesandequipmentintheregionincompliancewiththeapplicablesanctionswewillcontinueto monitorthegeopoliticalsituationinrussiaandtoevaluateouractivitiesandfutureoperationsinrussia actionstakeninresponsetotherussiaukrainewarincludetheimpositionofexportcontrolsandbroadfinancialand economicsanctionsagainstrussiabelarusandspecificareasofukraineadditionalsanctionsorothermeasuresmaybe imposedbytheglobalcommunityincludingbutnotlimitedtolimitationsonourabilitytofileprosecuteandmaintain johnsonjohnsonannualreport patentstrademarksandotherintellectualpropertyrightsfurthermoretherussiangovernmenthasalreadytakenaction allowingrussiancompaniesandindividualstoexploitinventionsownedbypatentholdersfromtheunitedstatesand manyothercountrieswithoutconsentorcompensationandwemaynotbeabletopreventthirdpartiesfrompracticingour inventionsinrussiaorfromsellingorimportingproductsinandintorussia wehaveexperiencedandexpecttocontinuetoexperienceotherrisksrelatedtothebroadeconomicconsequencesof therussiaukrainewarincludingforeigncurrencyvolatilitydecreaseddemandforourproductsincountriesaffectedby therussiaukrainewarandchallengestoourglobalsupplychainrelatedtoincreasedcostsofmaterialsandotherinput forourproductsandsuppliersoperatinginrussiaandukrainewealsocontinuetomonitorthevarioussanctionsand exportcontrolsimposedinresponsetotherussiaukrainewar thefullimpactoftherussiaukrainewarandactionstakeninresponsetotheongoingconflictontheglobaleconomy andgeopoliticalrelationsingeneralandonourbusinessinparticularremainuncertainanyoralloftheforegoingrisk couldhaveanadverseeffectonourbusinessresultsofoperationsorfinancialconditionparticularlyastheconflict continuesforanindefiniteperiodoftimegiventhatdevelopmentsconcerningtherussiaukrainewarareongoingand havebeenconstantlyevolvingadditionalimpactsandrisksmayarisethatarenotpresentlyknowntoustherussia ukrainewarmayalsohavetheeffectofheighteningmanyoftheotherrisksdescribedinthisriskfactorssection risk relate planned separation consumer health business theplannedseparationofthecompanysconsumerhealthbusinessmaynotbecompletedontheterm ortimelinecurrentlycontemplatedifatallandmaynotachievetheexpectedresult innovemberthecompanyannounceditsintentiontoseparatethecompanysconsumerhealthbusinesswiththe intentiontocreateastandalonepubliclytradedcompanywhichwassubsequentlynamedkenvueinckenvuethe plannedseparationisintendedtoqualifyasataxfreetransactionforusfederalincometaxpurposesthecompanyis targetingcompletionoftheplannedseparationincompletionoftheplannedseparationwillbesubjecttothe satisfactionofcertainconditionsincludingamongothersconsultationswithworkscouncilsandotheremployee representativebodiesasrequiredfinalapprovalbythecompanysboardofdirectorsthecontinuingeffectivenessand validityofthecompanysprivateletterrulingfromtheinternalrevenueserviceirsandreceiptoffavorableopinionsof thecompanysustaxadvisorswithrespecttothetaxfreenatureofthetransactionandthereceiptofotherregulatory approvalstherecanbenoassuranceregardingtheultimatetimingoftheplannedseparationorthatsuchseparationwill becompletedunanticipateddevelopmentscoulddelaypreventorotherwiseadverselyaffecttheplannedseparation includingbutnotlimitedtodisruptionsingeneralorfinancialmarketconditionsorpotentialproblemsordelaysinobtaining variousregulatoryandtaxapprovalsorclearance thecoststocompletetheplannedseparationwillbesignificantinadditionthecompanymaybeunable toachievesomeorallofthestrategicandfinancialbenefitsthatitexpectstoachievefromtheplanne separationofthecompanysconsumerhealthbusiness thecompanyhasincurredandisexpectedtoincursignificantexpensesinconnectionwiththeplannedseparationin additionthecompanymaynotbeabletoachievethefullstrategicandfinancialbenefitsthatareexpectedtoresultfrom theplannedseparationtheanticipatedbenefitsoftheplannedseparationarebasedonanumberofassumptionssome ofwhichmayproveincorrect followingtheplannedseparationthepriceofsharesofthecompanyscommonstockmay fluctuatesignificantly thecompanycannotpredicttheeffectoftheplannedseparationonthetradingpriceofsharesofitscommonstockand themarketvalueofsharesofitscommonstockmaybelessthanequaltoorgreaterthanthemarketvalueofsharesofit commonstockpriortotheplannedseparationinadditionthepriceofthecompanyscommonstockmaybemorevolatile aroundthetimeoftheplannedseparation theplannedseparationcouldresultinsubstantialtaxliability thecompanyhasreceivedaprivateletterrulingfromtheirsastothetaxfreenatureoftheplannedseparationunderthe usinternalrevenuecodeofasamendedtheplannedseparationisconditionedonamongotherthingsthe continuingeffectivenessandvalidityofthecompanysprivateletterrulingfromtheirsandreceiptoffavorableopinionsof thecompanysustaxadvisorstheprivateletterrulingandopinionswillbebasedonamongotherthingsvariousfact assumptionsrepresentationsandundertakingsfromthecompanyandkenvueregardingthepastandfutureconductof johnsonjohnsonannualreportthecompaniesrespectivebusinessesandothermattersifanyofthesefactsassumptionsrepresentationsor undertakingsareincorrectornototherwisesatisfiedthecompanyanditsshareholdersmaynotbeabletorelyonthe rulingortheopinionsoftaxadvisorsnotwithstandingtheprivateletterrulingandopinionsoftaxadvisorsifsubsequentto theplannedseparationtheirsdeterminesthatcertainstepsofthetransactiondonotqualifyfortaxfreetreatmentfor usfederalincometaxpurposestheresultingtaxliabilitytothecompanyanditsshareholderscouldbesubstantialthe plannedseparationmayalsonotqualifyfortaxfreetreatmentinothercountriesaroundtheworldandasaresultmay triggersubstantialtaxliabilitytothecompany risk ourbusinessdependsonourabilitytorecruitandretaintalentedhighlyskilledemployeesandadiverse workforce ourcontinuedgrowthrequiresustorecruitandretaintalentedemployeesrepresentingdiversebackgroundsexperience andskillsetsthemarketforhighlyskilledworkersandleadersinourindustryisextremelycompetitiveandourabilityto competedependsonourabilitytohiredevelopandmotivatehighlyskilledpersonnelinallareasofourorganization maintainingourbrandandreputationaswellasadiverseequitableandinclusiveworkenvironmentenablesustoattract toptalentifwearelesssuccessfulinourrecruitingeffortsorifwecannotretainhighlyskilledworkersandkeyleader ourabilitytodevelopanddeliversuccessfulproductsandservicesmaybeadverselyaffectedinadditioneffective successionplanningisimportanttoourlongtermsuccessanyunsuccessfulimplementationofoursuccessionplansor failuretoensureeffectivetransferofknowledgeandsmoothtransitionsinvolvingkeyemployeescouldadverselyaffectour businessfinancialconditionorresultsofoperation climatechangeorlegalregulatoryormarketmeasurestoaddressclimatechangemaynegativelyaffect ourbusinessandresultsofoperation climatechangeresultingfromincreasedconcentrationsofcarbondioxideandothergreenhousegasesintheatmosphere couldpresentriskstoouroperationsincludinganadverseimpactonglobaltemperaturesweatherpatternsandthe frequencyandseverityofextremeweatherandnaturaldisastersnaturaldisastersandextremeweatherconditionssuch asahurricanetornadoearthquakewildfireorfloodingmayposephysicalriskstoourfacilitiesanddisrupttheoperation ofoursupplychaintheimpactsofthechangingclimateonwaterresourcesmayresultinwaterscarcitylimitingourability toaccesssufficienthighqualitywaterincertainlocationswhichmayincreaseoperationalcost concernoverclimatechangemayalsoresultinneworadditionallegalorregulatoryrequirementsdesignedtoreduce greenhousegasemissionsandormitigatetheeffectsofclimatechangeontheenvironmentifsuchlawsorregulation aremorestringentthancurrentlegalorregulatoryobligationswemayexperiencedisruptioninoranincreaseinthecost associatedwithsourcingmanufacturinganddistributionofourproductswhichmayadverselyaffectourbusinessresult ofoperationsorfinancialconditionfurthertheimpactsofclimatechangehaveaninfluenceoncustomerpreference andfailuretoprovideclimatefriendlyproductscouldpotentiallyresultinlossofmarketshare aninformationsecurityincidentincludingacybersecuritybreachcouldhaveanegativeimpacttothe companysbusinessorreputation tomeetbusinessobjectivesthecompanyreliesonbothinternalinformationtechnologyitsystemsandnetworksand thoseofthirdpartiesandtheirvendorstoprocessandstoresensitivedataincludingconfidentialresearchbusiness plansfinancialinformationintellectualpropertyandpersonaldatathatmaybesubjecttolegalprotectionandensurethe continuityofthecompanyssupplychaintheextensiveinformationsecurityandcybersecuritythreatswhichaffect companiesgloballyposearisktothesecurityandavailabilityofthesesystemsandnetworksandtheconfidentiality integrityandavailabilityofthecompanyssensitivedatathecompanycontinuallyassessesthesethreatsandmake investmentstoincreaseinternalprotectiondetectionandresponsecapabilitiesaswellasensurethecompanysthird partyprovidershaverequiredcapabilitiesandcontrolstoaddressthisrisktodatethecompanyhasnotexperiencedany materialimpacttothebusinessoroperationsresultingfrominformationorcybersecurityattackshoweverbecauseofthe frequentlychangingattacktechniquesalongwiththeincreasedvolumeandsophisticationoftheattacksthereisthe potentialforthecompanytobeadverselyimpactedthisimpactcouldresultinreputationalcompetitiveoperationalor otherbusinessharmaswellasfinancialcostsandregulatoryactionthecompanymaintainscybersecurityinsurancein theeventofaninformationsecurityorcyberincidenthoweverthecoveragemaynotbesufficienttocoverallfinancial legalbusinessorreputationallosse asaresultoftherussiaukrainewartherehasbeenandweexpecttherewillcontinuetobeanincreasedriskof informationsecurityorcybersecurityincidentsincludingcyberattacksperpetratedbyrussiaorothersatitsdirection johnsonjohnsonannualreport althoughwehavetakenstepstoenhanceourprotectionsagainsttheseattackswemaynotbeabletoaddressthethreat ofinformationsecurityorcybersecurityincidentsproactivelyorimplementadequatepreventativemeasuresandwemay notbeabletodetectandaddressanysuchdisruptionorsecuritybreachpromptlyoratallwhichcouldadverselyaffect ourbusinessresultsofoperationsorfinancialconditionmoreoverweareawareofincidentsinwhichourthirdparty partnershavebeenthetargetofinformationsecurityorcybersecurityincidentsasaresultoftherussiaukrainewar althoughtodateouritsystemshavenotbeencompromisedbytheseincidentsitispossiblethatfutureinformation securityorcybersecurityincidentsinvolvingourcustomersmanufacturerssuppliersorotherthirdpartypartnerscould successfullycompromiseouritsystemswhichcouldadverselyaffectourbusinessresultsofoperationsorfinancial condition abreachofprivacylawsorunauthorizedaccesslossormisuseofpersonaldatacouldhaveanegative impacttothecompanysbusinessorreputation thecompanyissubjecttoprivacyanddataprotectionlawsacrosstheglobethatimposebroadcomplianceobligation onthecollectionusestorageaccesstransferandprotectionofpersonaldatabreachofsuchrequirementscouldresult insubstantialfinespenaltiesprivaterightofactionsclaimsanddamagetoourreputationandbusinessnewprivacylaws areexpectedinotherterritoriestogetherwithgreaterprivacyenforcementbygovernmentalauthoritiesgloballyparticularly ondatalocalizationrequirementsandinternationaldataflowsthecompanyhasestablishedprivacycomplianceprogram andcontrolsthatourbusinessesworldwidearerequiredtocomplywithbutwithmanytechnologyanddatadriven initiativesbeingprioritizedacrossthecompanyandinvolvingmultiplevendorsandthirdpartiestherearepotentialrisksof controlsimposedoncrossborderdataflowsunauthorizedaccessandlossofpersonaldatathroughinternalandexternal threatsthatcouldimpactourbusinessoperationsandresearchactivitie item unresolved staff comment notapplicable item property thecompanyssubsidiariesoperatemanufacturingfacilitiesoccupyingapproximatelymillionsquarefeetoffloor spacethemanufacturingfacilitiesareusedbytheindustrysegmentsofthecompanysbusinessapproximatelyas follow squarefeet segment inthousand consumerhealth pharmaceutical medtech worldwidetotal withintheusfourfacilitiesareusedbytheconsumerhealthsegmentfivebythepharmaceuticalsegmentandby themedtechsegmentoutsideoftheusfacilitiesareusedbytheconsumerhealthsegmentbythe pharmaceuticalsegmentandbythemedtechsegment thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollow squarefeet geographicarea numberoffacilitie inthousand unitedstate europe westernhemisphereexcludingus africaasiaandpacific worldwidetotal inadditiontothemanufacturingfacilitiesdiscussedabovethecompanymaintainsnumerousofficeandwarehouse facilitiesthroughouttheworld johnsonjohnsonannualreportthecompanyssubsidiariesgenerallyseektoownratherthanleasetheirmanufacturingfacilitiesalthoughsome principallyinnonuslocationsareleasedofficeandwarehousefacilitiesareoftenleasedthecompanyalsoengage contractmanufacturer thecompanyiscommittedtomaintainingallofitspropertiesingoodoperatingcondition segmentinformationonadditionstopropertyplantandequipmentiscontainedinnotesegmentsofbusinessand geographicareasofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport item legal proceeding theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinnotelegal proceedingsofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport item safety disclosure notapplicable johnsonjohnsonannualreport executive officer registrant listedbelowaretheexecutiveofficersofthecompanytherearenofamilyrelationshipsbetweenanyoftheexecutive officersandthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto whichtheexecutiveofficerwasselectedattheannualmeetingoftheboardofdirectorstheexecutiveofficersare electedbytheboardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualifiedoruntil earlierresignationorremoval informationwithregardtothedirectorsofthecompanyisincorporatedhereinbyreferencetothematerialcaptione itemelectionofdirectorsintheproxystatement age position vanessabroadhurst memberexecutivecommitteeexecutivevicepresidentglobal corporateaffairsa joaquinduato chairmanoftheboardchiefexecutiveofficerb petermfasolophd memberexecutivecommitteeexecutivevicepresidentchiefhuman resourcesofficerc elizabethforminard memberexecutivecommitteeexecutivevicepresidentgeneral counseld williamnhaitmdphd memberexecutivecommitteeexecutivevicepresidentchief externalinnovationandmedicalsafetyofficerinterimhead janssenrde ashleymcevoy memberexecutivecommitteeexecutivevicepresidentworldwide chairmanmedtechf thibautmongon memberexecutivecommitteeexecutivevicepresidentworldwide chairmanconsumerhealthg jamesswanson memberexecutivecommitteeexecutivevicepresidentchief informationofficerh jenniferltaubert memberexecutivecommitteeexecutivevicepresidentworldwide chairmanpharmaceuticalsi kathrynewengel memberexecutivecommitteeexecutivevicepresidentchief technicaloperationsriskofficerj josephjwolk memberexecutivecommitteeexecutivevicepresidentchief financialofficerk msvbroadhurstjoinedthecompanyinasworldwidevicepresidentanemiaoncologysupportivecareshethenwent ontobecomevicepresidentofthecardiovascularinstitutionalfranchiseinandpresidentofjanssentherapeuticsin beforebecominguspresidentinternalmedicineinfromtosheheldgeneralmanagerrolesatamgenin inflammationcardiovascularandcardiovascularboneinmsbroadhurstrejoinedjohnsonjohnsonasuspresident cardiovascularmetabolismandamemberofthejanssenamericasleadershipteaminthisroleshealsoprovidedoperational oversightofthefullportfolioofjanssenmedicinesinpuertoricoandcanadainshewasappointedcompanygroup chairmanglobalcommercialstrategyorganizationinmsbroadhurstwasnamedexecutivevicepresidentglobal corporateaffairsandamemberoftheexecutivecommitteeleadingthecompanysglobalmarketingcommunicationglobalpublic healthandphilanthropyfunctions mrjduatobecamechairmanoftheboardofdirectorsinjanuarysubsequenttohisappointmentaschiefexecutiveofficer andadirectorinjanuaryhejoinedthecompanyinwithjanssenfarmaceuticasaspainasubsidiaryofthe companyandheldexecutivepositionsofincreasingresponsibilityinallbusinesssectorsandacrossmultiplegeographiesand functionsinhewasnamedcompanygroupchairmanpharmaceuticalsandinhewasnamedworldwidechairman pharmaceuticalsinmrduatobecameamemberoftheexecutivecommitteeandwasnamedexecutivevicepresident worldwidechairmanpharmaceuticalsinjulymrduatowaspromotedtovicechairmanoftheexecutivecommitteewhere heprovidedstrategicdirectionforthepharmaceuticalandconsumerhealthsectorsandoversawboththeglobalsupplychain informationtechnologyandhealthwellnessteamsasadualcitizenofspainandtheunitedstatesmrduatosinternational perspectiveandgloballensgiveshimadeepappreciationofdiversethoughtsandopinion drpmfasolojoinedthecompanyinasworldwidevicepresidenthumanresourcesinthemedtechsegmentand subsequentlyservedasthecompanyschieftalentofficerheleftjohnsonjohnsonintojoinkohlbergkravisroberts coaschieftalentofficerdrfasoloreturnedtothecompanyinasthevicepresidentglobalhumanresourcesandin hebecameamemberoftheexecutivecommitteeinaprilhewasnamedexecutivevicepresidentchiefhuman resourcesofficerdrfasolohasresponsibilityforglobaltalentrecruitingdiversitycompensationbenefitsemployeerelationsand johnsonjohnsonannualreportallaspectsofthehumanresourcesagendaforthecompanyhealsoservesontheboardsofthehumanresourcespolicy associationtuftsuniversityandsavethechildrenandwasnamedafellowofthenationalacademyofhumanresourcesin mselizabethforminardjoinedthecompanyinasvicepresidentlawconsumerhealthcareglobalbusinessunitand continuedtoserveinrolesofincreasingresponsibilityinshewaspromotedtogeneralcounselmedicaldevice diagnosticsandbecamegeneralcounselconsumergroupsupplychaininshewasappointedworldwidevice presidentcorporategovernanceinfromtosheservedasgeneralcounselpharmaceuticalsinoctober shewasnamedexecutivevicepresidentgeneralcounselandbecameamemberoftheexecutivecommitteemsforminardhas worldwideresponsibilityforthelegalandprivacyfunctionsandleadsthedevelopmentandexecutionofthecompanysenvironment socialandgovernancestrategy drwhaitjoinedthecompanyinasseniorvicepresidentworldwideheadofoncologyresearchhethenservedasthe firstglobaltherapeuticareaheadforoncologyfromtoandthenasglobalheadjanssenresearchdevelopment fromthroughfromtohewasglobalheadjohnsonjohnsonglobalexternalinnovationinhe becameexecutivevicepresidentchiefexternalinnovationmedicalsafetyandglobalpublichealthofficerandamemberofthe executivecommitteeheisresponsibleforleadingexternalsourcingandcreationoftransformationalinnovationtohelpjohnson johnsonachieveitsmissiontoimprovehumanhealthutilizingthecompanysexcellenceinpharmaceuticalsmedicaldevicesand consumerproductshealsohasoversightoverglobalpublichealthandtheofficeofthechiefmedicalofficerasinterimheadof janssenrddrhaitsmissionistofocusthebestresearchanddevelopmentteamsintheworldattheintersectionofunmet medicalneedandbreakthroughsinscienceandtechnologytomakemedicineswithbenefitforpatientsworldwide msamcevoyjoinedthecompanyinasassistantbrandmanagerofmcneilconsumerhealthasubsidiaryofthecompany advancingthroughpositionsofincreasingresponsibilitiesuntilshewasappointedcompanygroupchairmanvisioncarein followedbycompanygroupchairmanconsumermedicaldevicesininjulymsmcevoywaspromotedtoexecutive vicepresidentworldwidechairmanmedtechandbecameamemberoftheexecutivecommitteemsmcevoyhasresponsibility forthesurgeryorthopaedicsinterventionalsolutionsandeyehealthbusinessesacrossethicondepuysynthesbiosensewebster abiomedandjohnsonjohnsonvision mrtmongonjoinedthecompanyinasdirectorofmarketingforthevisioncaregroupinfranceandsubsequentlyheld positionsofincreasingresponsibilityuntilhetransitionedtothepharmaceuticalsectorinastheglobalcommercialstrategy leaderfortheneurosciencetherapeuticareainhejoinedtheconsumerhealthsectorascompanygroupchairmanasia pacificinhewaspromotedtoexecutivevicepresidentandworldwidechairmanconsumerhealthandbecameamember oftheexecutivecommitteemrmongonhasresponsibilityfortheglobaldevelopmentofjohnsonjohnsonshealthandwellness productsandsolutionsinbeautyotcoralcarebabycarewomenshealthandwoundcare mrjswansonrejoinedthecompanyinaschiefinformationofficerofjohnsonjohnsonfrombayercropsciencewhere heservedasamemberoftheexecutiveleadershipteamandascioandheadofdigitaltransformationfromto mrswansonheldpositionsofincreasingresponsibilityatthecompanyincludingprojectmanagerdirectoritsrdirectoritand vicepresidentchiefinformationofficermrswansonisresponsibleforenhancingjohnsonjohnsonsbusinessimpactand shapingitsdirectionthroughthestrategicuseoftechnologymrswansonexecutivevicepresidententerprisechiefinformation officerjoinedtheexecutivecommitteeeffectivejanuary msjltaubertjoinedthecompanyinasworldwidevicepresidentandsheheldseveralexecutivepositionsofincreasing responsibilityinthepharmaceuticalsectorinshewasappointedcompanygroupchairmannorthamericapharmaceutical andinbecamecompanygroupchairmantheamericaspharmaceuticalsinjulymstaubertwaspromotedto executivevicepresidentworldwidechairmanpharmaceuticalsandbecameamemberoftheexecutivecommitteemstaubertis responsibleforthepharmaceuticalsectorgloballyincludingshapingthecompanysstrategyoftransformationalmedicalinnovation andforsuccessfullybringingtomarketcriticalnewmedicinesthatsignificantlyimprovethelivesofpatientslivingwithcancer immunerelateddiseasescardiovasculardiseaseinfectiousdiseasespulmonaryhypertensionandseriousmentalillness mskewengeljoinedthecompanyinasprojectengineerandengineeringsupervisoratjanssenasubsidiaryofthe companyduringhertenurewiththecompanyshehasheldavarietyofstrategicleadershipandexecutivepositionsincludingin roleswithinoperationsqualityengineeringnewproductsinformationtechnologyandothertechnicalandbusinessfunctionsin shewasnamedexecutivevicepresidentchiefglobalsupplychainofficerandbecameamemberoftheexecutive committeeinjanuaryshewasappointedexecutivevicepresidentchieftechnicaloperationsriskofficermswengel hasenterprisewideresponsibilitiesforkeytechnicaloperationsfunctionsincludingprocurementengineeringpropertyservices sustainabilityandcrosssectorsupplychainteamsfocusedonstandardsservicesstrategicprogramsanddatascienceand servesaschairofthecompanyssupplychainmanagementcommitteeshealsooverseescriticalriskfunctionsinclude qualitycompliancehealthcarecomplianceenvironmentalhealthsafetyglobalsecurityandglobalbrandprotection mrjjwolkjoinedthecompanyinasfinancemanagerbusinessdevelopmentfororthomcneilasubsidiaryofthe companyandthroughtheyearsheldavarietyofseniorleadershiprolesinseveralsegmentsandfunctionsacrossthecompany subsidiariesinpharmaceuticalsmedicaldevicesandsupplychainfromtoheservedasvicepresidentfinanceand chieffinancialofficerofthejanssenpharmaceuticalcompaniesofjohnsonjohnsoninmrwolkbecamethevice presidentinvestorrelationsinjulyhewasappointedexecutivevicepresidentchieffinancialofficerandbecameamember oftheexecutivecommitteemrwolkplaysastrategicroleintheoverallmanagementofthecompanyandleadsthedevelopment andexecutionofthecompanysgloballongtermfinancialstrategy johnsonjohnsonannualreport item market registrant common equity relate stockholder matter issuer purchase equity security asoffebruarytherewererecordholdersofcommonstockofthecompanyadditionalinformation calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisreportnotecommon stockstockoptionplansandstockcompensationagreementsofthenotestoconsolidatedfinancialstatement includedinitemanditemsecurityownershipofcertainbeneficialownersandmanagementandrelate stockholdermattersequitycompensationplaninformation issuer purchase equity security onseptemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyscommonstocksharerepurchasesmaybe madeatmanagementsdiscretionfromtimetotimeontheopenmarketorthroughprivatelynegotiatedtransactionsthe repurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytime thefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbythecompanyduringthefiscalfourth quarterofcommonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneed ofthecompanyscompensationprogramstherepurchasesbelowalsoincludethestockforstockoptionexercisesthat settledinthefiscalfourthquarter totalnumberof maximumnumberor sharesorunit approximatedollar purchasedaspart valueofsharesorunit totalnumber ofpublicly thatmayyetbe ofshare avgprice announcedplans purchasedunderthe fiscalperiod purchase paidpershare orprogram plansorprograms octoberthroughoctober octoberthrough november novemberthroughjanuary total duringthefiscalfourthquarterofthecompanyrepurchasedanaggregateofsharesofjohnsonjohnson commonstockinopenmarkettransactionsofwhichshareswerepurchasedpursuanttotherepurchaseprogramthat waspubliclyannouncedonseptemberandofwhichshareswerepurchasedaspartofasystematicplanto meettheneedsofthecompanyscompensationprograms asofjanuaryanaggregateofshareswerepurchasedforatotalofbillionsincetheinceptionofthe repurchaseprogramannouncedonseptember asofjanuarythemaximumnumberofsharesthatmayyetbepurchasedundertheplanisbasedontheclose priceofjohnsonjohnsoncommonstockonthenewyorkstockexchangeondecemberofpershare item reserve johnsonjohnsonannualreportitem management discussion analysis result operation financial condition organization business segment descriptionofthecompanyandbusinesssegment johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbee thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpharmaceuticalandmedtechthe consumerhealthsegmentincludesabroadrangeofproductsusedinthebabycareoralcareskinhealthbeauty overthecounterpharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedtothe generalpublicandsoldonlineecommerceandtoretailoutletsanddistributorsthroughouttheworldthe pharmaceuticalsegmentisfocusedonthefollowingtherapeuticareasincludingimmunologyinfectiousdiseases neuroscienceoncologypulmonaryhypertensionandcardiovascularandmetabolicdiseasesproductsinthissegment aredistributeddirectlytoretailerswholesalersdistributorshospitalsandhealthcareprofessionalsforprescriptionuse themedtechsegmentincludesabroadportfolioofproductsusedintheorthopaedicsurgeryinterventionalsolution cardiovascularandneurovascularandvisionfieldstheseproductsaredistributedtowholesalershospitalsandretailer andusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinics theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe consumerhealthpharmaceuticalandmedtechbusinesssegment inallofitsproductlinesthecompanycompeteswithothercompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolve competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotectingtheunderlyingintellectual propertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareasofitsbusinessthe competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthedevelopmentand maintenanceofcustomerdemandforthecompanysconsumerproductsinvolvessignificantexpendituresforadvertising andpromotion managementsobjective withourcredoasthefoundationthecompanyspurposeistoblendheartscienceandingenuitytoprofoundly changethetrajectoryofhealthforhumanitythecompanyiscommittedtobringingitsfullbreadthanddepthtoensure healthforpeopletodayandforfuturegenerationsunitedaroundthiscommonambitionthecompanyispoisedtofulfillits purposeandsuccessfullymeetthedemandsoftherapidlyevolvingmarketsinwhichitcompete thecompanyisbroadlybasedinhumanhealthcareandiscommittedtocreatingvaluebydevelopingaccessiblehigh qualityinnovativeproductsandservicesnewproductsintroducedwithinthepastfiveyearsaccountedforapproximately ofsalesinbillionwasinvestedinresearchanddevelopmentreflectingmanagement commitmenttocreatelifeenhancinginnovationsandtocreatevaluethroughpartnershipsthatwillprofoundlychangethe trajectoryofhealthforhumanity acriticaldriverofthecompanyssuccessisthediversityofitsemployeesworldwideemployeesare empoweredandinspiredtoleadwithourcredoandpurposeasguidesthisallowseveryemployeetousethe companysreachandsizetoadvancethecompanyspurposeandtoalsoleadwithagilityandurgencyleveragingthe extensiveresourcesacrosstheenterpriseenablesthecompanytoinnovateandexecutewithexcellencethisensuresthe companycanremainfocusedonaddressingtheunmetneedsofsocietyeverydayandinvestforanenduringimpact ultimatelydeliveringvaluetoitspatientsconsumersandhealthcareprofessionalsemployeescommunitiesand shareholders johnsonjohnsonannualreport snoillib snoillib srallod research acquisicidon net dividend pay development cash acquire share result operation analysisofconsolidatedsale fordiscussiononresultsofoperationsandfinancialconditionpertainingtothefiscalyearsandseethe companysannualreportonformkforthefiscalyearendedjanuaryitemmanagementsdiscussionand analysisofresultsofoperationsandfinancialcondition inworldwidesalesincreasedtobillionascomparedtoanincreaseofinthesesale changesconsistedofthefollowing salesincreasedecreasedueto volume price currency total thenetimpactofacquisitionsanddivestituresontheworldwidesalesgrowthwasanegativeimpactofinand anegativeimpactofin salesbyuscompanieswerebillioninandbillioninthisrepresentsincreasesofin andinsalesbyinternationalcompanieswerebillioninandbillioninthisrepresent adecreaseofinandanincreaseofin thefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively insalesbycompaniesineuropeexperiencedadeclineofascomparedtotheprioryearwhichinclude operationalgrowthofandanegativecurrencyimpactofsalesbycompaniesinthewesternhemisphere excludingtheusachievedgrowthofascomparedtotheprioryearwhichincludedoperationalgrowthof andanegativecurrencyimpactofsalesbycompaniesintheasiapacificafricaregionexperiencedadeclineof ascomparedtotheprioryearincludingoperationalgrowthofandanegativecurrencyimpactof inthecompanyutilizedthreewholesalersdistributingproductsforallthreesegmentsthatrepresente approximatelyandofthetotalconsolidatedrevenuesinthecompanyhadthreewholesaler distributingproductsforallthreesegmentsthatrepresentedapproximatelyandofthetotal consolidatedrevenue johnsonjohnsonannualreport sale geographic region billion sale segment billions europe western hemisphere consumer health pharmaceutical asiapacific africa medtech notevaluesmayhavebeenrounde analysis sale business segment consumerhealthsegment consumerhealthsegmentsalesinwerebillionadecreaseoffromwhichinclude operationalgrowthandanegativecurrencyimpactofusconsumerhealthsegmentsaleswerebillionan increaseofinternationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthanda negativecurrencyimpactofinacquisitionsanddivestitureshadanetnegativeimpactofonthe operationalsalesgrowthoftheworldwideconsumerhealthsegment majorconsumerhealthfranchisesale total operation currency dollarsinmillion change change change otc skinhealthbeauty oralcare babycare womenshealth woundcareother totalconsumerhealthsales certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation fiscalreflectsapproximatelybillionofcertaininternationalotcproductsprimarilyinchinawhichwerereclassifiedfrom thepharmaceuticalsegmenttotheconsumerhealthsegmentbasedonoperationalchange theotcfranchisesalesofbillionincreasedascomparedtotheprioryearoperationalgrowthwasprimarily attributabletoincreasedcoughcoldfluadultandpediatricincidencespriceactionsprimarilyintheusandincrease consumptioninchinaduetoeasingofcovidrestrictionsgrowthwaspartiallyoffsetbysupplyconstraint theskinhealthbeautyfranchisesalesofbilliondeclinedascomparedtotheprioryeartheoperational declinewasdrivenbysupplyconstraintsintheuspartiallyoffsetbypriceactionsandstrongnewproductperformance intheasiapacificandlatinamericaregion theoralcarefranchisesalesofbilliondeclinedascomparedtotheprioryeartheoperationaldeclinewas duetoportfoliosimplificationintheuscompetitivepressuresinemeaandchinacategorydeclineandprice pressuresinemeaaswellassuspensionofpersonalcaresalesinrussiaandnegativecovidimpactsinchina johnsonjohnsonannualreport thebabycarefranchisesalesofbilliondeclinedascomparedtotheprioryeartheoperationaldeclinewa drivenbycategorydecelerationandcompetitivepressuresintheussuspensionofpersonalcaresalesinrussiaand weaknessinindia thewomenshealthfranchisesalesofbilliondeclinedascomparedtotheprioryearoperationalgrowth drivenbylappingprioryearsupplyconstraintsinemeastrengthinindiaandpriceactionsinlatamwaspartiallyoffset bysuspensionofpersonalcaresalesinrussiaandnegativecurrencyimpact thewoundcareotherfranchisesalesofbilliondeclinedascomparedtotheprioryeartheoperational declinewasdrivenbylappingstrongprioryearconsumptioncompetitivepressureintheusanddecrease consumptioninchina innovemberthecompanyannounceditsintentiontoseparatethecompanysconsumerhealthbusinesskenvue asthenamefortheplannednewconsumerhealthcompanywiththeintentiontocreateanewpubliclytrade companybytheendofthefiscalyear johnsonjohnsonannualreportpharmaceutical segment pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofandanegativecurrencyimpactofussaleswerebillionanincreaseofinternational saleswerebillionanincreaseofwhichincludedoperationalgrowthandanegativecurrencyimpact ofinacquisitionsanddivestitureshadanetnegativeimpactofontheoperationalsalesgrowthofthe worldwidepharmaceuticalsegmentadjustmentstoprevioussalesreserveestimateswereapproximatelybillionand billioninfiscalyearsandrespectively majorpharmaceutical therapeuticareasale total operation currency dollarsinmillion change change change totalimmunology remicade simponisimponiaria stelara tremfya otherimmunology totalinfectiousdisease covidvaccine edurantrilpivirine prezistaprezcobixrezolstasymtuza otherinfectiousdisease totalneuroscience concertamethylphenidate invegasustennaxeplioninvegatrinzatrevicta risperdalconsta otherneuroscience totaloncology darzalex erleada imbruvica zytigaabirateroneacetate otheroncology totalpulmonaryhypertension opsumit uptravi otherpulmonaryhypertension totalcardiovascularmetabolismother xarelto invokanainvokamet totalpharmaceuticalsale certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation inclusiveofprocriteprexwhichwaspreviouslydisclosedseparately fiscalreflectsapproximatelybillionofcertaininternationalotcproductsprimarilyinchinawhichwerereclassifiedfrom thepharmaceuticalsegmenttotheconsumerhealthsegmentbasedonoperationalchange johnsonjohnsonannualreport immunologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearoperationalgrowthwasdrivenbystronguptakeofstelaraustekinumabincrohnsdiseaseandulcerative colitisandstrengthoftremfyaguselkumabinpsoriasisanduptakeinpsoriaticarthritisthiswaspartiallyoffsetby lowersalesofremicadeinfliximabduetobiosimilarcompetition biosimilarversionsofremicadehavebeenintroducedintheunitedstatesandcertainmarketsoutsidetheunite statesandadditionalcompetitorscontinuetoenterthemarketcontinuedinfliximabbiosimilarcompetitionwillresultina furtherreductioninsalesofremicade thelatestexpiringunitedstatespatentforstelaraustekinumabwillexpireinseptemberstelara ustekinumabussalesinfiscalwereapproximatelybillionandtheexpirationofthisproductpatentorlossof marketexclusivitywillresultinareductioninsales infectiousdiseaseproductssaleswerebillioninrepresentingadeclineofascomparedtotheprioryear operationalgrowthwasdrivenbythecovidvaccineoutsidetheuspartiallyoffsetbylowersalesofprezistaand prezcobixrezolstadarunavircobicistatduetoincreasedcompetitionandlossofexclusivityofprezistain certaincountriesoutsidetheus neuroscienceproductssaleswerebillioninrepresentingadeclineofascomparedtotheprioryear theoperationalsalesgrowthofinvegasustennaxeplionpaliperidonepalmitateandinvegatrinzatrevicta fromnewpatientstartsandpersistenceaswellasthelaunchofinvegahafyerawasoffsetbynegativecurrency impactsandlowersalesofrisperdalconsta oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearcontributionstooperationalgrowthwerestrongsalesofdarzalexdaratumumabdrivenbysharegainsinall regionscontinuedstrongmarketgrowthanduptakeofthesubcutaneousformulationaswellasthecontinuedglobal launchuptakeoferleadaapalutamidethiswaspartiallyoffsetbydecliningsalesofimbruvicaibrutinibdueto competitivepressuresandmarketsuppressionandzytigaduetolossofexclusivityintheeuropeanunioninthesecond halfof pulmonaryhypertensionproductssaleswerebillionadeclineofascomparedtotheprioryearthe operationalsalesgrowthofopsumitmacitentananduptraviselexipagduetocontinuedsharegainsandmarket growthwasoffsetbycovidrelatedimpactsandcontinueddeclinesinotherpulmonaryhypertension cardiovascularmetabolismotherproductssaleswerebillionadeclineofascomparedtotheprioryearthe operationaldeclinewasprimarilyattributabletolowersalesofinvokanainvokametcanagliflozinduetoshare erosionandprocriteprexepoetinalfaduetobiosimilarcompetition thecompanyupdateditspolicysothatnoendcustomerwillbepermitteddirectdeliveryofproducttoalocationother thanthebillinglocationthepolicyimpactscontractpharmacytransactionsinvolvingnongranteebcoveredentitie formostofthecompanysdrugssubjecttomultipleexceptionsbothgranteeandnongranteecoveredentitiescan maintaincertaincontractpharmacyarrangementsunderpolicyexceptionsthecompanyhasbeenandwillcontinueto offerbdiscountstocoveredentitiesonallofitscoveredoutpatientdrugsanditbelievesitspolicywillimproveits abilitytoidentifyinappropriateduplicatediscountsanddiversionprohibitedbythebstatutethebdrugprice programisausfederalgovernmentprogramrequiringdrugmanufacturerstoprovidesignificantdiscountsoncovere outpatientdrugstocoveredentitiesthispolicyupdatehaddiscountimplicationswhichpositivelyimpactedsalesto customersin johnsonjohnsonannualreportduringthecompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand additionalindicationsforexistingdrugsasfollows productnamechemical indication approval approval filing file aprocitentan treatmentfordifficulttotreathypertension cabenuvarilpivirineand hivtreatmentforadolescent cabotegravir carvykticiltacabtagene treatmentforpatientswithrelapsedorrefractorymultiple autoleucel myeloma erleadaapalutamide tabletreduction imbruvicaibrutinib treatmentforpediatricpatientswithchronicgraftversushost disease treatmentforfrontlinechroniclymphocyticleukemiaiv fixeddurationglow niraparib treatmentoflprostatecancermetastaticcastrationresistantin combinationwithabirateroneacetateandprednisone stelaraustekinumab treatmentofpediatricpatientswithjuvenilepsoriaticarthritis talquetamab treatmentofpatientswithrelapsedrefractorymultiplemyeloma teclistamabbcmacd treatmentofpatientswithrelapsedrefractorymultiplemyeloma johnsonjohnsonannualreport medtechsegment themedtechsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofandanegativecurrencyimpactofussaleswerebillionanincreaseofascompared totheprioryearinternationalsaleswerebillionadecreaseofascomparedtotheprioryearwhichinclude operationalgrowthofandanegativecurrencyimpactofinthenetimpactofacquisitionsand divestituresonthemedtechsegmentworldwideoperationalsalesgrowthwasapositive majormedtechfranchisesale total operation currency dollarsinmillion change change change surgery advanced general orthopaedic hip knee trauma spinesportsother vision contactlensesother surgical interventionalsolution totalmedtechsale certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation previouslyreferredtoasmedicaldevice thesurgeryfranchisesaleswerebillioninrepresentingadeclineoffromtheoperationalgrowth inadvancedsurgerywasprimarilydrivenbythefollowingendocuttermarketrecoveryandnewproductspartiallyoffset bycompetitivepressuresintheusbiosurgerymarketrecoveryandthesuccessofnewproductspartiallyoffsetby strongusmarketdemandintheprioryearforinfectionpreventionproductsandenergyproductsdrivenbymarket recoveryandnewproductpenetrationcoupledwithcompetitivesupplychallengestheoperationalgrowthingeneral surgerywasprimarilydrivenbymarketrecoveryandtechnologypenetration theorthopaedicsfranchisesaleswerebillioninwhichwasflattotheprioryeartheorthopaedicsfranchise includedoperationalsalesgrowthofoffsetbyanegativecurrencyimpactoftheoperationalgrowthinhip reflectsthemarketrecoverycombinedwithcontinuedstrengthoftheportfolioincludingtheactisstemandenable technologieskinciseandvelyshipnavigationthisgrowthwaspartiallyoffsetbyimpactsofvolumebased procurementinchinaandthetimingoftendersoutsidetheustheoperationalgrowthinkneeswasprimarilydrivenby procedurerecoverystrengthoftheattuneportfolioandpullthroughrelatedtothevelysroboticassistedsolution thisgrowthwaspartiallyoffsetbyimpactsofvolumebasedprocurementinchinaandtimingoftendersoutsidetheus theoperationalgrowthintraumawasdrivenbyglobalmarketrecoveryanduptakeofnewproductstheoperational growthinspinesportsotherwasprimarilydrivenbyprocedurerecoveryandnewproductintroductionsthisgrowth waspartiallyoffsetbycompetitivepressuresinspineandimpactsofvolumebasedprocurementinchina thevisionfranchiseachievedsalesofbillioninrepresentinganincreaseoffromthecontact lensesotheroperationalgrowthwasduetomarketrecoverypriceactionscommercialexecutionandbenefitsfromnew productssurgicalvisionoperationalgrowthwasprimarilyduetomarketrecoveryandthesuccessofnewproductsand waspartiallyoffsetbyahigherprioryearusrefractorymarket theinterventionalsolutionsfranchiseachievedsalesofbillioninrepresentinganincreaseoffrom operationalgrowthwasdrivenbymarketrecoveryandsuccessofnewproductsandcommercialstrategiesinterventional solutionsalsoincludessalesfromabiomedincabiomedwhichwerereflectedasofdecember johnsonjohnsonannualreportanalysisofconsolidatedearningsbeforeprovisionfortaxesonincome consolidatedearningsbeforeprovisionfortaxesonincomewasbillionandbillionfortheyearsand respectivelyasapercenttosalesconsolidatedearningsbeforeprovisionfortaxesonincomewasand inandrespectively earning provision taxis dollar billion percentage chart percent total sale costofproductssoldandsellingmarketingandadministrativeexpense cost product sell sell markecidng administracidve dollar billion percentage chart percent total sale costofproductssoldincreasedasapercenttosalesdrivenby onetimecovidvaccinemanufacturingexitrelatedcost currencyimpactsinthepharmaceuticalsegment commodityinflationinthemedtechandconsumerhealthsegment partiallyoffsetby supplychainbenefitsintheconsumerhealthsegment theintangibleassetamortizationexpenseincludedincostofproductssoldwasbillionandbillionforthefiscal yearsandrespectively sellingmarketingandadministrativeexpensesdecreasedasapercenttosalesdrivenby reductionofbrandmarketingexpensesinthepharmaceuticalandconsumerhealthbusinesse johnsonjohnsonannualreport researchanddevelopmentexpense researchanddevelopmentexpensebysegmentofbusinesswasasfollow dollarsinmillion ofsale ofsale consumerhealth pharmaceutical medtech totalresearchanddevelopmentexpense percentincreasedecreaseovertheprioryear asapercenttosegmentsale researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsupfrontpaymentsanddevelopmentalmilestone improvingexistingproductsaswellasensuringproductefficacyandregulatorycompliancepriortolaunchthecompany remainscommittedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproduct researchanddevelopmentdecreasedasapercenttosalesprimarilydrivenby lowermilestonepaymentsinthepharmaceuticalbusiness inprocessresearchanddevelopmentiprdinthefiscalyearthecompanyrecordedanintangibleasset impairmentchargeofapproximatelybillionrelatedtoaninprocessresearchanddevelopmentassetbermekimab jnjaninvestigationaldrugforthetreatmentofatopicdermatitisadandhidradenitissuppurativahs additionalinformationregardingefficacyoftheadindicationandhsindicationbecameavailablewhichledthecompany tothedecisiontoterminatethedevelopmentofbermekimabforbothadandhsthecompanyacquiredallrightsto bermekimabfromxbiotechincinthefiscalyearinfiscalyearthecompanyrecordedapartialiprdcharge ofbillionprimarilyrelatedtoexpecteddevelopmentdelaysinthegeneralsurgerydigitalroboticsplatformottava acquiredwiththeaurishealthacquisitionintheimpairmentchargewascalculatedbasedonrevisionstothe discountedcashflowvaluationmodelreflectingadelayoffirstinhumanproceduresofapproximatelytwoyearsfromthe initialacquisitionmodelassumptionofthesecondhalfofthecompanywillcontinuetomonitortheremaining billionottavaplatformintangibleassetasdevelopmentprogramactivitiesareongoing otherincomeexpensenetotherincomeexpensenetistheaccountwherethecompanyrecordsgainsand lossesrelatedtothesaleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnson innovationjjdcincjjdcchangesinthefairvalueofsecuritiesinvestmentincomelossrelatedtoemployeebenefit programsgainsandlossesondivestiturescertaintransactionalcurrencygainsandlossesacquisitionanddivestiture relatedcostslitigationaccrualsandsettlementsaswellasroyaltyincome otherincomeexpensenetforthefiscalyearwasunfavorablebybillionascomparedtotheprioryear primarilyduetothefollowe dollarsinbillionsincomeexpense change consumerhealthseparationcost litigationrelate changesinthefairvalueofsecuritie onetimecovidvaccinemanufacturingexitrelatedcost acquisitionintegrationanddivestiturerelate restructuringrelate employeebenefitplanrelate totalotherincomeexpensenet wasprimarilyrelatedtopelvicmeshandwasprimarilyrelatedtotalcandrisperdalgynecomastia wasprimarilycostsrelatedtotheacquisitionofabiomedwasprimarilyrelatedtodivestituregainsoftwopharmaceutical brandsoutsidetheus johnsonjohnsonannualreportinterestincomeexpenseinterestincomeexpenseinthefiscalofwasnetinterestincomeofmillionas comparedtointerestexpenseofmillioninthefiscalyearprimarilyduetohigherratesofinterestearnedon cashbalancescashcashequivalentsandmarketablesecuritiestotaledbillionattheendofandaverage billionascomparedtothecashcashequivalentsandmarketablesecuritiestotalofbillionandbillion averagecashbalanceinthetotaldebtbalanceattheendofwasbillionwithanaveragedebtbalance ofbillionascomparedtobillionattheendofandanaveragedebtbalanceofbillionthelower averagecashcashequivalentsandmarketablesecuritiesandhigheraveragedebtbalancewereprimarilyduetothe acquisitionofabiomedinlatedecemberof incomebeforetaxbysegment incomelossbeforetaxbysegmentofbusinesswereasfollow percentof incomebeforetax segmentsale segmentsale dollarsinmillions consumerhealth pharmaceutical medtech segmentearningsbeforetax lessexpensesnotallocatedtosegment lessconsumerhealthseparationcost worldwideincomebeforetax seenotetotheconsolidatedfinancialstatementsformoredetail amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense prioryearincomebeforetaxofapproximatelybillionhasbeenreclassifiedascertaininternationalotcproductsprimarilyin chinawerereclassifiedfromthepharmaceuticalsegmenttotheconsumerhealthsegmentbasedonoperationalchange consumerhealthsegmentintheconsumerhealthsegmentincomebeforetaxasapercentofsaleswa versusintheincreaseintheincomebeforetaxasapercentofsaleswasprimarilydrivenbythe follow lowerlitigationexpenseofbillioninversusbillionprimarilytalcrelatedin reductioninbrandmarketingexpensesinversus supplychainbenefitsin partiallyoffsetby commodityinflationin pharmaceuticalsegmentinthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswas versusinthedecreaseintheincomebeforetaxasapercentofsaleswasprimarilydrivenbythefollowe onetimecovidvaccinemanufacturingexitrelatedcostsofbillionin unfavorablechangesinthefairvalueofsecuritiesbillionlossinvsbilliongainin aniprdchargeofbillioninrelatedtobermekimabjnjaninvestigationaldrugforthe treatmentofatopicdermatitisadandhidradenitissuppurativahs lowerdivestituregainsofbillioninversusbillionrelatedtotwopharmaceuticalbrandsoutsidetheus infiscal currencyimpactsincostofproductssold johnsonjohnsonannualreport partiallyoffsetby lowerlitigationrelatedexpenseofbillioninversusbillionprimarilyrelatedtorisperdalgynecomastia lowerresearchdevelopmentmilestonepaymentsin lowerbrandmarketingexpensesinversus infiscalandthecompanyenteredintoaseriesofcontractmanufacturingarrangementsforvaccine productionwiththirdpartycontractmanufacturingorganizationsthesearrangementsprovidedthecompanywith supplementalcommercialcapacityforvaccineproductionandpotentiallytransferablerightstosuchproductionifcapacity isnotrequiredthecompanycontinuestoevaluateandmonitorbothitsinternalandexternalsupplyarrangementsin fiscalthecovidvaccinerelatedcostsmentionedaboveincludedtheremainingcommitmentsand obligationsincludingexternalmanufacturingnetworkexitandrelatedinventorycostsandrequiredclinicaltrialexpense associatedwiththecompanysmodificationofitscovidvaccineresearchprogramandmanufacturingcapacityto levelsthatmeetallremainingcustomercontractualrequirement medtechsegmentinthemedtechsegmentincomebeforetaxasapercenttosaleswasversus intheincreaseintheincomebeforetaxasapercenttosaleswasprimarilydrivenbythefollowe aniprdchargeofbillioninrelatedtothegeneralsurgeryofferingindigitalroboticsottavaacquiredwith theaurishealthacquisitionin partiallyoffsetby higherlitigationrelatedexpenseofbillioninprimarilyrelatedtopelvicmeshcostsversusbillionin acquisitionrelatedcostsofbillioninrelatedtotheabiomedacquisitionversusbillionin restructuringinthefiscalsecondquarterofthecompanyannouncedplanstoimplementactionsacrossit globalsupplychainthatareintendedtoenablethecompanytofocusresourcesandincreaseinvestmentsincritical capabilitiestechnologiesandsolutionsnecessarytomanufactureandsupplyitsproductportfolioofthefutureenhance agilityanddrivegrowththeglobalsupplychainactionsincludedexpandingitsuseofstrategiccollaborationsand bolsteringitsinitiativestoreducecomplexityimprovingcostcompetitivenessenhancingcapabilitiesandoptimizingit supplychainnetworkthecompanyhasachievedapproximatelybillioninannualpretaxcostsavingsasoutlinedin therestructuringactionsinthecompanyrecordedapretaxchargeofbillionwhichisincludedonthe followinglinesoftheconsolidatedstatementofearningsbillioninrestructuringbillioninotherincome expenseandbillionincostofproductssoldtotalprojectcostsofapproximatelybillionhavebeenrecorded sincetherestructuringwasannouncedtheprogramwascompletedinthefiscalfourthquarterof seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtotherestructuringprogram provisionfortaxesonincometheworldwideeffectiveincometaxratewasinandin inthefiscalthecompanyincurredapproximatelybillionnetincrementalinternationaltaxcostrelatedtothe legalseparationoftheconsumerhealthbusinessandmaycontinuetoincuradditionalcostinfiscal ondecembertheeuropeanunioneumemberstatesformallyadoptedtheeuspillartwodirectivewhich generallyprovidesforaminimumeffectivetaxrateofasestablishedbytheorganizationforeconomiccooperation anddevelopmentoecdpillartwoframeworkthatwassupportedbyovercountriesworldwidetheeueffective datesarejanuaryandjanuaryfordifferentaspectsofthedirective asignificantnumberofothercountriesareexpectedtoalsoimplementsimilarlegislationincludingsouthkoreawhich approvedlegislationondecemberwithafulleffectivedateofjanuarythecompanyiscontinuingto evaluatethepotentialimpactonfutureperiodsofthepillartwoframeworkpendinglegislativeadoptionbyadditional individualcountriesincludingthosewithintheeuropeanunion fordiscussionrelatedtothefiscalprovisionfortaxesrefertonotetotheconsolidatedfinancialstatement johnsonjohnsonannualreportliquidity capital resource liquiditycashflow cashandcashequivalentswerebillionattheendofascomparedtobillionattheendof theprimarysourcesandusesofcashthatcontributedtothebilliondecreasewere dollarsinbillion qcashandcashequivalentsbalance cashgeneratedfromoperatingactivitie netcashusedbyinvestingactivitie netcashusedbyfinancingactivitie effectofexchangerateandrounde qcashandcashequivalentsbalance inadditionthecompanyhadbillioninmarketablesecuritiesattheendoffiscalyearandbillionatthe endoffiscalyearseenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncashcash equivalentsandmarketablesecuritie cashflowfromoperationsofbillionwastheresultof dollarsinbillion netearning noncashexpensesandotheradjustmentsprimarilyfordepreciationandamortizationstockbasedcompensation andassetwritedownspartiallyoffsetbythedeferredtaxprovisionnetgainonsaleofassetsbusinessesand creditlossesandaccountsreceivableallowance adecreaseincurrentandnoncurrentliabilitie adecreaseinothercurrentandnoncurrentasset anincreaseinaccountspayableandaccruedliabilitie anincreaseinaccountsreceivableandinventorie cashflowfromoperation investingactivitiesuseofbillionofcashwasprimarilyusedfor dollarsinbillion additionstopropertyplantandequipment acquisition proceedsfromthedisposalofassetsbusinessesnet netsalesofinvestment creditsupportagreementsactivitynet otherprimarilylicensesandmilestonesandrounding netcashusedforinvestingactivitie johnsonjohnsonannualreport financingactivitiesuseofbillionofcashwasprimarilyusedfor dollarsinbillion dividendstoshareholder repurchaseofcommonstock netproceedsfromshortandlongtermdebt proceedsfromstockoptionsexercisedemployeewithholdingtaxonstockawardsnet netcashusedforfinancingactivitie asofjanuarythecompanysnotespayableandlongtermdebtwasinexcessofcashcashequivalentsand marketablesecuritiesasofjanuarythenetdebtpositionwasbillionascomparedtotheprioryearof billiontheincreasewasprimarilyduetotheacquisitionofabiomedincindecemberthedebtbalanceatthe endofwasbillionascomparedtobillioninconsideringrecentmarketconditionsthecompany hasreevaluateditsoperatingcashflowsandliquidityprofileanddoesnotforeseeanysignificantincrementalriskthe companyanticipatesthatoperatingcashflowstheabilitytoraisefundsfromexternalsourcesborrowingcapacityfrom existingcommittedcreditfacilitiesandaccesstothecommercialpapermarketswillcontinuetoprovidesufficient resourcestofundoperatingneedsincludingthecompanysremainingbalancetobepaidontheagreementtosettle opioidlitigationforapproximatelybillionandtheestablishmentofthebilliontrustfortalcrelatedliabilitiessee notetotheconsolidatedfinancialstatementsforadditionaldetailsinadditionthecompanymonitorstheglobal capitalmarketsonanongoingbasisandfromtimetotimemayraisecapitalwhenmarketconditionsarefavorable effectivebeginninginfiscaltheustaxcutsandjobactoftcjarequiresthecompanytodeductus andinternationalresearchanddevelopmentexpendituresfortaxpurposesovertoyearsinsteadofinthecurrent fiscalyearasaresultinfiscalthecompanyexperiencedanincreaseinannualcashtaxpaymentsofapproximately billionabovewhatotherwisewouldhavebeenremittedtotheustreasurythecompanyconcurrentlyrecordsa deferredtaxbenefitforthefutureamortizationoftheresearchanddevelopmentrdfortaxpurposestherequirement toexpenserdasincurredisunchangedforusgaappurposesandtheimpacttopretaxrdexpenseisnotaffecte bythisprovision onseptemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyscommonstocksharerepurchasesmaybe madeatmanagementsdiscretionfromtimetotimeontheopenmarketorthroughprivatelynegotiatedtransactionsthe repurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytimeanysharesacquire willbeavailableforgeneralcorporatepurposesthecompanyintendstofinancethesharerepurchaseprogramthrough availablecashthroughjanuaryapproximatelybillionhasbeenrepurchasedundertheprogram thefollowingtablesummarizesthecompanysmaterialcontractualobligationsandtheiraggregatematuritiesasof januarytosatisfytheseobligationsthecompanyintendstousecashfromoperations tax intereston legislation debt debt dollarsinmillion tcja obligation obligation total total fortaxmattersseenotetotheconsolidatedfinancialstatement johnsonjohnsonannualreportfinancingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflow accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosse onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar fromthejanuarymarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby billionconverselyadepreciationoftheusdollarfromthejanuarymarketrateswoulddecreasethe unrealizedvalueofthecompanysforwardcontractsbybillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflow thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelybillionineitherscenarioatmaturitythegainor lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedcashflow thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditratingthecounterpartiesto thesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremotethecompanyenteredintocreditsupportagreement csawithcertainderivativecounterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsand nettingagreementsseenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncreditsupport agreement thecompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate riskthefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrateswhilefloate ratesecuritiesmayproducelessincomethanpredictedifinterestratesfallabasispointschangeinspreadon thecompanysinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash equivalentsandcurrentmarketablesecuritiesbylessthanbillion thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilityofbillionwhichexpiresonseptemberinnovember thecompanysecuredanadditionaldayrevolvingcreditfacilityofbillionwhichhasanexpirationof novemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneithersecure overnightfinancingratesofrreferencerateorotherapplicablemarketrateasallowedplusapplicablemargin commitmentfeesundertheagreementarenotmaterial totalborrowingsattheendofandwerebillionandbillionrespectivelytheincreasein borrowingswasduetotheacquisitionofabiomedincinnetdebtcashandcurrentmarketablesecuritiesnetof debtwasbillioncomparedtonetdebtofbillionintotaldebtrepresentedoftotalcapital shareholdersequityandtotaldebtinandoftotalcapitalinshareholdersequitypershareattheend ofwascomparedtoatyearend asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatement dividend thecompanyincreaseditsdividendinforthethconsecutiveyearcashdividendspaidwerepersharein andpersharein onjanuarytheboardofdirectorsdeclaredaregularcashdividendofpersharepayableonmarch toshareholdersofrecordasoffebruary information criticalaccountingpoliciesandestimate managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompany consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin johnsonjohnsonannualreport theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosure actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockbasedawards revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofa contractwiththecustomeraresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthe companysglobalpaymenttermsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentive tradepromotionscouponsproductreturnsdiscountstocustomersandgovernmentalclawbackprovisionsareaccounte forasvariableconsiderationandrecordedasareductioninsale productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarket servedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof wholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccrual salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerhealthandpharmaceuticalsegmentsarealmostexclusivelynotresalablesale returnsforcertainfranchisesinthemedtechsegmentaretypicallyresalablebutarenotmaterialthecompany infrequentlyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyha beenapproximatelyofannualnettradesalesduringthefiscalyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsofcertain productswhichareincludedinsalestocustomersprofitsharepaymentswerelessthanofthetotalrevenuesin fiscalyearandlessthanofthetotalrevenuesinfiscalyearsandandareincludedinsalesto customer inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivitie amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivere basedontherelativesellingpriceupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover theperformanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaboration reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchange toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact johnsonjohnsonannualreportbelowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedjanuaryandjanuary consumerhealthsegment balanceat balanceat beginning payment endof dollarsinmillion ofperiod accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset pharmaceutical segment balanceat balanceat beginning payment endof dollarsinmillion ofperiod accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset includespriorperiodadjustment johnsonjohnsonannualreport medtechsegment balanceat balanceat beginning payment endof dollarsinmillion ofperiod accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset incometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitie thecompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesin taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilitie thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromit internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetaxeffectofthisrepatriationwouldbeapproximatelybillionunder currentlyenactedtaxlawsandregulationsandatcurrentcurrencyexchangeratesthisamountdoesnotincludethe possiblebenefitofusforeigntaxcreditswhichmaysubstantiallyoffsetthiscost seenoteandnotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxe legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimate thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimate johnsonjohnsonannualreportseenotesandtotheconsolidatedfinancialstatementsforfurtherinformationregardingproductliabilityandlegal proceeding longlivedandintangibleassetsthecompanyassesseschangesbothqualitativelyandquantitativelyineconomic conditionsandmakesassumptionsregardingestimatedfuturecashflowsinevaluatingthevalueofthecompany propertyplantandequipmentgoodwillandintangibleassetsastheseassumptionsandestimatesmaychangeovertime itmayormaynotbenecessaryforthecompanytorecordimpairmentcharge employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsmortalityratesexpectedsalaryincreaseshealthcare costtrendratesandattritionratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsonthese rate stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesbasedonthetypeofequityinstrumentthefairvalueisestimatedonthedate ofgrantusingeithertheblackscholesoptionvaluationmodeloracombinationofboththeblackscholesoption valuationmodelandmontecarlovaluationmodelandisexpensedinthefinancialstatementsovertheserviceperiodthe inputassumptionsusedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandexpected dividendyieldforperformanceshareunitsthefairmarketvalueiscalculatedforthetwocomponentgoalsatthedateof grantadjustedoperationalearningspershareandrelativetotalshareholderreturnthefairvaluesfortheearningsper sharegoalofeachperformanceshareunitwasestimatedonthedateofgrantusingthefairmarketvalueofthesharesat thetimeoftheawarddiscountedfordividendswhicharenotpaidontheperformanceshareunitsduringtheveste periodthefairvaluefortherelativetotalshareholderreturngoalofeachperformanceshareunitwasestimatedonthe dateofgrantusingthemontecarlovaluationmodelseenotetotheconsolidatedfinancialstatementsforadditional information newaccountingpronouncement refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofjanuary economicandmarketfactor thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymaker consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcern thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheusthe weightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproduct prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi thecompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallengesthe companycontinuestomonitorthesesituationsandtakeappropriateactionsinflationratescontinuetohaveaneffecton worldwideeconomiesandconsequentlyonthewaycompaniesoperatethecompanyhasaccountedforoperationsin argentinaandvenezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassedbeginning inthefiscalsecondquarterofthecompanyaccountedforoperationsinturkeyashighlyinflationaryastheprior threeyearcumulativeinflationratesurpassedthisdidnothaveamaterialimpacttothecompanysresultsinthe periodinthefaceofincreasingcoststhecompanystrivestomaintainitsprofitmarginsthroughcostreductionprograms productivityimprovementsandperiodicpriceincrease russiaukrainewar althoughthelongtermimplicationsofrussiasinvasionofukrainearedifficulttopredictatthistimethefinancialimpact oftheconflictinthefiscalincludingaccountsreceivableorinventoryreserveswasnotmaterialasofboththefiscal yearsendingjanuaryandjanuarythebusinessofthecompanysukrainesubsidiariesrepresentedless thanofthecompanysconsolidatedassetsandrevenuesasofboththefiscalyearsendingjanuaryand januarythebusinessofthecompanysrussiansubsidiariesrepresentedlessthanofthecompanys consolidatedassetsandrepresentedofrevenue inearlymarchthecompanytookstepstosuspendalladvertisingenrollmentinclinicaltrialsandanyadditional investmentinrussiaadditionallyattheendofmarchthecompanymadethedecisiontosuspendsupplyofpersonal johnsonjohnsonannualreport careproductsinrussiathecompanycontinuestosupplyitsotherproductsaspatientsrelyonmanyoftheproductsfor healthcarepurpose thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollaras comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelybillionandnetincomebyapproximatelybillion governmentsaroundtheworldconsidervariousproposalstomakechangestotaxlawswhichmayincludeincreasingor decreasingexistingstatutorytaxratesinconnectionwithvariousgovernmentinitiativescompaniesarerequiredto disclosemoreinformationtotaxauthoritiesonoperationsaroundtheworldwhichmayleadtogreaterauditscrutinyof profitsearnedinothercountriesachangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthe companysdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawis enactedthischangewouldresultinanexpenseorbenefitrecordedtothecompanysconsolidatedstatementof earningsthecompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperateschangestothe statutorytaxratemayoccuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarter andyearinwhichthelawchangeisenacte thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionspricingandreimbursementof healthcareproduct changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaye medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoe healthcareinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthe companysbusinesse thecompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrightsfirmshavefile abbreviatednewdrugapplicationsorbiosimilarbiologicalproductapplicationswiththeusfdaorotherwise challengedthecoverageandorvalidityofthecompanyspatentsseekingtomarketgenericorbiosimilarformsofmany ofthecompanyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsinthe eventthecompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuitsgenericor biosimilarversionsoftheproductsatissuewillbeintroducedtothemarketresultinginthepotentialforsubstantialmarket shareandrevenuelossesforthoseproductsandwhichmayresultinanoncashimpairmentchargeinanyassociate intangibleassetthereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionofthe productatissuefollowingregulatoryapprovaleventhoughoneormorevalidpatentsareinplace legalproceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialemploymentindemnificationandothermattersgovernmentalinvestigationsandother legalproceedingsthatarisefromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofjanuarythecompanyhas determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthe companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascfortheseand otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompany isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccruedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuchestimatesandjudgmentscanbe affectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtintheproceedingsare unsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedorisnotcompleteproceedingsarein earlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindisputeproceduralorjurisdictionalissue theuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachievecomprehensivemultiparty settlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerouspartiesinvolvedtothe extentadverseawardsjudgmentsorverdictshavebeenrenderedagainstthecompanythecompanydoesnotrecordan accrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimate johnsonjohnsonannualreportinthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsincludedinitemofthisreportforfurtherinformationregarde legalproceeding commonstock thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompany item quantitative qualitative disclosure market risk theinformationcalledforbythisitemisincorporatedhereinbyreferencetoitemmanagementsdiscussionand analysisofresultsofoperationsandfinancialconditionliquidityandcapitalresourcesfinancingandmarket riskofthisreportandnotesummaryofsignificantaccountingpoliciesfinancialinstrumentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreport item financial statement supplementary data indextoauditedconsolidatedfinancialstatement consolidatedbalancesheet consolidatedstatementsofearning consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflow notestoconsolidatedfinancialstatement reportofindependentregisteredpublicaccountingfirmpcaobid managementsreportoninternalcontroloverfinancialreporte johnsonjohnsonannualreport johnson johnson subsidiaries consolidate balance sheet atjanuaryandjanuary dollarsinmillionsexceptshareandpershareamountsnote asset currentasset cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccount inventoriesnotesand prepaidexpensesandotherreceivable totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherasset totalasset liabilitiesandshareholdersequity currentliabilitie loansandnotespayablenote accountspayable accruedliabilitie accruedrebatesreturnsandpromotion accruedcompensationandemployeerelatedobligation accruedtaxesonincomenote totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand longtermtaxespayablenote otherliabilitie totalliabilitie commitmentsandcontingenciesnote shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshare commonstockparvaluepersharenoteauthorizedsharesissue share accumulatedothercomprehensiveincomelossnote retainedearning lesscommonstockheldintreasuryatcostnotesharesandshare totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement earning dollarsandsharesinmillionsexceptpershareamountsnote salestocustomer costofproductssold grossprofit sellingmarketingandadministrativeexpense researchanddevelopmentexpense inprocessresearchanddevelopmentnote interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearning netearningspersharenotesand basic diluted averagesharesoutstandingnotesand basic diluted seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement comprehensive income dollarsinmillionsnote netearning othercomprehensiveincomelossnetoftax foreigncurrencytranslation security unrealizedholdinggainlossarisingduringperiod reclassificationstoearning netchange employeebenefitplans priorservicecreditcostnetofamortization gainlossnetofamortization effectofexchangerate netchange derivativeshedge unrealizedgainlossarisingduringperiod reclassificationstoearning netchange othercomprehensiveincomeloss comprehensiveincome thetaxeffectsinothercomprehensiveincomeforthefiscalyearsandrespectivelyforeigncurrency translationmillionmillionandmillionsecuritiesmillionandmillioninand employeebenefitplansmillionmillionandmillionderivativeshedgesmillionmillion andmillion seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement equity dollarsinmillionsnote accumulate common stock treasury retain comprehensive issue stock total earning incomeloss balancedecember netearning cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary netearning cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary netearning cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement cash flow dollarsinmillionsnote cashflowsfromoperatingactivitie netearning adjustmentstoreconcilenetearningstocashflowsfromoperatingactivitie depreciationandamortizationofpropertyandintangible stockbasedcompensation assetwritedown contingentconsiderationreversal netgainonsaleofassetsbusinesse deferredtaxprovision creditlossesandaccountsreceivableallowance changesinassetsandliabilitiesnetofeffectsfromacquisitionsanddivestiture increasedecreaseinaccountsreceivable increaseininventorie increaseinaccountspayableandaccruedliabilitie decreaseincreaseinothercurrentandnoncurrentasset decreaseincreaseinothercurrentandnoncurrentliabilitie netcashflowsfromoperatingactivitie cashflowsfrominvestingactivities additionstopropertyplantandequipment proceedsfromthedisposalofassetsbusinessesnet acquisitionsnetofcashacquirednote purchasesofinvestment salesofinvestment creditsupportagreementsactivitynet otherprimarilylicensesandmilestone netcashusedbyinvestingactivitie cashflowsfromfinancingactivitie dividendstoshareholder repurchaseofcommonstock proceedsfromshorttermdebt repaymentofshorttermdebt proceedsfromlongtermdebtnetofissuancecosts repaymentoflongtermdebt proceedsfromtheexerciseofstockoptionsemployeewithholdingtaxonstockawardsnet creditsupportagreementsactivitynet netcashusedbyfinancingactivities effectofexchangeratechangesoncashandcashequivalent decreaseincreaseincashandcashequivalent cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest interestnetofamountcapitalize incometaxe supplementalscheduleofnoncashinvestingandfinancingactivitie treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceedsemployee withholdingtaxonstockaward conversionofdebt acquisition fairvalueofassetsacquired fairvalueofliabilitiesassume netcashpaidforacquisitionsnote seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportnote consolidated financial statement summary significant accounting policy principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminatedcolumnsandrowswithintablesmaynotaddduetorounde percentageshavebeencalculatedusingactualnonroundedfigure descriptionofthecompanyandbusinesssegment thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbee thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpharmaceuticalandmedtechthe consumerhealthsegmentincludesabroadrangeofproductsusedinthebabycareoralcareskinhealthbeauty overthecounterpharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedtothe generalpublicandsoldonlineecommerceandtoretailoutletsanddistributorsthroughouttheworldthe pharmaceuticalsegmentisfocusedonthefollowingtherapeuticareasincludingimmunologyinfectiousdiseases neuroscienceoncologypulmonaryhypertensionandcardiovascularandmetabolicdiseasesproductsinthissegment aredistributeddirectlytoretailerswholesalersdistributorshospitalsandhealthcareprofessionalsforprescriptionuse themedtechsegmentincludesabroadportfolioofproductsusedintheorthopaedicsurgeryinterventionalsolution cardiovascularandneurovascularandvisionfieldstheseproductsaredistributedtowholesalershospitalsandretailer andusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinics innovemberthecompanyannounceditsintentiontoseparatethecompanysconsumerhealthbusinesskenvue asthenamefortheplannednewconsumerhealthcompanywiththeintentiontocreateanewpubliclytrade companybytheendofthefiscalyear newaccountingstandard recentlyadoptedaccountingstandard therewerenonewmaterialaccountingstandardsadoptedinfiscal recentlyissuedaccountingstandard notadoptedasofjanuary asuliabilitiessupplierfinanceprogramstopicdisclosureofsupplierfinanceprogram obligation thisupdaterequiresthatabuyerinasupplierfinanceprogramdiscloseadditionalinformationabouttheprogramtoallow financialstatementuserstobetterunderstandtheeffectoftheprogramsonanentitysworkingcapitalliquidityandcash flowsthisupdatewillbeeffectiveforthecompanyforfiscalyearsbeginningafterdecemberexceptforthe amendmentonrollforwardinformationwhichiseffectiveforfiscalyearsbeginningafterdecemberearly adoptionispermittedthecompanyiscurrentlyassessingtheimpactofthisupdateonitsdisclosuresandwilladoptthis standardinthefiscalfirstquarterof cashequivalent thecompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof purchaseascurrentmarketablesecuritiesthecompanyhasapolicyofmakinginvestmentsonlywithcommercial institutionsthathaveatleastaninvestmentgradecreditratingthecompanyinvestsitscashprimarilyingovernment securitiesandobligationscorporatedebtsecuritiesmoneymarketfundsandreverserepurchaseagreementsrra rrasarecollateralizedbydepositsintheformofgovernmentsecuritiesandobligationsforanamountnotlessthan oftheirvaluethecompanydoesnotrecordanassetorliabilityasthecompanyisnotpermittedtosellor johnsonjohnsonannualreport repledgetheassociatedcollateralthecompanyhasapolicythatthecollateralhasatleastanaorequivalentcredit ratingthecompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis maintainedatofthevalueoftherrasonadailybasisrraswithstatedmaturitiesofgreaterthanthreemonth fromthedateofpurchaseareclassifiedasmarketablesecuritie investment investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare reportedinearningsinvestmentsclassifiedasavailableforsaledebtsecuritiesarecarriedatestimatedfairvaluewith unrealizedgainsandlossesrecordedasacomponentofaccumulatedothercomprehensiveincomeavailableforsale securitiesavailableforcurrentoperationsareclassifiedascurrentassetsotherwisetheyareclassifiedaslongterm managementdeterminestheappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeof purchaseandreevaluatessuchdeterminationateachbalancesheetdatethecompanyreviewsitsinvestmentsfor impairmentandadjuststheseinvestmentstofairvaluethroughearningsasrequire propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheasset buildingandbuildingequipment year landandleaseholdimprovement year machineryandequipment year thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflow revenue recognition thecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofacontractwiththecustomer aresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthecompanysglobalpayment termsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentivestradepromotionscoupon productreturnsdiscountstocustomersandgovernmentalclawbackprovisionsareaccountedforasvariable considerationandrecordedasareductioninsalestheliabilityisrecognizedwithinaccruedrebatesreturnsand promotionsontheconsolidatedbalancesheet productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarket servedasignificantportionoftheliabilityrelatedtorebatesisfromthesaleofthecompanyspharmaceuticalproduct withintheusprimarilythemanagedcaremedicareandmedicaidprogramswhichamountedtobillionand billionasofjanuaryandjanuaryrespectivelythecompanyevaluatesmarketconditionsfor productsorgroupsofproductsprimarilythroughtheanalysisofwholesalerandotherthirdpartysellthroughandmarket researchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccrual johnsonjohnsonannualreportsalesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerhealthandpharmaceuticalsegmentsarealmostexclusivelynotresalablesale returnsforcertainfranchisesinthemedtechsegmentaretypicallyresalablebutarenotmaterialthecompany infrequentlyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyha beenapproximatelyofannualnettradesalesduringeachofthefiscalyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsforcertain productswhichareincludedinsalestocustomersprofitsharepaymentswerelessthanofthetotalrevenuesin fiscalyearandlessthanofthetotalrevenuesinfiscalyearsandandareincludedinsalesto customer seenotetotheconsolidatedfinancialstatementsforfurtherdisaggregationofrevenue shippingandhandle shippingandhandlingcostsincurredwerebillionbillionandbillioninfiscalyearsand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresente inventory inventoriesarestatedatthelowerofcostornetrealizablevaluedeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassesse annuallyforimpairmentthecompanycompleteditsannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedpurchasedinprocess researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscomplete atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetifwarrantedthepurchasedin processresearchanddevelopmentcouldbewrittenofforpartiallyimpaireddependingontheunderlyingprogram intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstrument asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearning orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash johnsonjohnsonannualreport flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instrument lease thecompanydetermineswhetheranarrangementisaleaseatcontractinceptionbyestablishingifthecontractconvey therighttocontroltheuseofidentifiedpropertyplantorequipmentforaperiodoftimeinexchangeforconsideration rightofuserouassetsandleaseliabilitiesforoperatingleasesareincludedinotherassetsaccruedliabilitiesand otherliabilitiesontheconsolidatedbalancesheettherouassetsrepresenttherighttouseanunderlyingassetforthe leasetermandleaseliabilitiesrepresentanobligationtomakeleasepaymentsarisingfromtheleasecommitmentsunder financeleasesarenotsignificantandareincludedinpropertyplantandequipmentloansandnotespayableandlong termdebtontheconsolidatedbalancesheet rouassetsandleaseliabilitiesarerecognizedattheleasecommencementdatebasedonthepresentvalueofall minimumleasepaymentsovertheleasetermthecompanyusesitsincrementalborrowingratebasedontheinformation availableatcommencementdateindeterminingthepresentvalueofleasepaymentswhentheimplicitrateisnotreadily determinableleasetermsmayincludeoptionstoextendorterminatetheleasetheseoptionsareincludedinthelease termwhenitisreasonablycertainthatthecompanywillexercisethatoptionoperatingleaseexpenseisrecognizedona straightlinebasisovertheleasetermthecompanyhaselectedthefollowingpolicyelectionsonadoptionuseof portfolioapproachonleasesofassetsundermasterserviceagreementsexclusionofshorttermleasesonthebalance sheetandnotseparatingleaseandnonleasecomponent thecompanyprimarilyhasoperatingleaseforspacevehiclesmanufacturingequipmentanddataprocessingequipment therouassetpertainingtooperatingleaseswasbillionandbillioninfiscalyearsand respectivelytheleaseliabilitywasbillionandbillioninfiscalyearsandrespectivelytheoperate leasecostswerebillioninfiscalyearsandrespectivelycashpaidforamountsincludedinthe measurementofleaseliabilitieswerebillioninfiscalyearsandrespectively productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially determinedestimateswhereapplicabletheaccrualsareadjustedperiodicallyasadditionalinformationbecome availablethecompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecost areprobableandcanbereasonablyestimatedtotheextentadverseverdictshavebeenrenderedagainstthecompany thecompanydoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimate thecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimate researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredinaccordancewithascresearchand developmentupfrontandmilestonepaymentsmadetothirdpartiesinconnectionwithresearchanddevelopment collaborationsareexpensedasincurreduptothepointofregulatoryapprovalpaymentsmadetothirdpartiessubsequent toregulatoryapprovalarecapitalizedandamortizedovertheremainingusefullifeoftherelatedproductamount capitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulatedamortization thecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormorepartie includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopmentamountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract johnsonjohnsonannualreportdevelopmentservicesisnotcentraltothecompanysoperationsingeneraltheincomestatementpresentationforthese collaborationsisasfollow naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproductprofitsharepaymentsreceive salestocustomer royaltiesmilestonespaidtocollaborativepartnerpost costofproductssold regulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartnerorgovernmententity milestonesarecapitalizedasintangibleassetsandamortizedtocostofproductssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidate researchanddevelopmentexpense thecompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersinclude xareltocodevelopedwithbayerhealthcareagandimbruvicadevelopedincollaborationandcomarketedwith pharmacyclicsllcanabbviecompany separatelythecompanyhasanumberoflicensingarrangementsforproductsandcompoundsincludingdarzalex licensedfromgenmabas advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninfiscalyearsandrespectively incometaxe incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesintaxlawsand ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition intheunitedstatesenactedintolawnewustaxlegislationtheustaxcutsandjobsacttcjathislaw includedprovisionsforacomprehensiveoverhaulofthecorporateincometaxcodeincludingareductionofthestatutory corporatetaxratefromtoeffectiveonjanuarythetcjaincludedaprovisionforataxonall previouslyundistributedearningsofuscompanieslocatedinforeignjurisdictionsundistributedearningsintheformof cashandcashequivalentsweretaxedatarateofandallotherearningsweretaxedatarateofthistaxis payableoveryearsandwillnotaccrueinterestthesepaymentsbeganinandwillcontinuethroughthe remainingbalanceattheendofthewasapproximatelybillionofwhichbillionisclassifiedasnoncurrent andreflectedaslongtermtaxespayableonthecompanysbalancesheetthebalanceofthisaccountisrelatedto receivablesfromtaxauthoritiesnotexpectedtobereceivedinthenextmonth thetcjaalsoincludesprovisionsforataxonglobalintangiblelowtaxedincomegiltigiltiisdescribedasthe excessofausshareholderstotalnetforeignincomeoveradeemedreturnontangibleassetsasprovidedbythetcja johnsonjohnsonannualreport injanuarythefasbissuedguidancethatallowscompaniestoelectasanaccountingpolicywhethertorecordthe taxeffectsofgiltiintheperiodthetaxliabilityisgeneratedieperiodcostorprovidefordeferredtaxassetsand liabilitiesrelatedtobasisdifferencesthatexistandareexpectedtoeffecttheamountofgiltiinclusioninfutureyears uponreversaliedeferredmethodthecompanyhaselectedtoaccountforgiltiunderthedeferredmethodthe deferredtaxamountsrecordedarebasedontheevaluationoftemporarydifferencesthatareexpectedtoreverseasgilti isincurredinfutureperiod thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromit internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetaxeffectofthisrepatriationwouldbeapproximatelybillionunder currentlyenactedtaxlawsandregulationsandatcurrentcurrencyexchangeratesthisamountdoesnotincludethe possiblebenefitofusforeigntaxcreditswhichmaysubstantiallyoffsetthiscost seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxe netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod useofestimate thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxeswithholdingtaxes depreciationamortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresults mayormaynotdifferfromthoseestimate thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrue annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweek andthereforeincludesadditionalshippingdaysaswasthecaseinfiscalyearandwillbethecaseagaininfiscal year reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation johnsonjohnsonannualreport cash cash equivalent current marketable security attheendofthefiscalyearandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof estimate cash current carry unrecognized fair cash marketable dollarsinmillion loss value equivalent security cash usreverserepurchaseagreement corporatedebtsecuritie moneymarketfund timedeposit subtotal usgovtsecuritie usgovtagencie corporateandotherdebtsecuritie subtotalavailableforsale totalcashcashequivalentsandcurrentmarketable security estimate cash current carry unrecognized fair cash marketable dollarsinmillion loss value equivalent security cash nonussovereignsecuritie usreverserepurchaseagreement corporatedebtsecuritie moneymarketfund timedeposit subtotal usgovtsecuritie corporateandotherdebtsecuritie subtotalavailableforsale totalcashcashequivalentsandcurrentmarketable security heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearning availableforsaledebtsecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinother comprehensiveincome fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinput johnsonjohnsonannualreport thecontractualmaturitiesoftheavailableforsaledebtsecuritiesatjanuaryareasfollow cost fair dollarsinmillion basis value duewithinoneyear dueafteroneyearthroughfiveyear dueafterfiveyearsthroughtenyear totaldebtsecuritie thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastaninvestmentgradecreditrate inventory attheendoffiscalyearsandinventorieswerecomprisedof dollarsinmillion rawmaterialsandsupplie goodsinprocess finishedgood totalinventorie property plant equipment attheendoffiscalyearsandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillion landandlandimprovement buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinfiscalyearsandwasmillionmillionandmillionrespectively depreciationexpenseincludingtheamortizationofcapitalizedinterestinfiscalyearsandwas billionbillionandbillionrespectively uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulate depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearning johnsonjohnsonannualreport intangible asset goodwill attheendoffiscalyearsandthegrossandnetamountsofintangibleassetswere dollarsinmillion intangibleassetswithdefinitelive patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelive trademark purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelive totalintangibleassetsnet thechangewasprimarilyrelatedtotheintangibleassetsacquiredwiththeacquisitionofabiomedincwhichwaspartiallyoffsetby amortizationexpenseofpreviouslyexistingintangibleassetsandtheresultofcurrencytranslationeffect themajorityiscomprisedofcustomerrelationship thereductionwasprimarilyrelatedtoanintangibleassetimpairmentchargeofapproximatelybillionrecordedinthefiscalyear relatedtoaninprocessresearchanddevelopmentassetbermekimabjnjaninvestigationaldrugforthe treatmentofatopicdermatitisadandhidradenitissuppurativahsacquiredwiththeacquisitionofxbiotechincinthefiscal yearadditionalinformationregardingefficacyoftheadandhsindicationsbecameavailablewhichledthecompanytothe decisiontoterminatethedevelopmentofbermekimabforadandhsanadditionalreductionofbillionwasdrivenbymonarch assetsthatreachedcommercializationandarenowclassifiedashavingdefinitelivesthiswaspartiallyoffsetbyapproximately billionofiprdacquiredwithabiomedinc goodwillasofjanuaryandjanuaryasallocatedbysegmentofbusinesswasasfollow dollarsinmillion consumerhealth pharmaceutical medtech total goodwillatjanuary goodwillrelatedtoacquisition goodwillrelatedtodivestiture currencytranslationother goodwillatjanuary goodwillrelatedtoacquisition goodwillrelatedtodivestiture currencytranslationother goodwillatjanuary theweightedaverageamortizationperiodforpatentsandtrademarksisyearstheweightedaverageamortization periodforcustomerrelationshipsandotherintangibleassetsisyearstheamortizationexpenseofamortizableasset includedincostofproductssoldwasbillionbillionandbillionbeforetaxforthefiscalyearsende januaryjanuaryandjanuaryrespectivelyintangibleassetwritedownsareincludedinother incomeexpensenet johnsonjohnsonannualreport theestimatedamortizationexpenseforapprovedproductsbeforetaxforthefivesucceedingyearsisapproximately dollarsinmillion seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtoacquisitionsanddivestiture fair value measurement thecompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarily relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthirdpartypurchasesofmaterial denominatedinaforeigncurrencythecompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsbothtypesofderivativesaredesignatedascashflowhedge additionallythecompanyprimarilyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixe rateborrowingsthesederivativesaredesignatedasfairvaluehedgesthecompanyusescrosscurrencyinterestrate swapsandforwardforeignexchangecontractsdesignatedasnetinvestmenthedgesadditionallythecompanyuse forwardforeignexchangecontractstooffsetitsexposuretocertainforeigncurrencyassetsandliabilitiestheseforward foreignexchangecontractsarenotdesignatedashedgesandthereforechangesinthefairvaluesofthesederivativesare recognizedinearningstherebyoffsettingthecurrentearningseffectoftherelatedforeigncurrencyassetsandliabilitie inthefiscalfourthquarterofthecompanyenteredintoforwardstartinginterestrateswapswithnotionalamount totalingbillionincontemplationofhedginginterestrateriskassociatedwithlongtermfinancingfortheconsumer healthsegmentseparationtheseforwardstartinginterestrateswapsarenotdesignatedashedgesandtherefore changesinthefairvaluesofthesederivativesarerecognizedinearningsattheendofthefiscalyearthechange infairvaluewasnotmaterialandthereforenotincludedinthetablebelow thecompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposesorthatcontaincredit riskrelatedcontingentfeaturesthecompanymaintainscreditsupportagreementscsawithcertainderivative counterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsandnettingagreementsasof januarythetotalamountofcashcollateralpaidbythecompanyunderthecsaamountedtobillionnet relatedtonetinvestmentandcashflowhedgesonanongoingbasisthecompanymonitorscounterpartycreditrating thecompanyconsiderscreditnonperformancerisktobelowbecausethecompanyprimarilyentersintoagreement withcommercialinstitutionsthathaveatleastaninvestmentgradecreditratingrefertothetableonsignificantfinancial assetsandliabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswiththesecommercial institutionsasofjanuarythecompanyhadnotionalamountsoutstandingforforwardforeignexchange contractscrosscurrencyinterestrateswapsandinterestrateswapsofbillionbillionandbillion respectivelyasofjanuarythecompanyhadnotionalamountsoutstandingforforwardforeignexchange contractscrosscurrencyinterestrateswapsandinterestrateswapsofbillionbillionandbillion respectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontractatinceptionallderivative areexpectedtobehighlyeffectiveforeignexchangecontractsdesignatedascashflowhedgesareaccountedforunder theforwardmethodandallgainslossesassociatedwiththesecontractswillberecognizedintheincomestatementwhen thehedgeditemimpactsearningschangesinthefairvalueofthesederivativesarerecordedinaccumulatedother comprehensiveincomeuntiltheunderlyingtransactionaffectsearningsandarethenreclassifiedtoearningsinthesame accountasthehedgedtransaction gainsandlossesassociatedwithinterestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesin interestratesarerecordedtointerestexpenseintheperiodinwhichtheyoccurgainsandlossesonnetinvestment hedgesareaccountedthroughthecurrencytranslationaccountwithinaccumulatedothercomprehensiveincomethe portionexcludedfromeffectivenesstestingisrecordedthroughinterestincomeexpenseusingthespotmethodonan ongoingbasisthecompanyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesof hedgeditemsifandwhenaderivativeisnolongerexpectedtobehighlyeffectivehedgeaccountingisdiscontinue johnsonjohnsonannualreportthecompanydesignateditseurodenominatednotesissuedinmaywithduedatesrangingfromtoas anetinvestmenthedgeofthecompanysinvestmentsincertainofitsinternationalsubsidiariesthatusetheeuroastheir functionalcurrencyinordertoreducethevolatilitycausedbychangesinexchangerates asofjanuarythebalanceofdeferrednetlossonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill bereclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthat periodthemaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexclude interestratecontractsandnetinvestmenthedgestheamountultimatelyrealizedinearningsmaydifferasforeign exchangerateschangerealizedgainsandlossesareultimatelydeterminedbyactualexchangeratesatmaturityofthe derivative thefollowingtableisasummaryoftheactivityrelatedtoderivativesandhedgesforthefiscalyearsendedjanuary andjanuarynetoftax january january costof interest costof interest product income income product income income dollarsinmillion sale sell expense expense expense sale sell expense expense expense theeffectsoffairvaluenetinvestmentand cashflowhedging gainlossonfairvaluehedge relationship interestrateswapscontract hedgeditem derivativesdesignatedashedge instrument gainlossonnetinvestment hedgingrelationship crosscurrencyinterestrateswap contract amountofgainorlossrecognizedin incomeonderivativeamountexcluded fromeffectivenesstesting amountofgainorlossrecognizedin aoci gainlossoncashflowhedge relationship forwardforeignexchangecontract amountofgainorlossreclassifiedfrom aociintoincome amountofgainorlossrecognizedin aoci crosscurrencyinterestrateswap contract amountofgainorlossreclassifiedfrom aociintoincome amountofgainorlossrecognizedin aoci johnsonjohnsonannualreport asofjanuaryandjanuarythefollowingamountswererecordedontheconsolidatedbalancesheet relatedtocumulativebasisadjustmentforfairvaluehedge cumulativeamountof fairvaluehedge adjustmentincludedin lineitemintheconsolidatedbalancesheetin carryingamountofthe thecarryingamountof whichthehedgeditemisinclude hedgedliability thehedgedliability january january january january dollarsinmillions longtermdebt thefollowingtableistheeffectofderivativesnotdesignatedashedginginstrumentforthefiscalyearsendedjanuary andjanuary locationofgain gainloss lossrecognizedin recognizedin dollarsinmillion incomeonderivative incomeonderivative derivativesnotdesignatedashedginginstrument january january foreignexchangecontract otherincomeexpense thefollowingtableistheeffectofnetinvestmenthedgesforthefiscalyearsendedjanuaryandjanuary gainloss gainloss locationofgainorlossreclassifie reclassifiedfrom recognizedin fromaccumulatedothercomprehensive accumulatedoci accumulatedoci incomeintoincome intoincome january january january january dollarsinmillion debt interestincomeexpense crosscurrencyinterestrateswap interestincomeexpense thecompanyholdsequityinvestmentswithreadilydeterminablefairvaluesandequityinvestmentswithoutreadily determinablefairvaluesthecompanymeasuresequityinvestmentsthatdonothavereadilydeterminablefairvaluesat costminusimpairmentifanyplusorminuschangesresultingfromobservablepricechangesinorderlytransactionsfor theidenticalorasimilarinvestmentofthesameissuer thefollowingtableisasummaryoftheactivityrelatedtoequityinvestmentsforthefiscalyearsendedjanuary andjanuary january january non changesinfairvalue current reflectedinnet sale dollarsinmillion carryingvalue income purchasesother carryingvalue asset equityinvestmentswithreadilydeterminable value equityinvestmentswithoutreadily determinablevalue january january non changesinfairvalue current reflectedinnet sale dollarsinmillion carryingvalue income purchasesother carryingvalue asset equityinvestmentswithreadilydeterminable value equityinvestmentswithoutreadily determinablevalue recordedinotherincomeexpense otherincludesimpactofcurrency johnsonjohnsonannualreportforthefiscalyearsendedjanuaryandjanuaryforequityinvestmentswithoutreadilydeterminablemarket valuesmillionandmillionrespectivelyofthechangesinfairvaluereflectedinnetincomeweretheresultof impairmentstherewereoffsettingimpactsofmillionandmillionrespectivelyofchangesinthefairvalue reflectedinnetincomeduetochangesinobservablepricesandgainsonthedisposalofinvestmentstheimpactinfiscal yearwasdrivenbythegainondisposalofthegrailinvestmentinfiscalyearthecompanysoldallofit equityinvestmentsinargenxseforproceedsofbillion fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbase measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilityin accordancewithascathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevelswithinthe hierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thefairvalueofaderivativefinancialinstrumentieforwardforeignexchangecontractsinterestratecontractsisthe aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand subsequentlyconvertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethat fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor maturityorthatthechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsor financialpositionthecompanyalsoholdsequityinvestmentswhichareclassifiedaslevelanddebtsecuritieswhich areclassifiedaslevelthecompanyholdsacquisitionrelatedcontingentliabilitiesbaseduponcertainregulatoryand commercialeventswhichareclassifiedaslevelwhosevaluesaredeterminedusingdiscountedcashflow methodologiesorsimilartechniquesforwhichthedeterminationoffairvaluerequiressignificantjudgmentorestimation thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilitie levelsignificantotherobservableinput levelsignificantunobservableinput thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofthefiscalyearendedjanuary andjanuarywereasfollow dollarsinmillion level level level total total derivativesdesignatedashedginginstrument asset forwardforeignexchangecontract interestratecontract total liability forwardforeignexchangecontract interestratecontract total derivativesnotdesignatedashedginginstrument asset forwardforeignexchangecontract liability forwardforeignexchangecontract availableforsaleotherinvestment equityinvestment debtsecuritie otherliabilitie contingentconsideration johnsonjohnsonannualreport grosstonetderivativereconciliation dollarsinmillion totalgrossasset creditsupportagreementcsa totalnetasset totalgrossliabilitie creditsupportagreementcsa totalnetliabilitie summarizedinformationaboutchangesinliabilitiesforcontingentconsiderationisasfollow dollarsinmillion beginningbalance changesinestimatedfairvalue addition payment endingbalance assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofequityinvestmentsofmillionwhichareclassified aslevelandcontingentconsiderationofmillionclassifiedaslevel includescrosscurrencyinterestrateswapsandinterestrateswap classifiedasnoncurrentotherasset classifiedascashequivalentsandcurrentmarketablesecuritie includesmillionmillionandmillionclassifiedasnoncurrentotherliabilitiesasofjanuaryjanuary andjanuaryrespectivelyincludesmillionmillionandmillionclassifiedascurrentliabilitiesasof januaryjanuaryandjanuaryrespectively ongoingfairvalueadjustmentamountsarerecordedprimarilyinresearchanddevelopmentexpensethecompanyrecordeda contingentconsiderationreversalofmillioninrelatedtothetimingofcertaindevelopmentalmilestonesassociatedwith theaurishealthacquisitionthereversalofthecontingentconsiderationwasrecordedinotherincomeandexpense infiscalyearthecompanyrecordedmillionofcontingentconsiderationrelatedtoabiome seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowing thecomponentsoflongtermdebtareasfollow effective effective dollarsinmillion rate rate notesduebeuro notesdue debenturesdue notesdue notesdue notesduemmeurommeuro notesduemmgbpmmgbp notesdue notesdue notesdue notesdue notesdue notesduemmeurommeuro notesdue notesdue notesdue debenturesdue notesdue notesduebeurobeuro notesdue notesdue notesdue debenturesdue notesdue debenturesdue notesdue notesdue notesdue notesdue notesdue notesdue notesdue notesdue subtotal lesscurrentportion totallongtermdebt weightedaverageeffectiverate translationrateatjanuary translationrateatjanuary johnsonjohnsonannualreport theexcessofthecarryingvalueoverthefairvalueofdebtwasbillionattheendoffiscalyearandtheexcessofthefair valueoverthecarryingvalueofdebtwasbillionattheendoffiscalyear fairvalueofthelongtermdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerpricesand significantotherobservableinput thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilityofbillionwhichexpiresonseptemberinnovember thecompanysecuredanadditionaldaycreditfacilityofbillionwhichexpiresonnovemberinterest chargedonborrowingsunderthecreditlineagreementisbasedoneitherthetermsofrreferencerateorother applicablemarketratesasallowedunderthetermsoftheagreementplusapplicablemarginscommitmentfeesunderthe agreementsarenotmaterial throughoutfiscalyearsandthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpaper marketshorttermborrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionand billionattheendoffiscalyearsandrespectivelythecurrentportionofthelongtermdebtwa billionandbillioninandrespectivelyandtheremainderiscommercialpaperandlocalborrowingby internationalsubsidiarie thecurrentdebtbalanceasofjanuaryincludesbillionofcommercialpaperwhichhasaweightedaverage interestrateofandaweightedaveragematurityofapproximatelytwomonth aggregatematuritiesoflongtermdebtobligationscommencinginare dollarsinmillion income taxis theprovisionfortaxesonincomeconsistsof dollarsinmillion currentlypayable ustaxe internationaltaxe totalcurrentlypayable defer ustaxe internationaltaxe totaldeferre provisionfortaxesonincome johnsonjohnsonannualreportacomparisonofincometaxexpenseattheusstatutoryrateofinfiscalyearsandtothe companyseffectivetaxrateisasfollow dollarsinmillion international earningsbeforetaxesonincome taxrate usstatutoryrate internationaloperation consumerhealthseparation ustaxesoninternationalincome taxbenefitsfromlossoncapitalasset taxbenefitsonsharebasedcompensation allother effectiverate forallperiodspresentedthecompanyhassubsidiariesoperatinginpuertoricoundervarioustaxincentivesinternational operationsreflecttheimpactsofoperationsinjurisdictionswithstatutorytaxratesdifferentthantheusparticularlyireland switzerlandandpuertoricowhichisafavorableimpactontheeffectivetaxrateascomparedwiththeusstatutoryratethe amountsincludethereorganizationofinternationalsubsidiariestheamountsincludetheimpactofthenewtaxlegislation enactmentinswitzerlandbothofwhicharefurtherdescribedbelow includestheimpactofthegiltitaxtheforeignderivedintangibleincomedeductionandotherforeignincomethatistaxableunder theustaxcodetheamountincludestheimpactofcertainprovisionsofthetcjathatbecameeffectiveinfiscal theamountsincludethereorganizationofinternationalsubsidiariestheamountsincludetheimpactofthenewtax legislationenactmentinswitzerlandbothofwhicharefurtherdescribedbelow certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation thefiscalyeareffectivetaxrateincreasedascomparedtothefiscalyeareffectivetaxrateaspartofthe plannedseparationofthecompanysconsumerhealthbusinessthecompanyhasrecognizedapproximatelybillion innetincrementaltaxcostsinfiscalyearwhichincreasedtheeffectivetaxratebyapproximately additionallythecompanyrecordedcertainnonrecurringfavorabletaxitemsinfiscalyearwhichresultedinan unfavorableimpacttothecompanysfiscaleffectivetaxratewhencomparedtothepriorfiscalyeartheseitemsare describedbelowthecompanystaxratealsobenefitedfromcertainprovisionsofthetaxcutsandjobsactof thatbecameeffectiveinfiscaltheimpairmentofbermekimabforadandhsiprdforfurtherinformation seenoteofthekconsolidatedfinancialstatementsandchangesinthefairvalueofsecuritiesinthe companysinvestmentportfoliobothrecordedattheusstatutoryrate thefiscalyeartaxratedecreasedbycomparedtothefiscalyeartaxratewhichwasprimarilydrivenby thefollowingitemsinfiscalyearthecompanyreorganizedtheownershipstructureofcertainwhollyowne internationalsubsidiariesaspartofthisreorganizationthecompanyincreasedthetaxbasisofcertainassetstofairvalue inaccordancewithapplicablelocalregulationsthenetimpactofthisrestructuringwasapproximatelybillionnet benefitorbenefittothecompanysannualeffectivetaxratecomprisedofthefollowingitem approximatelybillionoflocaldeferredtaxassetstorecordtheremeasurementofthetaxbasisoftheseassetsto fairvaluethisbenefithasbeenreflectedasinternationaloperationsonthecompanyseffectivetaxratereconciliation approximatelybillionofusdeferredtaxexpenserelatingtothegiltideferredtaxliabilityresultingfromthe remeasurementofthesedeferredtaxassetsthisexpensehasbeenreflectedasustaxoninternationalincomeon thecompanyseffectivetaxratereconciliation alsointhefiscalfourthquarterofthecompanyrecognizedalossoncertainusaffiliatesrelatedtothepreviously impairedbookvalueofcertainintangibleswhichreducedthetaxratebyapproximatelywhichisreflectedasa johnsonjohnsonannualreport taxbenefitsfromlossoncapitalassetsontheeffectivetaxratereconciliationadditionallyotherfiscalimpactsto theratewereprimarilydrivenbylitigationandacquisitionrelateditemsasfollow thecompanyaccruedadditionallegalexpensesofapproximatelybillionfortalcataneffectivetaxrateof andbillionforrisperdalgynecomastiasettlementsataneffectivetaxrateofseenotetothe consolidatedfinancialstatementsformoredetail thecompanyrecordedapartialiprdchargeofbillionfortheottavaintangibleassetacquiredwiththeauris healthacquisitioninataneffectiverateof infiscalyearswitzerlandenactedthefederalactontaxreformandahvfinancingtrafandbecameeffective forfiscalyearthefederaltransitionalprovisionsoftrafallowcompaniesundercertainconditionstoadjustthe taxbasisincertainassetstofairvalueiestepuptobedepreciatedandamortizedresultinginanincrementalswiss taxdeductionoverthetransitionalperiod trafalsoprovidesforparameterswhichenabletheswisscantonstoestablishlocalizedtaxratesandregulationsfor companiesthenewcantonaltaxparametersincludefavorabletaxbenefitsforpatentsandadditionalresearchand developmenttaxdeductionsthecantonaltransitionalprovisionsoftrafallowedcompaniestoelecteithertaxbasis stepupsimilartothefederaltransitionbenefitoralternativestatutorytaxrateforaperiodnottoexceedyearsthe companyhasoperationslocatedinvariousswisscanton duringthefiscalyearthefinalcantonwherethecompanymaintainssignificantoperationsenactedtraf legislationadditionallythecompanyreceivedrulingsfromtheswissfederalandcantonaltaxauthoritiesintheremaine jurisdictionswhereithassignificantoperationstheserulingsresultedinthecompanyrevisingitsestimateonthetax basisadjustmentiestepupforitsassetsandasaresultthecompanyrecordedadditionaldeferredtaxbenefitsin thecompanyrecognizedanetbenefitinthefiscalyearforswisstaxreformofapproximatelybillionor benefittothecompanysannualeffectivetaxratecomprisedofthefollowingitem approximatelybilliontaxbenefitrelatingtotheremeasurementofswissdeferredtaxassetsandliabilitiesforthe changeinthefederalandcantonaltaxrateswhereenactmentoccurredinthefiscalyearthisbenefithasbeen reflectedasinternationaloperationsonthecompanyseffectivetaxratereconciliation amilliondeferredtaxassetrelatedtotheestimatedvalueofafederaltaxbasisstepupofthecompanysswiss subsidiariesassetsasdescribedabovethisbenefithasbeenreflectedasinternationaloperationsonthecompany effectivetaxratereconciliation approximatelybillionofusdeferredtaxexpenserelatingtothegiltideferredtaxliabilityresultingfromthe remeasurementoftheswissdeferredtaxassetsandliabilitiesinthefiscalyearthisbenefithasbeenreflectedas ustaxoninternationalincomeonthecompanyseffectivetaxratereconciliation thecompanydoesnotexpecttoreceivefuturerulingsregardingthetransitionalprovisionsoftraf alsointhefiscalyearthecompanyrecognizedacapitallossoncertainusaffiliatesrelatedtothepreviously impairedbookvalueofcertainintangibleswhichreducedthetaxratebyapproximatelywhichisreflectedasa taxbenefitsfromlossoncapitalassetsontheeffectivetaxratereconciliationinadditioninthefiscalyearthe companyhadlowerincomeinhighertaxjurisdictionsprimarilydrivenby theimpactoftheaccrualoflitigationcostsrelatedtotalcforbillionwhichreducedtheusearningsbeforetaxes ataneffectivetaxrateof theaccrualofadditionallegalcostsincludinganadditionalbillionassociatedwitharevisedagreementinprinciple tosettleopioidlitigationataneffectivetaxrateof thecompanyalsoreducedthecontingentconsiderationliabilityrelatedtotheaurishealthacquisitioninand reversedsomeofitsunrecognizedtaxbenefitsduetothecompletionofseveralyearsoftaxexaminationsincertain jurisdictionsduringthefiscalyear johnsonjohnsonannualreporttemporarydifferencesandcarryforwardsattheendoffiscalyearsandwereasfollow deferredtax deferredtax dollarsinmillion asset liability asset liability employeerelatedobligation stockbasedcompensation depreciationofpropertyplantandequipment goodwillandintangible rdcapitalizedfortax reservesliabilitie incomereportedfortaxpurpose netrealizableoperatinglosscarryforward undistributedforeignearning globalintangiblelowtaxedincome miscellaneousinternational miscellaneousus totaldeferredincometaxe certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation amountisinclusiveofthebilliondeferredtaxassetestablishedaspartofthereorganizedownershipstructureof certainwhollyownedinternationalsubsidiariesaspreviouslydescribe amountisinclusiveofthebilliondeferredtaxliabilityduetotheacquisitionofabiome netofvaluationallowancesofbillioninbothand thecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenetlossesthecompanybelievesthatitis morelikelythannotthatthesesubsidiarieswillgeneratefuturetaxableincomesufficienttoutilizethesedeferredtaxasset howeverincertainjurisdictionsvaluationallowanceshavebeenrecordedagainstdeferredtaxassetsforloss carryforwardsthatarenotmorelikelythannottoberealize thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefit dollarsinmillion beginningofyear increasesrelatedtocurrentyeartaxposition increasesrelatedtopriorperiodtaxposition decreasesrelatedtopriorperiodtaxposition settlement lapseofstatuteoflimitation endofyear theunrecognizedtaxbenefitsofbillionatjanuaryifrecognizedwouldaffectthecompanysannualeffectivetax ratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxauditsinprogresswith anumberoftaxauthoritieswithrespecttotheunitedstatestheirshascompleteditsauditforthetaxyearsthrough andiscurrentlyauditingtaxyearsthroughinthefiscalyearthecompanymadeitsfinalpaymentsfor approximatelybilliontotheustreasuryrelatedtothefinalsettlementoftaxauditliability inothermajorjurisdictionswherethecompanyconductsbusinesstheyearsthatremainopentotaxauditsgobacktothe yearthecompanybelievesitispossiblethatsometaxauditsmaybecompletedoverthenexttwelvemonthsby taxingauthoritiesinsomejurisdictionsincludingintheunitedstateshoweverthecompanyisnotabletoprovidea reasonablyreliableestimateofthetimingofanyotherfuturetaxpaymentsorchangeinuncertaintaxpositionsifany thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilitie interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompany johnsonjohnsonannualreport recognizedaftertaxinterestexpenseofmillionmillionandmillioninfiscalyearsand respectivelythetotalamountofaccruedinterestwasmillionandmillioninfiscalyearsand respectively employee relate obligation attheendoffiscalandfiscalemployeerelatedobligationsrecordedontheconsolidatedbalancesheet dollarsinmillion pensionbenefit postretirementbenefit postemploymentbenefit deferredcompensation totalemployeeobligation lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareinclude inotherassetsontheconsolidatedbalancesheet pension benefit plan thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependent manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant intheusnonunionpensionbenefitsforemployeeshiredbeforejanuaryareprimarilybasedontheemployee compensationduringthelastfiveyearsbeforeretirementandthenumberofyearsofservicethefinalaveragepay formulauspensionbenefitsforemployeeshiredafterarecalculatedusingadifferentformulabasedonemployee compensationovertotalyearsofservicetheretirementvalueformula injanuarythecompanyannouncedthateffectiveonjanuaryalleligibleusnonunionemployee regardlessofhiredatewillearnbenefitsundertheretirementvalueformulathisamendmentdoesnotaffectthebenefits accruedunderthefinalaveragepayformulaforservicebeforejanuary internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrusteesannuitiesarepurchasedundergroup contractsorreservesareprovided thecompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture inandthecompanyuseddecemberanddecemberrespectivelyasthemeasurement dateforallusandinternationalretirementandotherbenefitplans netperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponent retirementplan otherbenefitplan dollarsinmillion servicecost interestcost expectedreturnonplanasset amortizationofpriorservicecost recognizedactuariallossesgain curtailmentsandsettlement netperiodicbenefitcostcredit johnsonjohnsonannualreporttheservicecostcomponentofnetperiodicbenefitcostispresentedinthesamelineitemsontheconsolidate statementofearningswhereotheremployeecompensationcostsarereportedincludingcostofproductssoldresearch anddevelopmentexpenseandsellingmarketingandadministrativeexpensesallothercomponentsofnetperiodic benefitcostarepresentedaspartofotherincomeexpensenetontheconsolidatedstatementofearning unrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgain andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheaccumulatedpostretirementbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridor areamortizedovertheaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheaverageremainingfutureserviceofplan participantsatthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedover theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment thefollowingtablerepresentstheweightedaverageactuarialassumption retirementplan otherbenefitplan worldwidebenefitplan netperiodicbenefitcost servicecostdiscountrate interestcostdiscountrate rateofincreaseincompensationlevel expectedlongtermrateofreturnonplanasset benefitobligation discountrate rateofincreaseincompensationlevel thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilitiesthecompanys methodologyindeterminingserviceandinterestcostusesdurationspecificspotratesalongthatyieldcurvetotheplans liabilitycashflow theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsource longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividual healthcareplan healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate johnsonjohnsonannualreport thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatfiscalyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplan otherbenefit retirementplan plan dollarsinmillion changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontribution amendment actuarialgainslosse divestituresacquisition curtailmentssettlementsrestructure benefitspaidfromplan effectofexchangerate projectedbenefitobligationendofyear changeinplanasset planassetsatfairvaluebeginningofyear actualreturnlossonplanasset companycontribution planparticipantcontribution settlement divestituresacquisition benefitspaidfromplanasset effectofexchangerate planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowe noncurrentasset currentliabilitie noncurrentliabilitie totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowe netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffect accumulatedbenefitobligationsendofyear theactuarialgainforretirementplansinandwasprimarilyrelatedtoincreasesindiscountrate johnsonjohnsonannualreportotherbenefit retirementplan plan dollarsinmillion amountsrecognizedinnetperiodicbenefitcostandothercomprehensive income netperiodicbenefitcostcredit netactuarialgainloss amortizationofnetactuarialloss priorservicecostcredit amortizationofpriorservicecostcredit effectofexchangerate totallossincomerecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticea fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunde inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberanddecemberrespectively usplans internationalplans qualifiedplan nonqualifiedplans fundedplan unfundedplan dollarsinmillion planasset projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplan dollarsinmillion projectedfuturebenefitpayment retirementplan otherbenefitplan thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplanstheseamount donotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillion projectedfuturecontribution johnsonjohnsonannualreport eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard considersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicle separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretiree durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplan permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefund thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareas follow percentof target planasset allocation worldwideretirementplan equitysecuritie debtsecuritie totalplanasset determinationoffairvalueofplanasset theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquote marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilitie equityordebtpricesforeignexchangeratesandcreditcurve whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevel withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thenetassetvaluenavisbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthen dividedbythenumberofsharesoutstanding afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentfundscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamount heldondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenav providedbytheadministratorofthefundthenavisaquotedpriceinamarketthatisnotactiveandclassifiedas level governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket onwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby johnsonjohnsonannualreportusingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassifie aslevelleveldebtinstrumentsarepricedbasedonunobservableinput equitysecuritiesequitysecuritiesarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallequitysecuritiesareclassifiedwithinlevelofthevaluationhierarchy commingledfundstheseinvestmentvehiclesarevaluedusingthenavprovidedbythefundadministratorassetsin thelevelcategoryhaveaquotedmarketprice otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipstheseinvestmentvehiclesarevalue usingthenavprovidedbythefundadministratorotherassetsthatareexchangelistedandactivelytradedare classifiedaslevelwhileinactivelytradedassetsareclassifiedaslevel thefollowingtablesetsforththeretirementplansinvestmentsmeasuredatfairvalueasofdecemberand december quotedprice significant inactive significant investment marketsfor observable unobservable measuredat identicalasset input input netasset level level level value totalasset dollarsinmillion shortterminvestmentfund governmentandagencysecuritie debtinstrument equitysecuritie commingledfund otherasset investmentsatfairvalue theactivityforthelevelassetsisnotsignificantforallyearspresente thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionatdecemberanddecemberrespectively thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatdecember saving plan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninfiscalyearsandrespectively johnsonjohnsonannualreport capital treasury stock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousand share balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary aggregatesharesofcommonstockissuedwereapproximatelysharesattheendoffiscalyear cashdividendspaidwerepershareinfiscalyearcomparedwithdividendsofpershareinfiscalyear andpershareinfiscalyear onjanuarytheboardofdirectorsdeclaredaregularcashdividendofpersharepayableonmarch toshareholdersofrecordasoffebruary onseptemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstocksharerepurchase maybemadeatmanagementsdiscretionfromtimetotimeontheopenmarketorthroughprivatelynegotiate transactionstherepurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytime throughjanuaryapproximatelybillionhasbeenrepurchasedundertheprogram accumulate comprehensive income loss componentsofothercomprehensiveincomelossconsistofthefollowe total gainloss accumulate foreign gainloss employee currency benefit derivative comprehensive dollarsinmillion translation security plan hedge incomeloss december netchange january netchange january netchanges january amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome detailsonreclassificationsoutofaccumulatedothercomprehensiveincome gainlossonsecuritiesreclassificationsreleasedtootherincomeexpensenet johnsonjohnsonannualreportemployeebenefitplansreclassificationsareincludedinnetperiodicbenefitcostseenoteforadditionaldetail gainlossonderivativeshedgesreclassificationstoearningsarerecordedinthesameaccountasthehedge transactionseenoteforadditionaldetail international currency translation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyear orwhereasubstantialportionofitscashflowsarenotinthelocalcurrencyforthemajorityofthecompanyssubsidiarie thelocalcurrencyisthefunctionalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulate othercomprehensiveincometheothercurrentandnoncurrentassetslinewithinthestatementofcashflowsinclude theimpactofforeigncurrencytranslationthisequityaccountincludestheresultsoftranslatingcertainbalancesheet assetsandliabilitiesatcurrentexchangeratesandsomeaccountsathistoricalratesexceptforthoselocatedinhighly inflationaryeconomiesargentinaandvenezuelabeginninginthefiscalsecondquarterofthecompanyalso accountedforoperationsinturkeyashighlyinflationarythetranslationofbalancesheetaccountsforhighlyinflationary economiesarereflectedintheoperatingresult arollforwardofthechangesduringfiscalyearsandforforeigncurrencytranslationadjustmentsis includedinnote netcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillion andmillioninfiscalyearsandrespectively earning share thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsende januaryjanuaryandjanuary inmillionsexceptpershareamount basicnetearningspershare averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplan lesssharesrepurchasedundertreasurystockmethod adjustedaveragesharesoutstandingdilute dilutednetearningspershare thedilutednetearningspersharecalculationforthefiscalyearsandincludedallsharesrelatedtostock optionsastheexercisepriceoftheseoptionswaslessthantheaveragemarketvalueofthecompanysstock thedilutednetearningspersharecalculationforfiscalyearexcludedmillionsharesrelatedtostockoptionsa theexercisepriceoftheseoptionswasgreaterthantheaveragemarketvalueofthecompanysstock common stock stock option plan stock compensation agreement atjanuarythecompanyhadonestockbasedcompensationplanthesharesoutstandingareforcontract underthecompanyslongtermincentiveplanandthelongtermincentiveplanthelongterm incentiveplanexpiredonaprilallawardsstockoptionsrestrictedsharesunitsandperformanceshareunit grantedsubsequenttothatdatewereunderthelongtermincentiveplanunderthelongtermincentive planthecompanymayissueuptomillionsharesofcommonstockofwhichuptomillionsharesofcommon stockmaybeissuedsubjecttostockoptionsorstockappreciationrightsanduptomillionsharesofcommonstock maybeissuedsubjecttofullvalueawardsawardswillgenerallybecountedonaforbasisagainstthesharereserve providedthatifmorethanmillionfullvalueawardsaregrantedeachfullvalueawardinexcessofmillionwillbe countedonaforbasisagainstthesharereservesharesavailableforfuturegrantsunderthelongterm incentiveplanweremillionattheendoffiscalyear johnsonjohnsonannualreport thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforfiscalyearsandrespectivelythetotalincometaxbenefitrecognizedintheincome statementforsharebasedcompensationcostswasmillionmillionandmillionforfiscalyear andrespectivelythecompanyalsorecognizedadditionalincometaxbenefitsofmillionmillion andmillionforfiscalyearsandrespectivelyforwhichoptionswereexercisedorrestrictedshare werevestedthetotalunrecognizedcompensationcostwasmillionmillionandmillionforfiscalyears andrespectivelytheweightedaverageperiodforthiscosttoberecognizedwasyear yearsandyearsforfiscalyearsandrespectivelysharebasedcompensationcost capitalizedaspartofinventorywereinsignificantinallperiod thecompanysettlesemployeebenefitequityissuanceswithtreasurysharestreasurysharesarereplenishedthrough marketpurchasesthroughouttheyearforthenumberofsharesusedtosettleemployeebenefitequityissuance stockoption stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrant thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableforandgrantsexpectedvolatilityrepresentsa blendedrateofyearweeklyhistoricaloverallvolatilityrateandaweekaverageimpliedvolatilityratebasedonatthe moneytradedjohnsonjohnsonoptionswithalifeofyearsforallgrantshistoricaldataisusedtodeterminethe expectedlifeoftheoptiontheriskfreeratewasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinfiscalyearsand respectivelythefairvaluewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyear expecteddividendyield asummaryofoptionactivityundertheplanasofjanuaryjanuaryandjanuaryandchange duringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weight value outstanding average dollarsin sharesinthousand share exerciseprice millions sharesatdecember optionsgrante optionsexercised optionscanceledforfeite sharesatjanuary optionsgrante optionsexercised optionscanceledforfeite sharesatjanuary optionsgrante optionsexercised optionscanceledforfeited sharesatjanuary johnsonjohnsonannualreportthetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninfiscalyear andrespectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatjanuary sharesinthousand outstanding exercisable weighted weight average average average exercise exercise exercisepricerange option life price option price averagecontractualliferemaininginyear stockoptionsoutstandingatjanuaryandjanuarywereandanaveragelifeofyearsand andanaveragelifeofyearsrespectivelystockoptionsexercisableatjanuaryandjanuary wereatanaveragepriceofandatanaveragepriceofrespectively restrictedshareunitsandperformance shareunit thecompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrommonthstoyearsthe companyalsograntsperformanceshareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockafterthe endofathreeyearperformanceperiodperformancesharesweregrantedwithtwoequallyweightedgoalsthatdirectly alignwithorhelpdrivelongtermtotalshareholderreturnadjustedoperationalearningspershareandrelativetotal shareholderreturnthenumberofsharesactuallyearnedattheendofthethreeyearperiodwillvarybasedonlyonactual performancefromtoofthetargetnumberofperformanceshareunitsgrante asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofjanuaryis presentedbelow outstanding outstanding restricted performance sharesinthousand shareunit shareunit sharesatjanuary grant issue canceledforfeitedadjuste sharesatjanuary theaveragefairvalueoftherestrictedshareunitsgrantedwasandinfiscalyear andrespectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswa discountedfordividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueof restrictedshareunitsissuedwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitsgrantedwasandinfiscal yearsandcalculatedusingtheweightedaveragefairmarketvalueforeachofthecomponentgoalsat thedateofgrant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelthefairvalueof performanceshareunitsissuedwasmillionmillionandmillioninfiscalyearsand respectively johnsonjohnsonannualreport segment business geographic area salestocustomer change dollarsinmillion consumerhealth otc international worldwide skinhealthbeauty international worldwide oralcare international worldwide babycare international worldwide womenshealth international worldwide woundcareother international worldwide totalconsumerhealth international worldwide johnsonjohnsonannualreportsalestocustomer change dollarsinmillion pharmaceutical immunology international worldwide remicade usexport international worldwide simponisimponiaria international worldwide stelara international worldwide tremfya international worldwide otherimmunology international worldwide infectiousdisease international worldwide covidvaccine international worldwide edurantrilpivirine international worldwide prezistaprezcobixrezolstasymtuza international worldwide johnsonjohnsonannualreport salestocustomer change dollarsinmillion otherinfectiousdisease international worldwide neuroscience international worldwide concertamethylphenidate international worldwide invegasustennaxeplioninvegatrinzatrevicta international worldwide risperdalconsta international worldwide otherneuroscience international worldwide oncology international worldwide darzalex international worldwide erleada international worldwide imbruvica international worldwide zytigaabirateroneacetate international worldwide johnsonjohnsonannualreportsalestocustomer change dollarsinmillion otheroncology international worldwide pulmonaryhypertension international worldwide opsumit international worldwide uptravi international worldwide international worldwide cardiovascularmetabolismother international worldwide xarelto international worldwide invokanainvokamet international worldwide international worldwide totalpharmaceutical international worldwide johnsonjohnsonannualreport salestocustomer change dollarsinmillion medtech interventionalsolution international worldwide orthopaedic international worldwide hip international worldwide knee international worldwide trauma international worldwide spinesportsother international worldwide surgery international worldwide advance international worldwide general international worldwide vision international worldwide contactlensesother international worldwide johnsonjohnsonannualreportsalestocustomer change dollarsinmillion surgical international worldwide totalmedtech international worldwide worldwide international worldwide certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthanornotmeaningful approximatelybillioninboththefiscalandofcertaininternationalotcproductsprimarilyinchinawere reclassifiedfromthepharmaceuticalsegmenttotheconsumerhealthsegmentbasedonoperationalchange inclusiveofprocriteprexwhichwaspreviouslydisclosedseparately previouslyreferredtoasmedicaldevice incomelossbeforetax identifiableasset dollarsinmillion consumerhealth pharmaceutical medtech total lessexpensenotallocatedtosegment lessconsumerhealthseparationcost generalcorporate worldwidetotal incomebeforetaxofapproximatelybillionandbillioninthefiscalyearsandrespectivelyhasbeenreclassifie ascertaininternationalotcproductsprimarilyinchinawerereclassifiedfromthepharmaceuticalsegmenttotheconsumerhealth segmentbasedonoperationalchange additionstoproperty depreciationand plantequipment amortization dollarsinmillions consumerhealth pharmaceutical medtech segmentstotal generalcorporate worldwidetotal johnsonjohnsonannualreport salestocustomer longlivedasset dollarsinmillion unitedstate europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedasset worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperate exportsalesarenotsignificantinfiscalyearthecompanyutilizedthreewholesalersdistributingproductsforall threesegmentsthatrepresentedapproximatelyandofthetotalconsolidatedrevenuesinfiscalyear thecompanyhadthreewholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately andofthetotalconsolidatedrevenuesinfiscalyearthecompanyhadthreewholesaler distributingproductsforallthreesegmentsthatrepresentedapproximatelyandofthetotal consolidatedrevenue amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense generalcorporateincludescashcashequivalentsandmarketablesecuritie consumerhealthinclude litigationexpenseofbillion arestructuringrelatedchargeofbillion pharmaceuticalinclude onetimecovidvaccinemanufacturingexitrelatedcostsofbillion anintangibleassetimpairmentchargeofapproximatelybillionrelatedtoaninprocessresearchand developmentassetbermekimabjnjaninvestigationaldrugforthetreatmentofatopicdermatitisad andhidradenitissuppurativahsacquiredwiththeacquisitionofxbiotechincinthefiscalyearadditional informationregardingefficacyoftheadandhsindicationsbecameavailablewhichledthecompanytothedecision toterminatethedevelopmentofbermekimabforadandhs litigationexpenseofbillion lossofbillionrelatedtothechangeinthefairvalueofsecuritie arestructuringrelatedchargeofbillion medtechinclude litigationexpenseofbillionprimarilyforpelvicmeshrelatedcost arestructuringrelatedchargeofbillion acquisitionandintegrationrelatedcostsofbillionprimarilyrelatedtotheacquisitionofabiome amedicaldeviceregulationchargeofbillion consumerhealthinclude litigationexpenseofbillionprimarilytalcrelatedcost arestructuringrelatedchargeofbillion pharmaceuticalinclude litigationexpenseofbillionprimarilyrelatedtorisperdalgynecomastia divestituregainsofbillion gainsofbillionrelatedtothechangeinthefairvalueofsecuritie arestructuringrelatedchargeofbillion johnsonjohnsonannualreportmedtechinclude arestructuringrelatedchargeofbillion aninprocessresearchanddevelopmentexpenseofbillionrelatedtoottava amedicaldeviceregulationchargeofbillion litigationexpenseofbillion consumerhealthinclude litigationexpenseofbillionprimarilytalcrelatedcostsandcertainsettlement pharmaceuticalinclude litigationexpenseofbillionprimarilyrelatedtotheagreementinprincipletosettleopioidlitigation againofbillionrelatedtothechangeinthefairvalueofsecuritie arestructuringrelatedchargeofbillion medtechinclude acontingentconsiderationreversalofbillionrelatedtothetimingofcertaindevelopmentalmilestone associatedwiththeaurishealthacquisition litigationexpenseofbillion arestructuringrelatedchargeofbillion aninprocessresearchanddevelopmentexpenseofbillion amedicaldeviceregulationchargeofbillion longlivedassetsincludepropertyplantandequipmentnetforfiscalyearsandofand respectivelyandintangibleassetsandgoodwillnetforfiscalyearsandofand respectively acquisition divestiture duringthefiscalyearcertainbusinesseswereacquiredforbillionincashandbillionofliabilitie assumedtheseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshave beenincludedinthefinancialstatementsfromtheirrespectivedatesofacquisition theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandha beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thefiscalyearacquisitionsprimarilyincludedabiomedincabiomedtheremainingacquisitionswerenot material ondecemberthecompanycompletedtheacquisitionofabiomedaleadingfirsttomarketproviderof cardiovascularmedicaltechnologywithafirstinkindportfolioforthetreatmentofcoronaryarterydiseaseandheartfailure whichalsohasanextensiveinnovationpipelineoflifesavingtechnologiesthetransactionbroadensthecompany positionasagrowingcardiovascularinnovatoradvancingthestandardofcareinheartfailureandrecoveryoneof healthcareslargestareasofunmetneedthetransactionwasaccountedforasabusinesscombinationandtheresultsof operationswereincludedinthemedtechsegmentasofthedateoftheacquisitiontheacquisitionwascomplete throughatenderofferforalloutstandingsharestheconsiderationpaidintheacquisitionconsistedofanupfrontpayment ofpershareincashamountingtobillionnetofcashacquiredaswellasanontradeablecontingent valuerightcvrentitlingtheholdertoreceiveuptopershareincashwhichwithrespecttothecvrstotal approximatelybillionintheaggregateifcertaincommercialandclinicalmilestonesareachievedthecorresponding enterprisevaluewithouttakingintoaccountthecvrsofapproximatelybillionincludescashcashequivalentsand marketablesecuritiesacquire themilestonesofthecvrconsistof apersharepayableifnetsalesforabiomedproductsexceedsbillionduringjohnsonjohnsonsfiscal secondquarterofthroughfiscalfirstquarteroforifthisthresholdisnotmetduringthisperiodandis subsequentlymetduringanyrollingfourquarterperioduptotheendofjohnsonjohnsonsfiscalfirstquarterof pershare bpersharepayableuponfdapremarketapplicationapprovaloftheuseofimpellaproductsinstelevate myocardialinfarctionstemipatientswithoutcardiogenicshockbyjanuaryand johnsonjohnsonannualreport cpersharepayableuponthefirstpublicationofaclassirecommendationfortheuseofimpellaproduct inhighriskpciorstemiwithorwithoutcardiogenicshockwithinfouryearsfromtheirrespectiveclinicalendpoint publicationdatesbutinallcasesnolaterthandecember thefairvalueoftheacquisitionwasallocatedtoassetsacquiredofbillionnetofbillioncashacquire primarilytogoodwillforbillionamortizableintangibleassetsforbillioniprdforbillionmarketable securitiesofbillionandliabilitiesassumedofbillionwhichincludesthefairvalueofthecontingent considerationmentionedaboveforbillionanddeferredtaxesofbillionthegoodwillisprimarilyattributableto thecommercialaccelerationandexpansionoftheportfolioandisnotexpectedtobedeductiblefortaxpurposesthe contingentconsiderationwasrecordedinotherliabilitiesontheconsolidatedbalancesheet astheacquisitionoccurredindecemberthecompanyisstillfinalizingtheallocationofthepurchasepricetothe individualassetsacquiredandliabilitiesassumedtheallocationofthepurchasepriceincludedinthecurrentperiod balancesheetisbasedonthebestestimateofmanagementandispreliminaryandsubjecttochangetoassist managementintheallocationthecompanyengagedvaluationspecialiststoprepareappraisalsthecompanywillfinalize theamountsrecognizedastheinformationnecessarytocompletetheanalysisisobtainedthecompanyexpectsto finalizetheseamountsassoonaspossiblebutnolaterthanoneyearfromtheacquisitiondate theamortizableintangibleassetswereprimarilycomprisedofalreadyinmarketproductsoftheimpellaplatformwithan averageweightedlifeofyearstheiprdassetswerevaluedfortechnologyprogramsforunapprovedproductsthe valueoftheiprdwascalculatedusingprobabilityadjustedcashflowprojectionsdiscountedfortheriskinherentinsuch projectstheprobabilityofsuccessfactorrangedfromtothediscountrateappliedwas inthecompanyrecordedacquisitionrelatedcostsbeforetaxofapproximatelybillionwhichwasrecordedin otherincomeexpense duringfiscalyearthecompanydidnotmakeanymaterialacquisition duringfiscalyearcertainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumed theseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeen includedinthefinancialstatementsfromtheirrespectivedatesofacquisition theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thefiscalyearacquisitionsprimarilyincludedallrightstotheinvestigationalcompoundbermekimabwhichha multipledermatologicalindicationsalongwithcertainemployeesfromxbiotechincxbiotechmomenta pharmaceuticalsincmomentaacompanythatdiscoversanddevelopsnoveltherapiesforimmunemediateddisease andtheoutstandingsharesinverbsurgicalincacompanywithsignificantroboticsanddatasciencecapabilitie duringthefiscalfirstquarterofthecompanycompletedtheacquisitionofallrightstotheinvestigationalcompound bermekimabwhichhasmultipledermatologicalindicationsalongwithcertainemployeesfromxbiotechincfora purchasepriceofbillionthefairvalueoftheacquisitionwasallocatedprimarilytononamortizableintangibleasset primarilyiprdforbillionapplyingaprobabilityofsuccessfactorthatrangedfromtotoreflectinherent developmentregulatoryandcommercialriskforthedifferentindicationsthediscountrateappliedwasapproximately thetransactionwasaccountedforasabusinesscombinationandincludedinthepharmaceuticalsegmentinfiscal thecompanyrecordedanintangibleassetimpairmentchargeofapproximatelybillionrelatedtothisin processresearchanddevelopmentasset additionallyinthefiscalfirstquarterofthecompanycompletedtheacquisitionofalloutstandingsharesinverb surgicalincacompanywithsignificantroboticsanddatasciencecapabilitiesincludingthosesharespreviouslyheldby verilythetransactionwasaccountedforasabusinesscombinationandincludedinthemedtechsegmentthefairvalue oftheacquisitionwasallocatedprimarilytononamortizableintangibleassetsprimarilyiprdforbilliongoodwillfor billionotherassetsofbillionandliabilitiesassumedofbillionthefairvalueofthecompanyspreviously heldequityinvestmentinverbsurgicalincwasbillion onoctoberthecompanycompletedtheacquisitionofmomentaforapurchasepriceofapproximately billionnetofcashacquiredthefairvalueoftheacquisitionwasallocatedprimarilytononamortizableintangible assetsiprdofbilliongoodwillofbillionotherassetsofbillionandliabilitiesofbilliontheasset acquiredareintendedtoaddresssubstantialunmetmedicalneedinmaternalfetaldisordersneuroinflammatory disordersrheumatologydermatologyandautoimmunehematologydependingontheassetprobabilityofsuccess factorsrangingfromtowereusedinthefairvaluecalculationtoreflectinherentdevelopmentandregulatory johnsonjohnsonannualreportriskoftheiprdthediscountrateappliedwasapproximatelythegoodwillisprimarilyattributabletosynergie expectedtoarisefromthebusinessacquisitionandisnotexpectedtobedeductiblefortaxpurposesthetransactionwa accountedforasabusinesscombinationandincludedinthepharmaceuticalsegment inaccordancewithusgaapstandardsrelatedtobusinesscombinationsandgoodwillandotherintangibleasset supplementalproformainformationforfiscalyearsandisnotprovidedastheimpactofthe aforementionedacquisitionsdidnothaveamaterialeffectonthecompanysresultsofoperation divestiture duringfiscalyearthecompanydidnotmakeanymaterialdivestiture duringfiscalyearinseparatetransactionsthecompanydivestedtwobrandsoutsidetheuswithinthe pharmaceuticalsegmentthecompanyrecognizedapretaxgainrecordedinotherincomeexpensenetof approximatelybillion duringfiscalyearthecompanysoldmillionsharesofidorsialtdidorsiaoritsownershipinthe companyatthattimethetransactionresultedingrossproceedsofapproximatelychfmillionmillionbased onasalespriceofchfshareandresultedinanimmaterialnetlossattheendoffiscalthecompanyhad rightstoapproximatelymillionsharesthroughaconvertibleloanwithaprincipalamountofchfmillionduejune duringfiscalyearthecompanyconvertedchfmillionmillionofthisloanintoapproximately millionsharesofidorsiawhichwerereflectedatfairvalueasofjanuaryduringthefiscalthirdquarterof thecompanysundrawncreditfacilitywithidorsiawasterminate legal proceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialindemnificationandothermattersgovernmentalinvestigationsandotherlegal proceedingsthatarisefromtimetotimeintheordinarycourseoftheirbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofjanuarythecompanyhas determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthe companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascfortheseand otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompany isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccruedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuchestimatesandjudgmentscanbe affectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtintheproceedingsare unsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedorisnotcompleteproceedingsarein earlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindisputeproceduralorjurisdictionalissue theuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachievecomprehensivemultiparty settlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerouspartiesinvolvedtothe extentadverseawardsjudgmentsorverdictshavebeenrenderedagainstthecompanythecompanydoesnotrecordan accrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimate inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod productliability thecompanyandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving multipleproductsclaimantsinthesecasesseeksubstantialcompensatoryandwhereavailablepunitivedamageswhile thecompanybelievesithassubstantialdefensesitisnotfeasibletopredicttheultimateoutcomeoflitigationfromtime totimeevenifithassubstantialdefensesthecompanyconsidersisolatedsettlementsbasedonavarietyof circumstancesthecompanyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewith johnsonjohnsonannualreport ascbasedoncurrentlyavailableinformationwhichinsomecasesmaybelimitedthecompanyaccruesan estimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonably estimatedforcertainofthesemattersthecompanyhasaccruedadditionalamountssuchasestimatedcostsassociated withsettlementsdamagesandotherlossesproductliabilityaccrualscanrepresentprojectedproductliabilityfor thousandsofclaimsaroundtheworldeachindifferentlitigationenvironmentsandwithdifferentfactpatternschangesto theaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable themostsignificantofthesecasesincludethedepuyasrxlacetabularsystemanddepuyasrhipresurfacing systemthepinnacleacetabularcupsystempelvicmeshesrisperdalbodypowderscontainingtalcprimarily johnsonsbabypowderethiconphysiomeshflexiblecompositemeshelmironandtylenolasof januaryintheunitedstatestherewereapproximatelyplaintiffswithdirectclaimsinpendinglawsuit regardinginjuriesallegedlyduetothedepuyasrxlacetabularsystemanddepuyasrhipresurfacingsystem withrespecttothepinnacleacetabularcupsystemwithrespecttopelvicmesheswithrespectto risperdalwithrespecttobodypowderscontainingtalcwithrespecttoethiconphysiomesh flexiblecompositemeshwithrespecttoelmironandwithrespecttotylenolthenumberofpending lawsuitsisexpectedtofluctuateascertainlawsuitsaresettledordismissedandadditionallawsuitsarefile inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemasrhipusedinhipreplacementsurgeryclaimsforpersonalinjury havebeenmadeagainstdepuyandthecompanycasesfiledinfederalcourtsintheunitedstateshavebeenorganize asamultidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictofohiolitigationhasalsobeen filedincountriesoutsideoftheunitedstatesprimarilyintheunitedkingdomcanadaaustraliairelandgermanyindia anditalyinnovemberdepuyreachedanagreementwithacourtappointedcommitteeoflawyersrepresente asrhipplaintiffstoestablishaprogramtosettleclaimswitheligibleasrhippatientsintheunitedstateswhohad surgerytoreplacetheirasrhipsknownasrevisionsurgeryasofaugustdepuyreachedadditionalagreementsin februaryandmarchwhichfurtherextendedthesettlementprogramtoincludeasrhippatientswhohad revisionsurgeriesafteraugustandpriortofebruarythissettlementprogramhasresolvedmorethan claimstherebybringingtoresolutionsignificantasrhiplitigationactivityintheunitedstateshoweverlawsuit intheunitedstatesremainandthesettlementprogramdoesnotaddresslitigationoutsideoftheunitedstatesin australiaaclassactionsettlementwasreachedthatresolvedtheclaimsofthemajorityofasrhippatientsinthat countryincanadathecompanyhasreachedagreementstosettletheclassactionsfiledinthatcountrythecompany continuestoreceiveinformationwithrespecttopotentialadditionalcostsassociatedwiththisrecallonaworldwidebasis thecompanyhasestablishedaccrualsforthecostsassociatedwiththeunitedstatessettlementprogramandasrhip relatedproductliabilitylitigation claimsforpersonalinjuryhavealsobeenmadeagainstdepuyorthopaedicsincandthecompanycollectivelydepuy relatingtothepinnacleacetabularcupsystemusedinhipreplacementsurgeryproductliabilitylawsuitscontinueto befiledandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casesmostcasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationinthe unitedstatesdistrictcourtforthenortherndistrictoftexastexasmdlbeginningonjunethejudicialpanel onmultidistrictlitigationceasedtransferofnewcasesintothetexasmdlandtherearenowcasespendinginfederal courtoutsidethetexasmdllitigationalsohasbeenfiledinstatecourtsandincountriesoutsideoftheunitedstates priortoseveraladverseverdictshadbeenrenderedagainstdepuyoneofwhichwasreversedonappealand remandedforretrialduringthefirstquarterofdepuyestablishedaunitedstatessettlementprogramtoresolve thesecasesaspartofthesettlementprogramadverseverdictshavebeensettledthecompanyhasestablishedan accrualforproductliabilitylitigationassociatedwiththepinnacleacetabularcupsystemandtherelatedsettlement program claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandthecompanyarisingoutofethiconspelvic meshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethecompanycontinuestoreceive informationwithrespecttopotentialcostsandadditionalcasescasesfiledinfederalcourtsintheunitedstateshad beenorganizedasamultidistrictlitigationmdlintheunitedstatesdistrictcourtforthesoutherndistrictofw virginiainmarchthemdlcourtenteredanorderclosingthemdlthemdlcourthasremandedcasesfortrialto thejurisdictionswherethecasewasoriginallyfiledandadditionalpelvicmeshlawsuitshavebeenfiledandremain outsideofthemdlthecompanyhassettledorotherwiseresolvedthemajorityoftheunitedstatescasesandthe estimatedcostsassociatedwiththesesettlementsandtheremainingcasesarereflectedinthecompanysaccrualsin additionclassactionsandindividualpersonalinjurycasesorclaimsseekingdamagesforallegedinjuryresultingfrom ethiconspelvicmeshdeviceshavebeencommencedinvariouscountriesoutsideoftheunitedstatesincludingclaim andcasesintheunitedkingdomthenetherlandsbelgiumfranceirelanditalyspainandsloveniaandclassactionsin israelaustraliacanadaandsouthafricainnovemberthefederalcourtofaustraliaissuedajudgmentregarde johnsonjohnsonannualreportitsfindingswithrespecttoliabilityinrelationtothethreeleadapplicantsandgenerallyinrelationtothedesign manufacturepreandpostmarketassessmentsandtestingandsupplyandpromotionofthedevicesinaustraliausedto treatstressurinaryincontinenceandpelvicorganprolapseinseptemberafterexhaustingitsappealsthecompany reachedaninprincipleagreementtoresolvethetwopelvicmeshclassactionsinaustraliapendingfederalcourt approvalinnovembertheapplicationforapprovalofthesettlementwasfiledandahearingonthesettlementhas beenscheduledfortheendoffebruarytheclassactionsincanadawerediscontinuedinasaresultofa settlementofagroupofcasesandanagreementtoresolvetheisraeliclassactionwasreachedinmaytheparties intheisraeliclassactionarecurrentlyfinalizingthetermsofthesettlementamotiontoapprovethesettlementwasfile withthecourtthecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigationassociatedwithethicon pelvicmeshproduct followingajuneworldwidemarketwithdrawalofethiconphysiomeshflexiblecompositemesh physiomeshclaimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandthecompanyallege personalinjuryarisingoutoftheuseofthisherniameshdevicecasesfiledinfederalcourtsintheunitedstateshave beenorganizedasamultidistrictlitigationmdlintheunitedstatesdistrictcourtforthenortherndistrictofgeorgiaa multicountylitigationmclalsohasbeenformedinnewjerseystatecourtandassignedtoatlanticcountyforcase pendinginnewjerseyinadditiontothemattersinthemdlandmclthereareadditionallawsuitspendinginthe unitedstatesdistrictcourtforthesoutherndistrictofohiowhicharepartofthemdlforpolypropylenemeshdevice manufacturedbycrbardincandlawsuitspendingintwonewjerseymclsformedforproceedproceedventral patchandproleneherniasystemsandlawsuitspendingoutsidetheunitedstatesinmayethiconandlead counselfortheplaintiffsenteredintoatermsheettoresolveapproximatelyphysiomeshcasescovering approximatelyplaintiffspendinginthemdlandmclatthattimeamastersettlementagreementmsawas enteredintoinseptemberandincludescasesinthemdlandmclalldeadlinesandtrialsettingsinthose proceedingsarecurrentlystayedpendingthecompletionofthesettlementagreementofthecasessubjecttothemsa havebeendismissedwithprejudicepostsettlementcasesinthephysiomeshmdlandmclaresubjecttodocket controlordersrequiringearlyexpertreportsanddiscoveryrequirementsasofjanuarythereareapproximately activecasessubjecttotheseorderswhicharebeingreviewedandevaluate claimshavealsobeenfiledagainstethiconandthecompanyallegingpersonalinjuriesarisingfromtheproceedmesh andproceedventralpatchherniameshproductsinmarchthenewjerseysupremecourtenteredanorder consolidatingthesecasespendinginnewjerseyasanmclinatlanticcountysuperiorcourtadditionalcaseshave beenfiledinvariousfederalandstatecourtsintheunitedstatesandinjurisdictionsoutsidetheunitedstates ethiconandthecompanyalsohavebeensubjecttoclaimsforpersonalinjuriesarisingfromtheprolenepolypropylene herniasysteminjanuarythenewjerseysupremecourtcreatedanmclinatlanticcountysuperiorcourtto handlesuchcasescasesinvolvingthisproducthavealsobeenfiledinotherfederalandstatecourtsintheunitedstate inoctoberanagreementinprinciplesubjecttovariousconditionswasreachedtosettlethemajorityofthe pendingcasesinvolvingproceedproceedventralpatchproleneherniasystemandrelatedmultilayeredmeshproduct alllitigationactivitiesinthetwonewjerseymclsarestayedpendingresolutionoftheproposedsettlementfuturecase thatarefiledinthenewjerseymclswillbesubjecttodocketcontrolordersrequiringearlyexpertreportsanddiscovery requirement thecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigationassociatedwithethicon physiomeshflexiblecompositemeshproceedmeshandproceedventralpatchandprolenepolypropylene herniasystemproduct claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandthecompanyarisingoutoftheuse ofrisperdalandrelatedcompoundsindicatedforthetreatmentofschizophreniaacutemanicormixedepisode associatedwithbipolaridisorderandirritabilityassociatedwithautismlawsuitsprimarilyhavebeenfiledinstatecourtsin pennsylvaniacaliforniaandmissouriotheractionsarependinginvariouscourtsintheunitedstatesandcanada productliabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotential costsandtheanticipatednumberofcasesthecompanyhassuccessfullydefendedanumberofthesecasesbutthere havebeenverdictsagainstthecompanyincludingaverdictinoctoberofbillionofpunitivedamagesrelate tooneplaintiffwhichthetrialjudgereducedtomillioninjanuaryinseptemberthecompanyentere intoasettlementinprinciplewiththecounselrepresentingplaintiffsinthismatterandinsubstantiallyalloftheoutstande casesintheunitedstatesthecostsassociatedwiththisandothersettlementsarereflectedinthecompanysaccrual claimsforpersonalinjuryarisingoutoftheuseofxareltoanoralanticoagulanthavebeenmadeagainstjanssen pharmaceuticalsincjpithecompanyandjpiscollaborationpartnerforxareltobayerhealthcareagandcertain johnsonjohnsonannualreport ofitsaffiliatescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationinthe unitedstatesdistrictcourtfortheeasterndistrictoflouisianainadditioncaseswerefiledinstatecourtsacrossthe unitedstatesmanyofthesecaseswereconsolidatedintoastatemasstortlitigationinphiladelphiapennsylvaniaandin acoordinatedproceedinginlosangelescaliforniaclassactionlawsuitsalsohavebeenfiledincanadainmarch jpiandthecompanyannouncedanagreementinprincipletosettlethexareltocasesintheunitedstatesthe settlementagreementwasexecutedinmaythesettlementbecamefinalindecemberandthesettlementwa fundedinjanuarythisresolvedthemajorityofcasespendingintheunitedstatesthecompanyhasestablishe accrualsforitscostsassociatedwiththeunitedstatessettlementprogramandxareltorelatedproductliability litigation asignificantnumberofpersonalinjuryclaimsallegingthattalccausescancerweremadeagainstjohnsonjohnson consumerincandthecompanyarisingoutoftheuseofbodypowderscontainingtalcprimarilyjohnsonsbaby powderthenumberofthesepersonalinjurylawsuitsfiledinstateandfederalcourtsintheunitedstatesaswellas outsideoftheunitedstatescontinuedtoincrease intalccasesthatpreviouslyhavegonetotrialthecompanyhasobtainedanumberofdefenseverdictsbuttherealso havebeenverdictsagainstthecompanymanyofwhichhavebeenreversedonappealinjunethemissouricourt ofappealsreversedinpartandaffirmedinpartajulyverdictofbillionininghamvjohnsonjohnsonetal noedmoappreducingtheoverallawardtobillionanapplicationfortransferofthecasetothe missourisupremecourtwassubsequentlydeniedandinjuneapetitionforcertiorariseekingareviewofthe inghamdecisionbytheunitedstatessupremecourtwasdeniedinjunethecompanypaidtheawardwhich includinginteresttotaledapproximatelybillionthefactsandcircumstancesincludingthetermsoftheawardwere uniquetotheinghamdecisionandnotrepresentativeofotherclaimsbroughtagainstthecompanythecompany continuestobelievethatithasstronglegalgroundstocontesttheothertalcverdictsthatithasappeale notwithstandingthecompanysconfidenceinthesafetyofitstalcproductsincertaincircumstancesthecompanyha settledcase inoctoberjohnsonjohnsonconsumerincoldjjciimplementedacorporaterestructuringthe corporaterestructuringasaresultofthatrestructuringoldjjciceasedtoexistandthreenewentitieswerecreate altlmanagementllcanorthcarolinalimitedliabilitycompanyltlordebtorbroyaltyamllcanorth carolinalimitedliabilitycompanyandadirectsubsidiaryofltlramandcthedebtorsdirectparentjohnson johnsonconsumerincanewjerseycompanynewjjcithedebtorreceivedcertainofoldjjcisassetsandbecame solelyresponsibleforthetalcrelatedliabilitiesofoldjjciincludingallliabilitiesrelatedinanywaytoinjuryordamageor allegedinjuryordamagesustainedorincurredinthepurchaseoruseoforexposuretotalcincludingtalccontainedin anyproductortotheriskoforresponsibilityforanysuchdamageorinjuryexceptforanyliabilitiesforwhichthe exclusiveremedyisprovidedunderaworkerscompensationstatuteoractthetalcrelatedliabilitie inoctobernotwithstandingthecompanysconfidenceinthesafetyofitstalcproductsthedebtorfiledavoluntary petitionwiththeunitedstatesbankruptcycourtforthewesterndistrictofnorthcarolinacharlottedivisionseeke reliefunderchapterofthebankruptcycodetheltlbankruptcycaseasaresultoftheltlbankruptcycasethe northcarolinabankruptcycourtenteredatemporaryrestrainingorderstayingalllitigationagainstltlandoldjjcion novemberthenorthcarolinabankruptcycourtconfirmedthescopeofthestayissuingapreliminaryinjunction piprohibitingandenjoiningthecommencementandprosecutionoftalcrelatedclaimsagainstltloldjjcinewjjci thecompanyotheroftheircorporateaffiliatesidentifiedretailersinsurancecompaniesandcertainotherpartiesthe protectedpartiestheltlbankruptcycasewastransferredtotheunitedstatesbankruptcycourtforthedistrictof newjerseyinnovemberandthatcourtextendedthepithroughtheendoffebruaryclaimantsfiledmotion todismisstheltlbankruptcycaseandfollowingamultipledayhearingthenewjerseybankruptcycourtdeniedthose motionsbyorderissuedinmarchthenewjerseybankruptcycourtsimultaneouslyissuedanotherorderextende thestayastotheprotectedpartiestheclaimantssubsequentlyfilednoticesofappealastothedenialofthemotionsto dismissandtheextensionofthestayinmaythethirdcircuitcourtofappealsgrantedthepetitionstoappealthe briefingandoralargumentontheappealwerecompletedinseptemberonjanuarythethirdcircuit reversedthebankruptcycourtsrulingandremandedtothebankruptcycourttodismisstheltlbankruptcyltlfileda petitionforrehearingonthedecision whilethenewjerseybankruptcycourtsordereffectivelystaysallofthecompanystalcrelatedpersonalinjurylitigation ltlhasagreedtoliftthestayonasmallnumberofappealswhereappealbondshavebeenfile thecompanyhasagreedtoprovidefundingtoltlforthepaymentofamountsthenewjerseybankruptcycourt determinesareowedbyltlandtheestablishmentofabilliontrustinfurtheranceofthispurposethecompanyhas establishedareserveforapproximatelybillioninconnectionwiththeaforementionedtrustafterandasaresultofthe johnsonjohnsonannualreportfilingoftheltlbankruptcycasethecompanydeconsolidatedltlwhichisarelatedpartytheimpactofthede consolidationisnotmaterialtothecompanythepartieshavenotyetreachedaresolutionofalltalcmattersintheltl bankruptcycaseandthecompanyisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountaccrue aclassactionadvancingclaimsrelatingtoindustrialtalcwasfiledagainstthecompanyandothersinnewjerseystate courtinmaytheedleyclassactiontheedleyclassactionassertsamongotherthingsthatthecompany fraudulentlydefendedpastasbestospersonalinjurylawsuitsarisingfromexposuretoindustrialtalcminedmilledand manufacturedbeforejanuarybythecompanysthenwhollyownedsubsidiarywindsormineralsincwhichis currentlyadebtorintheimerysbankruptcydescribedhereafterthecompanyremovedtheedleyclassactiontofederal courtinthedistrictofnewjerseyinjulyimerysfiledamotionintheimerysbankruptcytostaytheedleyclass actionwhichwasdeniedinaugustinoctoberthecompanyfiledmotionstodismissandtodeny certificationofaclasstopursuetheedleyclassactioninthenewjerseydistrictcourt infebruarythecompanystalcsupplierimerystalcamericaincandtwoofitsaffiliatesimerystalcvermontinc andimerystalccanadainccollectivelyimerysfiledavoluntarypetitionunderchapteroftheunitedstatescode thebankruptcycodeintheunitedstatesbankruptcycourtforthedistrictofdelawareimerysbankruptcytheimerys bankruptcyrelatestoimerysspotentialliabilityforpersonalinjuryfromexposuretotalcumpowdersoldbyimerysinit bankruptcyimerysallegesithasclaimsagainstthecompanyforindemnificationandrightstojointinsuranceproceedsin mayimerysitsparentimeryssathetortclaimantscommitteetccandthefutureclaimantsrepresentative fcrcollectivelytheplanproponentsfiledtheirplanofreorganizationtheplanandthedisclosurestatementrelate theretotheplanproponentshavesincefilednumerousamendmentstotheplananddisclosurestatementahearingon theplanproponentsdisclosurestatementwasheldinjanuaryandthecourtenteredanorderapprovingthe disclosurestatementallowingimerystoproceedwithsolicitingvotesontheplan inmarchthecompanyvotedtorejecttheplanandoptedoutoftheconsensualreleasesintheplaninapril theplanproponentsannouncedtheplanhadreceivedtherequisitenumberofacceptingvotestoconfirmtheplanthe companychallengedcertainimproprietieswithrespecttoportionsofthevoteandsoughttodisqualifythosevotesin octoberthebankruptcycourtissuedarulingdeemingthousandsofvotesaswithdrawn inoctoberimeryscancelledtheconfirmationhearingontheplanimerysthetccthefcrcertainofimeryss insurersandcertainpartiesinthecyprusmineschaptercasedescribedbelowcollectivelythemediationpartie agreedtoengageinmediationthemostrecenttermofthemediationendedondecember injulyimeryscommencedanadversaryproceedingagainstthecompanyintheimerysbankruptcytheimerys adversaryproceedingtheimerysadversaryproceedingsoughtamongotherthingscertaindeclarationswithrespectto theindemnificationobligationsallegedlyowedbythecompanytoimerysthetccandfcrsimultaneouslyfiledamotion fortemporaryrestrainingorderandpreliminaryinjunctionseekingtoenjointhecompanyfromundergoingacorporate restructuringthatwouldseparatethecompanystalcliabilitiesfromitsotherassetsthebankruptcycourtdeniedthe motionthecompanythereafterfiledamotiontodismisstheadversaryproceedingthebankruptcycourthasnotyet decidedthemotiontodismissinoctoberthecompanyfiledanoticeofbankruptcyfilingandstayof proceedingsclarifyingthattheautomaticstayarisinguponthefilingoftheltlbankruptcycaseshouldapplytothe imerysadversaryproceede injunecyprusminescorporationanditsparentcyprusamaxmineralscompanycamctogethercyprus whichhadownedcertainimerystalcminesfiledanadversaryproceedingagainstthecompanyandimerysintheimerys bankruptcyseekingadeclarationofindemnityrightsundercertaincontractualagreementsthecyprusadversary proceedingthecompanydeniessuchindemnificationisowedandfiledamotiontodismisstheadversarycomplaintin februarycyprusfiledavoluntarypetitionforreliefunderchapterofthebankruptcycodeandfileditsdisclosure statementandplanthecyprusplanthecyprusplancontemplatesasettlementwithimerysandtalcclaimantswhere cypruswouldmakeamonetarycontributiontoatrustestablishedundertheimerysplaninexchangeforaninjunction againsttalcclaimsassertedagainstitandcertainprotectedpartiescyprushasnotyetsoughtapprovalofitsdisclosure statementandplancyprusalongwiththetccandfcrappointedinthecypruschaptercasehaveagreedto participateinthemediationwiththemediationpartiesinoctoberthecompanyfiledanoticeofbankruptcyfiling andstayofproceedingsclarifyingthattheautomaticstayarisinguponthefilingoftheltlbankruptcycaseshouldapply tothecyprusadversaryproceedinginjunecypruscommencedanadversaryproceedinginitschaptercase seekinganorderenforcingtheautomaticstaybyenjoiningpartiesfromcommencingorcontinuingtalcrelatedclaim againstcamcinjunethecourtenteredapreliminaryinjunctionorderenjoiningclaimantsfrompursuingtalc relatedclaimsagainstcamcthroughjanuary johnsonjohnsonannualreport infebruaryseveralofthecompanysinsurersinvolvedincoveragelitigationinnewjerseystatecourtthe coverageactionfiledamotionintheimerysbankruptcycourtproceedingseekingadeterminationthattheautomatic staydoesnotapplytothecoverageactionandinthealternativeseekingrelieffromtheautomaticstaytoallowthemto continuetolitigatetheirclaimsinthecoverageactioninmarchthecompanyfiledalimitedresponseand reservationofrightswithrespecttothemotionthecourtenteredanagreedordermodifyingthestaytoallowthe litigationinthecoverageactiontocontinueinoctoberltlfiledanoticeofbankruptcyfilingandstayof proceedingsclarifyingthattheautomaticstayarisinguponthefilingoftheltlbankruptcycaseshouldapplytothe coverageactioninmarchthenewjerseybankruptcycourtruledthattheltlautomaticstayappliedtothe coverageaction infebruaryasecuritiesclassactionlawsuitwasfiledagainstthecompanyandcertainnamedofficersinthe unitedstatesdistrictcourtforthedistrictofnewjerseyallegingthatthecompanyviolatedthefederalsecuritieslawsby failingtodiscloseallegedasbestoscontaminationinbodypowderscontainingtalcprimarilyjohnsonsbabypowder andthatpurchasersofthecompanyssharessufferedlossesasaresultplaintiffisseekingdamagesinaprilthe companymovedtodismissthecomplaintandbriefingonthemotionwascompleteasofaugustindecember thecourtdeniedinpartthemotiontodismissinmarchthecompanyansweredthecomplaintinapril briefingonplaintiffsmotionforclasscertificationwascompletedinjulythecompanyfiledanoticeofsupplemental authorityinoppositiontoplaintiffsmotionforclasscertificationandplaintifffiledaresponseindecemberthe companyfiledamotiontosupplementtheclasscertificationrecordandinjanuaryplaintiffrespondedin marchltlaskedthenewjerseybankruptcycourttostaythesecuritiesclassactioninaprildefendantsfile asecondmotiontosupplementtheclasscertificationrecordinmaythenewjerseybankruptcycourtenteredan orderstayingthesecuritiesclassactionplaintiffhasappealedthebankruptcycourtsorder alawsuitwasbroughtagainstthecompanyinthesuperiorcourtofcaliforniaforthecountyofsandiegoallege violationsofcaliforniasconsumerlegalremediesactclrarelatingtojohnsonsbabypowderinthatlawsuitthe plaintiffsallegethatthecompanyviolatedtheclrabyfailingtoproviderequiredpropositionwarningsinjuly thecompanyfiledanoticeofremovaltotheunitedstatesdistrictcourtforthesoutherndistrictofcaliforniaand plaintiffsfiledasecondamendedcomplaintshortlythereafterinoctoberthecompanymovedtodismissthe secondamendedcomplaintforfailuretostateaclaimuponwhichreliefmaybegrantedinresponsetothosemotion plaintiffsfiledathirdamendedcomplaintindecemberthecompanymovedtodismissthethirdamendedcomplaint forfailuretostateaclaimuponwhichreliefmaybegrantedinaprilthecourtgrantedthemotiontodismissbut grantedleavetoamendinmayplaintiffsfiledafourthamendedcomplaintbutindicatedthattheywouldbefilinga motionforleavetofileafifthamendedcomplaintplaintiffsfiledafifthamendedcomplaintinaugustthecompany movedtodismissthefifthamendedcomplaintforfailuretostateaclaimuponwhichreliefmaybegrantedin januarythecourtissuedanorderandopinionrulinginthecompanysfavorandgrantingthemotiontodismiss withprejudiceinfebruaryplaintiffsfiledanoticeofappealwiththeninthcircuitplaintiffsfiledtheiropeningbrief injulythecompanyfileditsresponsivebriefinoctoberinoctobernoticeofsuggestionof bankruptcywasfiledwiththeninthcircuitabankruptcystaywasimposedindecemberandthecourtheldthe replydeadlineinabeyanceinfebruarythebankruptcycourtissuedanorderextendingthestaytheappeal continuestobeheldinabeyancewiththecompanybeingrequiredtofileperiodicstatusupdate inadditionthecompanyhasreceivedinquiriessubpoenasandrequeststoproducedocumentsregardingtalcmatter andtheltlbankruptcycasefromvariousgovernmentalauthoritiesthecompanyhasproduceddocumentsand respondedtoinquiriesandwillcontinuetocooperatewithgovernmentinquirie claimsforpersonalinjuryhavebeenmadeagainstanumberofjohnsonjohnsoncompaniesincludingjanssen pharmaceuticalsincandthecompanyarisingoutoftheuseofinvokanaaprescriptionmedicationindicatedto improveglycemiccontrolinadultswithtypediabetesindecemberlawsuitsfiledinfederalcourtsinthe unitedstateswereorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofnewjersey caseshavealsobeenfiledinstatecourtsclassactionlawsuitshavebeenfiledincanadaproductliabilitylawsuit continuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipate numberofcasesthecompanyhassettledorotherwiseresolvedmanyofthecasesandclaimsintheunitedstatesand thecostsassociatedwiththesesettlementsarereflectedinthecompanysaccrual claimsforpersonalinjuryhavebeenmadeagainstanumberofjohnsonjohnsoncompaniesincludingjanssen pharmaceuticalsincandthecompanyarisingoutoftheuseofelmironaprescriptionmedicationindicatedforthe reliefofbladderpainordiscomfortassociatedwithinterstitialcystitistheselawsuitswhichallegethatelmiron contributestothedevelopmentofpermanentretinalinjuryandvisionlosshavebeenfiledinbothstateandfederalcourts acrosstheunitedstatesindecemberlawsuitsfiledinfederalcourtsintheunitedstatesincludingputativeclass johnsonjohnsonannualreportactioncasesseekingmedicalmonitoringwereorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtfor thedistrictofnewjerseyinadditioncaseshavebeenfiledinvariousstatecourtsofnewjerseywhichhavebeen coordinatedinamulticountylitigationinbergencountyaswellasthecourtofcommonpleasinphiladelphiawhich havebeencoordinatedandgrantedmasstortdesignationinadditionthreeclassactionlawsuitshavebeenfiledin canadaproductliabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespectto potentialcostsandtheanticipatednumberofcasesthecompanyhasestablishedaccrualsfordefenseandindemnity costsassociatedwithelmironrelatedproductliabilitylitigation claimsforpersonalinjuryhavebeenmadeagainstjohnsonandjohnsonconsumerincjjciarisingoutoftheuseof tylenolanoverthecounterpainmedicationallegingthatprenatalexposuretoacetaminophenisassociatedwiththe developmentofautismspectrumdisorderandorattentiondeficithyperactivitydisorderinoctoberlawsuitsfiledin federalcourtsintheunitedstateswereorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthe southerndistrictofnewyorkinadditionlawsuitshavebeenfiledincanadaproductliabilitylawsuitscontinuetobe filedandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casesthecompanyhasestablishedaccrualsfordefensecostsassociatedwithtylenolrelatedproductliability litigation intellectualproperty certainsubsidiariesofthecompanyaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedtopatent trademarkandotherintellectualpropertymattersarisingoutoftheirbusinessesmanyofthesemattersinvolvechallenge tothecoverageandorvalidityofthepatentsonvariousproductsandallegationsthatcertainofthecompanysproduct infringethepatentsofthirdpartiesalthoughthesesubsidiariesbelievethattheyhavesubstantialdefensestothese challengesandallegationswithrespecttoallsignificantpatentstherecanbenoassuranceastotheoutcomeofthese mattersalossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproductsresultin lossofsalesduetolossofmarketexclusivityrequirethepaymentofpastdamagesandfutureroyaltiesandmayresultin anoncashimpairmentchargeforanyassociatedintangibleassetsignificantmattersaredescribedbelow medtech inaugustintuitivesurgicalincandintuitivesurgicaloperationsinccollectivelyintuitivefiledapatent infringementsuitagainstaurishealthincaurisinunitedstatesdistrictcourtforthedistrictofdelawareinthesuit intuitiveallegeswillfulinfringementofuspatentnosand basedonaurismonarchplatformaurisfilediprpetitionswiththeuspatentandtrademark officeusptoregardingtheandpatentsindecembertheusptodeniedreviewofthe patentinfebruaryandmarchtheusptoinstitutedreviewoftheandpatentsanddeniedreview ofthepatentinmarchtheusptoruledthatthechallengedclaimsoftheandpatentsarenot invalidaurisappealedandinapriltheunitedstatescourtofappealsforthefederalcircuitvacatedthedecision thatthepatentwasnotinvalidandremandedthedecisiontotheusptoforfurtherreviewinmaythe unitedstatescourtofappealsforthefederalcircuitconfirmedtherulingthatclaimofthepatentwasnot invalidvacatedthedecisionthattheremainingclaimsofthepatentwerenotinvalidandremandedthedecisionto theusptoforfurtherreviewaurisfiledarequestforreexaminationofthepatentinnovemberandin januarytheusptograntedthereexaminationrequesttrialisscheduledtobegininseptember inaugustrsbspinellcrsbspinefiledapatentinfringementsuitagainstdepuysynthesincinthe unitedstatesdistrictcourtforthedistrictofdelawareinoctoberrsbspineamendedthecomplainttochange thenameddefendantstodepuysynthessalesincanddepuysynthesproductsincinthesuitrsbspineallege willfulinfringementofuspatentnosandbyoneormoreofthefollowingproduct zeropvaspacerzeropspacerzeropnaturalplatesynfixlrspacerandsynfixevolutionsystemrsb spineseeksmonetarydamagesandinjunctivereliefinnovemberthesuitwasconsolidatedforpretrialpurpose withotherpatentinfringementsuitsbroughtbyrsbspineintheunitedstatesdistrictcourtforthedistrictofdelaware againstlifespineincmedactausaincandprecisionspineincinjunedepuyfiledpotentiallydispositive summaryjudgmentmotionsthatthepatentisinvalidasanticipatedandthepatentisnotinfringedin novemberthecourtgranteddepuyssummaryjudgmentmotionthatthepatentisinvalidasanticipatedand denieddepuysmotionthatthepatentisnotinfringedindecemberthecourtconductedajurytrialonthe patentwherethejuryfoundthatthepatentwasnotliterallyinfringedbutthatdepuyinfringedunderthe doctrineofequivalentsdoethejuryawardedrsbmillionindamagessubjecttoposttrialmotionsandappeals johnsonjohnsonannualreport inoctoberrasmusseninstrumentsllcrasmussenfiledapatentinfringementsuitagainstdepuysynthe productsincdepuysynthessalesincandmedicaldevicebusinessservicesinccollectivelydepuyinthe unitedstatesdistrictcourtforthedistrictofmassachusettsrasmussenallegesthatdepuywillfullyinfringesuspatent nosandbymakingandsellingtheattunebalancedsizerinapril rasmussensoughtpermissiontoamenditsinfringementcontentionstoallegethatdepuyalsowillfullyinfringesthe patentbymakingandsellingtheattunebalancingblocksrasmussenseekstrebledamagesforwillfulinfringement trialconcludedinmarchwiththejuryreturningaverdictinfavorofrasmussenfindingwillfulinfringementofthe patentandawardingdamagesintheamountofmilliondepuychallengedtheverdictinitsposttrialmotionsin julyahearingwasheldontheposttrialmotion pharmaceutical litigationagainstfilersofabbreviatednewdrugapplicationsanda thefollowingsummarizeslawsuitsthecompanyssubsidiarieshavebroughtagainstgenericcompaniesthathavefile andaswiththeusfdaorundertakensimilarregulatoryprocessesoutsideoftheunitedstatesseekingtomarket genericformsofproductssoldbyvarioussubsidiariesofthecompanypriortoexpirationoftheapplicablepatent coveringthoseproductstheseandastypicallyincludeallegationsofnoninfringementandinvalidityoftheapplicable patentstheinterpartesreviewiprprocesswiththeusptocreatedundertheamericainventsactisalso beingusedattimesbygenericcompaniesinconjunctionwithandasandlawsuitstochallengetheapplicablepatentsin theeventthecompanyssubsidiariesarenotsuccessfulinanactionortheautomaticstatutorystayoftheandasexpire beforetheunitedstatesdistrictcourtrulingsareobtainedthegenericcompaniesinvolvedwouldhavetheabilityupon approvaloftheusfdatointroducegenericversionsoftheirproductstothemarketresultinginthepotentialfor substantialmarketshareandrevenuelossesfortheapplicableproductsandwhichmayresultinanoncashimpairment chargeinanyassociatedintangibleassetinadditionfromtimetotimethecompanyssubsidiariesmaysettlethesetype ofactionsandsuchsettlementscaninvolvetheintroductionofgenericversionsoftheproductsatissuetothemarket priortotheexpirationoftherelevantpatent zytiga beginninginjanuaryjanssenincjanssenoncologyincandbtginternationalltdcollectivelyjanssen initiatedstatementsofclaimundersectionofthepatentedmedicinesnoticeofcomplianceregulationsincanada againstapotexincapotexpharmascienceincpharmascienceanddrreddyslaboratoriesltdanddrreddys laboratoriesinccollectivelydrlinresponsetothosepartiesfilingofabbreviatednewdrugsubmissionsands seekingapprovaltomarketgenericversionsofzytigabeforetheexpirationofthecanadianpatentno thetrialintheseactionsconcludedinnovemberandthecourtissuedadecisionholdingthepatent invalidinjanuaryinfebruaryjanssenappealedthedecisiontheappealhearingtookplacein septemberinnovemberjanssensappealwasdismisse inapriljulyandaprilrespectivelyapotexdrlandpharmascienceinitiatedstatementsofclaim undersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainstjanssenseekingdamagesin respectofthosepartiesgenericzytigatabletstrialsagainstapotexanddrlarescheduledforjuneatrialdatefor thepharmascienceactionhasnotbeenset xarelto beginninginmarchjanssenpharmaceuticalsincjpiandbayerpharmaagandbayeragcollectivelybayer filedpatentinfringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofdelawareagainstanumberof genericcompanieswhofiledandasseekingapprovaltomarketgenericversionsofxareltomgbeforeexpiration ofuspatentnothefollowinggenericdrugcompaniesarenameddefendantsdrreddys laboratoriesincanddrreddyslaboratoriesltdlupinlimitedandlupinpharmaceuticalsinctaropharmaceutical industriesltdandtaropharmaceuticalsusaincandtevapharmaceuticalsusaincinoctoberthecourt consolidatedthedelawarelawsuitsforallpurposesincludingtrialtrialfortheconsolidateddelawarelawsuitsis scheduledtobegininmay injulyjpiandbayerfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthenortherndistrict ofwestvirginiaagainstmylanpharmaceuticalsincandmylaninccollectivelymylanwhichfiledanandaseeke approvaltomarketagenericversionofxareltomgbeforeexpirationofthepatentinaugustjpiand bayerfiledamotionbeforetheunitedstatesjudicialpanelonmultidistrictlitigationthemdlpaneltotransferthis johnsonjohnsonannualreportlawsuittotheunitedstatesdistrictcourtforthedistrictofdelawareforcoordinatedandconsolidatedpretrial proceedingsindecemberthemdlpanelgrantedthemotioninaugustafterreceivingasecondnotice letterfrommylanregardingthesameandajpiandbayerfiledasecondpatentinfringementlawsuitintheunitedstates districtcourtforthenortherndistrictofwestvirginiaagainstmylaninseptembermylanmovedtodismissthe secondlawsuitinseptemberthemdlpaneltransferredthesecondlawsuittothedistrictofdelawarenotrial datehasbeensetforthesetwolawsuitsinoctobermylanvoluntarilywithdrewitsmotiontodismiss ineachoftheselawsuitsjpiandbayerareseekinganorderenjoiningdefendantsfrommarketingtheirgenericversionof xareltomgbeforetheexpirationofthepatentinjanuarythecourtissuedanorderstayingthe lawsuitsuntilafterafinalwrittendecisionisissuedintheinterpartesreviewproceedingsonthepatent infebruarymylanpharmaceuticalsincfiledapetitionforinterpartesreviewiprwiththeunitedstatespatent andtrademarkofficeusptoseekingtoinvalidatethepatentinaugustthepatenttrialandappealboard ptabissuedadecisioninstitutingipr inseptemberinvagenpharmaceuticalsincfiledapetitionforiprwiththeusptoseekingtoinvalidatethe patentalsoinseptembertevapharmaceuticalsusaincfiledapetitionforiprwiththeusptoseekingto invalidatethepatentinoctobertheptabissueddecisionsinstitutingiprinbothproceedingsandjoine themwiththeearlieriprproceedingfiledbymylanpharmaceuticalsinc inseptemberjpibayerandbayerintellectualpropertygmbhbipinitiatedapatentinfringementlawsuitinthe unitedstatesdistrictcourtforthedistrictofnewjerseyagainstusvprivatelimitedusvwhofiledanandaseeke approvaltomarketgenericversionsofxareltomgmgmgandmgbeforetheexpirationofthe patentanduspatentnojpibayerandbipareseekinganorderenjoiningusvfrommarkete itsgenericversionofxareltomgbeforetheexpirationofthepatentanditsgenericversionsofxarelto mgmgandmgbeforetheexpirationofthepatentinnovemberthemdlpaneltransferredthis lawsuittotheunitedstatesdistrictcourtforthedistrictofdelaware inseptemberjpibayeragandbipinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtfor thedistrictofnewjerseyagainstmankindpharmalimitedmankindwhofiledanandaseekingapprovaltomarket genericversionsofxareltomgmgandmgbeforetheexpirationofthepatentjpibayeragandbip areseekinganorderenjoiningmankindfrommarketingitsgenericversionsofxareltobeforetheexpirationofthe patent innovemberjpibayerandbipinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofdelawareagainstepicpharmallcepicwhofiledanandaseekingapprovaltomarketgenericversionsof xareltomgmgmgandmgbeforetheexpirationofthepatentandthepatentjpibayer andbipareseekinganorderenjoiningepicfrommarketingitsgenericversionofxareltomgbeforetheexpiration ofthepatentanditsgenericversionsofxareltomgmgandmgbeforetheexpirationofthe patent indecemberjpiandbayerinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofdelawareagainstapotexincandapotexcorpcollectivelyapotexwhofiledanandaseekingapprovaltomarket genericversionsofxareltomgbeforetheexpirationofthepatentjpiandbayerareseekinganorder enjoiningapotexfrommarketingitsgenericversionofxareltomgbeforetheexpirationofthepatent opsumit inmayjanssenincjanssenandactelionpharmaceuticalsltdactelioninitiatedastatementofclaimunder sectionofthepatentedmedicinesnoticeofcomplianceregulationsagainstsandozcanadaincsandozincanada inresponsetosandozsfilingofanandsseekingapprovaltomarketagenericversionofopsumitmgbeforethe expirationofcanadianpatentnosandozstipulatedtoinfringementofthepatenttrialagainst sandozontheissueofvalidityconcludedinfebruaryandinmaythecourtissuedadecisioninfavorof janssenandactelioninjunesandozappealedthedecision inmayjanssenandactelioninitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexincapotexincanadainresponsetoapotexsfilingofanandsseeke approvaltomarketagenericversionofopsumitmgbeforetheexpirationofthepatentapotexstipulatedto validityofthepatenttrialagainstapotexontheissueofinfringementconcludedinmarchandinmay thecourtissuedadecisioninfavorofjanssenandactelioninjuneapotexappealedthedecision johnsonjohnsonannualreport injanuaryjanssenandactelioninitiatedastatementofclaimundersectionofthepatentedmedicinesnotice ofcomplianceregulationsagainstgenericmedicalpartnersincgmpincanadainresponsetogmpsfilingofan andsseekingapprovaltomarketagenericversionofopsumitmgbeforetheexpirationofcanadianpatentnos ineachofthesecanadianactionsjanssenandactelionareseekinganorderenjoiningthedefendantsfrommarkete theirgenericversionsofopsumitbeforetheexpirationoftherelevantpatent injanuaryactelionpharmaceuticalsltdandactelionpharmaceuticalsusinccollectivelyactelioninitiateda patentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainstsunpharmaceutical industrieslimitedandsunpharmaceuticalindustriesinccollectivelysunwhofiledanandaseekingapprovalto marketagenericversionofopsumitbeforetheexpirationofuspatentnosand actelionisseekinganorderenjoiningsunfrommarketingtheirgenericversionsofopsumitbeforetheexpirationofthe andpatents invegasustenna injanuaryjanssenpharmaceuticanvandjanssenpharmaceuticalsinccollectivelyjansseninitiatedapatent infringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainsttevapharmaceuticalsusa inctevawhichfiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforethe expirationofuspatentnotrialconcludedinoctoberinoctoberthecourtissueda decisioninjanssensfavortevahasappealedthedecision inaugustjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstmylanlaboratorieslimitedmylanwhichfiledanandaseekingapprovaltomarketagenericversion ofinvegasustennabeforetheexpirationofthepatentpursuanttoanagreementbythepartiesjudgmentin favorofjanssenwasenteredindecembermylanappeale indecemberjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtsforthedistrictsof newjerseyanddelawareagainstpharmascienceincmallinckrodtplcandspecgxllccollectivelypharmascience whichfiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforetheexpirationofthe patent innovemberjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof delawareagainsttolmarinctolmartherapeuticsinctolmarpharmaceuticalsincandtolmarholdinginc collectivelytolmarwhichfiledanandaseekingapprovaltomarketagenericversionofinvegasustennabefore theexpirationofthepatentatrialisscheduledtobegininoctober infebruaryjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstaccordhealthcareincaccordhealthcareltdandintaspharmaceuticalsltdcollectivelyaccord whofiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforetheexpirationofthe patent ineachoftheseuslawsuitsjanssenisseekinganorderenjoiningthedefendantfrommarketingagenericversionof invegasustennabeforetheexpirationoftherelevantpatent infebruaryjanssenincandjanssenpharmaceuticanvcollectivelyjanssencanadainitiatedastatementof claimundersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainsttevacanadalimite tevacanadainresponsetotevasfilingofanandsseekingapprovaltomarketagenericversionofinvega sustennabeforetheexpirationofcanadianpatentnosandjanssensubsequently discontinuedtheportionofthelawsuitrelatingtothepatentinmaythecanadianfederalcourtissueda publicjudgmentandreasonsdeclaringthattevacanadasgenericversionofinvegasustennaifapprovedwould infringecertainclaimsofthepatentandthattheclaimsofthepatentarenotinvalidtevacanadaappeale innovemberjanssencanadainitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstpharmascienceincinresponsetopharmascienceincsfilingofanandsseeke approvaltomarketagenericversionofinvegasustennabeforetheexpirationofthepatentasummarytrialon theissueofinfringementtookplaceinnovemberinjanuarythecourtissuedadecisioninfavorofjanssen ontheissueofinfringementpharmasciencefiledanappealinmarchjanssencanadainitiatedastatementof claimundersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainstpharmascienceinresponse topharmasciencesfilingofanandsseekingapprovaltomarketagenericversionofanadditionalstrengthof johnsonjohnsonannualreportinvegasustennabeforetheexpirationofthepatenttheactionhasbeenconsolidatedwiththenovember actionfortrialwhichtookplaceinjulyinaugustthecourtissuedadecisionfindingtheclaimsof thepatentarenotinvalidpharmascienceappeale injanuaryjanssencanadainitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexincapotexinresponsetoapotexsfilingofanandsoriginalandsseeke approvaltomarketagenericversionofinvegasustennabeforetheexpirationofthepatentasummarytrialon theissueofinfringementtookplaceindecemberinjanuarythecourtissuedadecisioninfavorofjanssen ontheissueofinfringementapotexappeale injunejanssencanadainitiatedstatementsofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexinresponsetoapotexsnoticeofallegationofinvaliditywithrespecttothe originalandsandinresponsetoapotexsfilingofanandsseekingapprovaltomarketagenericversionofanadditional strengthofinvegasustennabeforetheexpirationofthepatentatrialisscheduledtobegininmarch ineachofthesecanadianlawsuitsjanssencanadaisseekinganorderenjoiningthedefendantfrommarketingageneric versionofinvegasustennabeforetheexpirationoftherelevantpatents invegatrinza inseptemberjanssenpharmaceuticalsincjanssenpharmaceuticanvandjanssenresearchdevelopment llccollectivelyjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstmylanlaboratorieslimitedmylanpharmaceuticalsincandmylaninstitutionalllccollectively mylanmylanfiledanandaseekingapprovaltomarketgenericversionsofinvegatrinzamgbeforeexpiration ofuspatentnorelatingtoinvegatrinzamg inaugustjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstmylanmylanfiledanandaseekingapprovaltomarketgenericversionsofinvegatrinzamg beforeexpirationofthepatent inoctoberjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstmylanmylanfiledanandaseekingapprovaltomarketgenericversionsofinvegatrinzamgand mgbeforeexpirationofthepatent injanuarythecourtconsolidatedthethreecasesintothecasefiledinseptemberineachofthese consolidatedcasesjanssenisseekinganorderenjoiningmylanfrommarketingitsgenericversionsofinvegatrinza beforeexpirationofthepatenttrialwasconductedinnovemberanddecemberandposttrialbriefingis proceedingclosingargumentswillbeheldinmarch imbruvica inmarchpharmacyclicsllcpharmacyclicsandjanssenbiotechincjbifiledapatentinfringementlawsuitin theunitedstatesdistrictcourtforthedistrictofdelawareagainstalvogenpinebrookllcandnatcopharmaltd collectivelyalvogenwhichfiledanandaseekingapprovaltomarketgenericversionsofimbruvicatabletsasserte infringementofuspatentnos injunepharmacyclicsandjbiamendedtheircomplaintagainstalvogentofurtherallegeinfringement ofuspatentno trialagainstalvogentookplaceinoctoberinaugustthedistrictcourtissuedadecisioninfavorof pharmacyclicsandjanssenfindingtheassertedclaimsagainstalvogentobeinfringedandnotinvalidinnovember theunitedstatescourtofappealsforthefederalcircuitaffirmedthedistrictcourtsdecision inseptemberpharmacyclicsandjanssenincjanssencanadainitiatedstatementsofclaimundersectionof thepatentedmedicinesnoticeofcomplianceregulationsagainstnatcopharmacanadaincnatcoinresponseto natcosfilingoftwoandssseekingapprovaltomarketgenericversionsofimbruvicacapsulesbeforetheexpirationof canadianpatentnos andinthislawsuitpharmacyclicsandjanssencanadaareseekinganorder enjoiningnatcofrommarketingitsgenericversionofimbruvicabeforetheexpirationoftherelevantpatentstrialis scheduledtobegininjuly johnsonjohnsonannualreport inoctoberpharmacyclicsandjanssencanadainitiatedasecondstatementofclaimundersectionofthe patentedmedicinesnoticeofcomplianceregulationsagainstnatcoinresponsetonatcosfilingofanandsseeke approvaltomarketagenericversionofimbruvicacapsulesbeforetheexpirationoftheand patentsandcanadianpatentnointhislawsuitpharmacyclicsandjanssencanadaareseekinganorder enjoiningnatcofrommarketingitsgenericversionofimbruvicacapsulesbeforetheexpirationoftherelevantpatent trialinthissecondactionisscheduledtobegininaugust infebruarypharmacyclicsandjanssencanadainitiatedastatementofclaimundersectionofthepatente medicinesnoticeofcomplianceregulationsagainstsandozcanadaincsandozinresponsetosandozsfilingofan andsseekingapprovaltomarketagenericversionofimbruvicacapsulesbeforetheexpirationofthe andpatentsalsoinfebruarypharmacyclicsandjansseninitiatedastatementofclaimundersectionof thepatentedmedicinesnoticeofcomplianceregulationsagainstsandozassertingtheandpatentswhich arealsolistedinhealthcanadaspatentregisterforimbruvicaintheselawsuitspharmacyclicsandjanssencanada areseekinganorderenjoiningsandozfrommarketingitsgenericversionofimbruvicacapsulesbeforetheexpirationof therelevantpatentsatrialdatefortheseactionshasnotbeenset symtuza innovemberjanssenproductslpandjanssensciencesirelandunlimitedcompanycollectivelyjanssenand gileadsciencesincandgileadsciencesirelanduccollectivelygileadinitiatedapatentinfringementlawsuitinthe unitedstatesdistrictcourtforthedistrictofdelawareagainstlupinlimitedlupinpharmaceuticalsincmsn laboratoriesprivateltdmsnlifesciencesprivateltdandmsnpharmaceuticalsinccollectivelylupinwhichfile anandaseekingapprovaltomarketagenericversionofsymtuzabeforetheexpirationofuspatentno andthetrialisscheduledtobegininoctober inoctoberjanssenproductslpandjanssensciencesirelandunlimitedcompanycollectivelyjanssenand gileadsciencesincandgileadsciencesirelanduccollectivelygileadinitiatedapatentinfringementlawsuitinthe unitedstatesdistrictcourtforthedistrictofdelawareagainstapotexincandapotexcorpcollectivelyapotexwhich filedanandaseekingapprovaltomarketagenericversionofsymtuzabeforetheexpirationoftheand patent ineachoftheseuslawsuitsjanssenisseekinganorderenjoiningthedefendantfrommarketingagenericversionof symtuzabeforetheexpirationoftherelevantpatent erleada inmayaragonpharmaceuticalsincandjanssenbiotechinccollectivelyjanssenandsloanketteringinstitute forcancerresearchskiinitiatedpatentinfringementlawsuitsinunitedstatesdistrictcourtforthedistrictsof newjerseyanddelawareagainstlupinlimitedandlupinpharmaceuticalsinccollectivelylupinwhichfiledananda seekingapprovaltomarketagenericversionoferleadabeforetheexpirationofuspatentnoin augustjanssenandskifiledafirstamendedcomplaintagainstlupinaddinguspatentnos andtothesuitjanssenandskiareseekinganorderenjoine lupinfrommarketingitsgenericversionoferleadabeforetheexpirationoftheandpatent inaugustjanssenandskivoluntarilydismissedthedelawarecomplaintthenewjerseyactionisproceede inmayjanssenandskiinitiatedapatentinfringementlawsuitinunitedstatesdistrictcourtforthedistrictof newjerseyagainstzydusworldwidedmcczyduspharmaceuticalsusaincandzyduslifescienceslimite collectivelyzyduswhichfiledanandaseekingapprovaltomarketagenericversionoferleadabeforetheexpiration oftheandpatentsjanssenandskiareseekinganorderenjoiningzydusfrommarketingit genericversionoferleadabeforetheexpirationoftheandpatent inmayjanssentheregentsoftheuniversityofcaliforniaucandskiinitiatedpatentinfringementlawsuitsin unitedstatesdistrictcourtforthedistrictsofnewjerseyanddelawareagainstsandozincsandozwhichfiledan andaseekingapprovaltomarketagenericversionoferleadabeforetheexpirationofthepatentanduspatent nosandinaugustjanssenucand skifiledafirstamendedcomplaintagainstsandozaddingtheandpatentstothesuitinaugust janssenucandskivoluntarilydismissedthedelawarecomplaintindecemberjanssenucandskifile asecondamendedcomplaintagainstsandozwithdrawingtheandpatentsfromthesuitwithout prejudicejanssenucandskiareseekinganorderenjoiningsandozfrommarketingitsgenericversionoferleada beforetheexpirationoftheandpatentsthenewjerseyactionisproceeding johnsonjohnsonannualreportinmayjanssenucandskiinitiatedpatentinfringementlawsuitsinunitedstatesdistrictcourtforthedistrictsof newjerseyanddelawareagainsteugiapharmaspecialitieslimitedaurobindopharmausaincandauromedic pharmallccollectivelyeugiawhichfiledanandaseekingapprovaltomarketagenericversionoferleadabefore theexpirationoftheandpatentsinseptemberjanssenucandskifiledafirst amendedcomplaintagainsteugiaaddinguspatentnosand tothesuitinseptemberjanssenucandskivoluntarilydismissedthedelawarecomplaint janssenucandskiareseekinganorderenjoiningeugiafrommarketingitsgenericversionoferleadabeforethe expirationoftheandpatentsthenewjerseyactionisproceeding inmayjanssenucandskiinitiatedpatentinfringementlawsuitsinunitedstatesdistrictcourtforthedistrictsof newjerseyanddelawareagainstheterolabslimitedunitvandheterousainccollectivelyheterowhichfiledan andaseekingapprovaltomarketagenericversionoferleadabeforetheexpirationofthe andpatentsjanssenucandskiareseekinganorderenjoiningheterofrommarketingitsgenericversionof erleadabeforetheexpirationoftheandpatentsinaugustjanssenucand skivoluntarilydismissedthedelawarecomplaintthenewjerseyactionisproceede uptravi inaugustactelionpharmaceuticalsltdandjansseninccollectivelyjanssenandnipponshinyakuconippon shinyakuinitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeofcomplianceregulation againstsandozcanadaincinresponsetosandozsfilingofanandsseekingapprovaltomarketgenericversionsof uptravitabletsbeforetheexpirationofcanadianpatentnosandinthislawsuitjanssenand nipponshinyakuareseekinganorderenjoiningsandozfrommarketingitsgenericversionofuptravibeforethe expirationoftherelevantpatentsatrialisscheduledtobegininmay innovemberactelionpharmaceuticalsusincandactelionpharmaceuticalsltdcollectivelyactelionandnippon shinyakucoltdnipponshinyakuinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofdelawareagainstalembicpharmaceuticalslimitedandalembicpharmaceuticalsinccollectivelyalembic whofiledanandaseekingapprovaltomarketgenericversionsofuptraviinjectionforintravenoususebeforeexpiration ofuspatentnosandrelatingtouptraviinthislawsuitactelionandnippon shinyakuareseekinganorderenjoiningalembicfrommarketingagenericversionofuptravibeforetheexpirationofthe relevantpatentsatrialdatehasnotbeenset infebruaryactelionandnipponshinyakuinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourt forthedistrictofdelawareagainstlupinltdandlupinpharmaceuticalsinccollectivelylupinwhofiledananda seekingapprovaltomarketgenericversionsofuptraviinjectionforintravenoususebeforeexpirationoftheand patentsrelatingtouptraviinthislawsuitactelionandnipponshinyakuareseekinganorderenjoininglupinfrom marketingagenericversionofuptravibeforetheexpirationoftherelevantpatentsatrialdatehasnotbeenset otherlitigation innovemberjanssenpharmaceuticanvjanssenprovidedtoalkermespharmairelandlimitedelanpharma internationallimitedandelandrugdeliveryincthreemonthsnoticeofterminationofalicenseagreementbyand amongelanpharmaceuticalresearchcorpdbananosystemselanpharmainternationallimitedandjanssen executedinmarchinnovemberjanssenalsoprovidedtoalkermespharmairelandlimitedthreemonth noticeofterminationofalicenseagreementbetweenelanpharmainternationallimitedandjanssenexecutedinjuly inaprilinresponsetothesenoticesalkermespharmairelandlimitedalkermesinitiatedarbitrationinthe internationalinstituteforconflictpreventionandresolutionthepartiesexchangedopeningbriefsinjulyand responsivebriefsinseptemberindecemberthearbitrationtribunalissuedaninterimdecisionfindingthat janssenmayterminatetheagreementsbutitmaynotcontinuetosellproductsdevelopedduringthetermofthe agreementswithoutcontinuingtopayroyaltiestoalkermes governmentproceedings likeothercompaniesinthepharmaceuticalconsumerhealthandmedicaldevicesindustriesthecompanyandcertainof itssubsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunitedstate andothercountriesinwhichtheyoperatesuchregulationhasbeenthebasisofgovernmentinvestigationsandlitigations themostsignificantlitigationbroughtbyandinvestigationsconductedbygovernmentagenciesarelistedbelowitis possiblethatcriminalchargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfromgovernment investigationsorlitigation johnsonjohnsonannualreport averagewholesalepriceawplitigation thecompanyandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompanieswerenamedasdefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolving allegationsthatthepricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwise actionableconductbecauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesaleprice awpforthedrugsatissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsthe plaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseof thedrugsatissuebasedonawpandstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissue basedonawpmanyofthesecasesbothfederalactionsandstateactionsremovedtofederalcourtwereconsolidate forpretrialpurposesinamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofmassachusettswhere allclaimsagainstthejjawpdefendantswereultimatelydismissedthejjawpdefendantsalsoprevailedinacase broughtbythecommonwealthofpennsylvaniaotherawpcaseshavebeenresolvedthroughcourtorderorsettlement thecasebroughtbyillinoiswassettledaftertrialinnewjerseyaputativeclassactionbaseduponawpallegationsis pendingagainstcentocorincandorthobiotechincbothnowjanssenbiotechincthecompanyandalza corporationallothercaseshavebeenresolve opioidlitigation beginninginandcontinuingtothepresentthecompanyandjanssenpharmaceuticalsincjpialongwithother pharmaceuticalcompanieshavebeennamedinclosetolawsuitsrelatedtothemarketingofopioidsinclude duragesicnucyntaandnucyntaerthesuitsalsoraiseallegationsrelatedtopreviouslyownedactive pharmaceuticalingredientsuppliersubsidiariestasmanianalkaloidsptyltdandnoramcoincbothsubsidiarieswere divestedinthemajorityofthecaseshavebeenfiledbystateandlocalgovernmentssimilarlawsuitshavealso beenfiledbyprivateplaintiffsandorganizationsincludingbutnotlimitedtothefollowingindividualplaintiffsonbehalfof childrenbornwithneonatalabstinencesyndromehospitalsandhealthinsurerspayorstodatecomplaintsagainst pharmaceuticalmanufacturersincludingthecompanyandjpihavebeenfiledbythestateattorneysgeneralin arkansasfloridaidahoillinoiskentuckylouisianamississippimissourinevadanewhampshirenewjerseynew mexiconewyorkohiooklahomasouthdakotatexaswashingtonandwestvirginiacomplaintsagainstthe manufacturersalsohavebeenfiledinstateorfederalcourtbycitycountyandlocalgovernmentagenciesineverystate butalaskathegovernmentofpuertoricofiledsuitinsuperiorcourtofsanjuan thecompanyjpiandotherpharmaceuticalcompanieshadalsoreceivedsubpoenasorrequestsforinformationrelate toopioidsmarketingpracticesfromthefollowingstateattorneysgeneralalaskaindianamontananewhampshire southcarolinatennesseetexasandwashingtoninseptemberthecompanyandjpiwerecontactedbythe texasandcoloradoattorneygeneralsofficesonbehalfofapproximatelystatesregardingamultistateattorney generalinvestigation inthetrialinthematterfiledbytheoklahomaattorneygeneralresultedinajudgmentagainstthecompanyandjpi intheamountofmillionthecompanyandjpiappealedthejudgmentandinnovembertheoklahoma supremecourtreversedthetrialcourtsjudgmentanddirectedentryofjudgmentfordefendantsinoctoberthe companyandjpiannouncedasettlementofthefirstcasesetfortrialinthemdlwithtwocountiesinohioinapril threecaliforniacountiesandthecityofoaklandcommencedatrialincaliforniastatecourtagainstthecompanyandjpi andotheraffiliatesaswellasthreeotherpharmaceuticalmanufacturersthetrialconcludedinoctoberandin decemberthecourtenteredafinaltrialjudgmentinfavorofdefendantsonallclaimsinfebruaryplaintiff motiontosetasideandvacatethejudgmentwasdeniedplaintiffsappealedthejudgmentbutlaterfiledarequestto dismisstheappealafterelectingtoparticipateinthenationalsettlementagreement inoctoberthecompanyannouncedaproposedagreementinprinciplethatwouldincludethecompanypaye billionassettlementofthesemattersthathadnotbeentriedorsettledinoctoberthecompanyagreedto contributeuptoanadditionalbilliontoanallinsettlementamountthatwouldresolveopioidlawsuitsfiledandfuture claimsbystatescitiescountiesandtribalgovernmentsforatotalofbillionwhichhasbeenaccruedsubjectto variousconditionsandanagreementbeingfinalizedthisagreementisnotanadmissionofliabilityorwrongdoingin julythecompanyannouncedthatthetermsoftheagreementtosettlethestateandsubdivisionclaimshadbeen finalizedandapproximatelyhalfoftheallinsettlementwasexpectedtobepaidbytheendoffiscalyeardepende uponthelevelofparticipationbythestatesandtheirsubdivisionsthetermsprovidedaperiodoftimeforstatestoelect toparticipateintheagreementandthereafteraperiodforthesubdivisionsoftheparticipatingstatestooptinbasedon expectedparticipationthecompanycommittedinadvancetoproceedwiththesettlementinfiveoftheparticipating statesnewyorktexasfloridanevadaandnewmexicoandwithtribalgovernmentsbylatefebruarystate johnsonjohnsonannualreportfiveterritoriesthedistrictofcolumbiaandthevastmajorityofeligiblesubdivisionshadelectedtoparticipateinthe settlementandthecompanyconfirmedthatthelevelofparticipationwassufficienttoproceedwiththeagreementasto allparticipantstheagreementwaseffectiveinaprilalsoinaprilthecompanyenteredintosettlement agreementswiththestatesofalabamaandwestvirginiaandtheirparticipatingsubdivisionsinjulythecompany reachedasettlementagreementwithalllitigatingoklahomasubdivisionsandinseptemberthecompanysettle withthestateofnewhampshireanditsparticipatingsubdivisionsconsequentlybytheendofthefiscalyearthe companyhadsettledtheopioidclaimsadvancedbyallstatesexceptwashington thereareapproximatelycasesremainingpostsettlementinvariousstatecourtsthereareapproximately remainingfederalcasesagainstthecompanyandjpicoordinatedinafederalmultidistrictlitigationmdlpendingin theusdistrictcourtforthenortherndistrictofohioandapproximatelyadditionalcasespendingagainstthe companyandjpiinotherfederalcourtsinadditiontheprovinceofbritishcolumbiafiledsuitagainstthecompanyand itscanadianaffiliatejanssenincandmanyotherindustrymembersincanadaandisseekingtohavethataction certifiedasanoptinclassactiononbehalfofotherprovincialterritorialandthefederalgovernmentsincanadaadditional proposedclassactionshavebeenfiledincanadaagainstthecompanyandjanssenincandmanyotherindustry membersbyandonbehalfofpeoplewhousedopioidsforpersonalinjuriesmunicipalitiesandfirstnationsbandsin octoberanantitrustcomplaintwasfiledbyprivateplaintiffsinfederalcourtintennesseeandispendingtransferto themdltheseactionsallegeavarietyofclaimsrelatedtoopioidmarketingpracticesincludingfalseadvertisingunfair competitionpublicnuisanceconsumerfraudviolationsdeceptiveactsandpracticesfalseclaimsandunjustenrichment thesuitsgenerallyseekpenaltiesandorinjunctiveandmonetaryreliefandinsomeofthesuitstheplaintiffsareseeke jointandseveralliabilityamongthedefendantsanadversejudgmentinanyoftheselawsuitscouldresultintheimposition oflargemonetarypenaltiesandsignificantdamagesincludingpunitivedamagescostofabatementsubstantialfines equitableremediesandothersanction inaugustthecompanyreceivedagrandjurysubpoenafromtheunitedstatesattorneysofficefortheeastern districtofnewyorkfordocumentsrelatedtothecompanysantidiversionpoliciesandproceduresanddistributionofit opioidmedicationsinwhatthecompanyunderstandstobepartofabroaderinvestigationintomanufacturersand distributorsmonitoringprogramsandreportingunderthecontrolledsubstancesact fromjunethroughdecemberthecompanysboardofdirectorsreceivedaseriesofshareholderdemand lettersallegingbreachesoffiduciarydutiesrelatedtothemarketingofopioidstheboardretainedindependentcounselto investigatetheallegationsinthedemandsandinaprilindependentcounseldeliveredareporttotheboard recommendingthatthecompanyrejecttheshareholderdemandsandtakethestepsthatarenecessaryorappropriateto securedismissalofrelatedderivativelitigationtheboardunanimouslyadoptedtherecommendationsoftheindependent counselsreport innovemberoneoftheshareholderswhosentademandfiledaderivativecomplaintagainstthecompanyasthe nominaldefendantandcertaincurrentandformerdirectorsandofficersasdefendantsinthesuperiorcourtofnew jerseythecomplaintallegesbreachesoffiduciarydutiesrelatedtothemarketingofopioidsandthatthecompanyhas suffereddamagesasaresultofthoseallegedbreachesaseriesofadditionalderivativecomplaintsmakingsimilar allegationsagainstthesameandsimilardefendantswerefiledinnewjerseystateandfederalcourtsinand byallbuttwostatecourtcaseshadbeenvoluntarilydismissedinfebruarythestatecourtgrantedthe companysmotiontodismissoneofthetwocasesandtheshareholderthatbroughtthesecondcasefiledanoticeof dismissaltheshareholderwhosecomplaintwasdismissedfiledamotionforreconsiderationinmaythestatecourt heldoralargumentonthemotionforreconsiderationandsubsequentlydeniedthemotiontheshareholderhasappeale thestatecourtsdismissalord inaugustdepuyorthopaedicsincdepuyincnowknownasdepuysynthesincandjohnsonjohnson servicesinccollectivelydepuyreceivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictof massachusettsandthecivildivisionoftheunitedstatesdepartmentofjusticetheunitedstatesfortheproductionof materialsrelatingtothedepuyasrxlhipdeviceinjulytheunitedstatesnotifiedtheunitedstatesdistrict courtforthedistrictofmassachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttothefalseclaim actagainstthecompaniesconcerningthehipdevicesinfebruarythedistrictcourtgrantedthecompanie motiontodismisswithprejudiceunsealedthequitamcomplaintanddeniedthequitamrelatorsrequestforleavetofilea furtheramendedcomplaintthequitamrelatorsappealedthecasetotheunitedstatescourtofappealsforthefirst circuitinjulythefirstcircuitaffirmedthedistrictcourtsdismissalinpartreversedinpartandaffirmedthe decisiontodenytherelatorsrequesttofileathirdamendedcomplaintinmarchdepuyfileditsmotiontostrikeand johnsonjohnsonannualreport dismisstherelatorssecondamendedcomplaintthedistrictcourtdenieddepuysmotiontostrikeanddismissin julydepuyfiledamotionforreconsiderationofthedistrictcourtsjulyrulinginnovemberthedistrict courtgranteddepuysmotionforreconsiderationanddismissedthecasewithprejudicethedistrictcourtsorderwa unsealedindecembertherelatorsfiledseveralpostdismissalmotionsincludingajanuaryomnibusmotion forreconsiderationwhichthedistrictcourtdeniedfollowingthedistrictcourtsorderdismissingthecasewith prejudicedepuyfiledadecembermotionseekingtherecoveryofattorneysfeesandcostswhichthedistrict courtdeniedexceptastocoststherelatorshaveappealedthedistrictcourtsdismissalofthecasetothefirstcircuit thebriefingontheappealiscompletethefirstcircuitheldoralargumentondecemberandthefirstcircuit decisionremainspende inoctoberthecompanywascontactedbythecaliforniaattorneygeneralsofficeregardingamultistateattorney generalinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesbythe companyssubsidiaryethiconincethiconinmaycaliforniaandwashingtonfiledcivilcomplaintsagainstthe companyethiconandethiconusllcallegingviolationsoftheirconsumerprotectionstatutessimilarcomplaintswere filedagainstthecompaniesbythefollowingstateskentuckymississippiwestvirginiaandoregoninaprilthe companyandethiconsettledthewashingtoncaseinoctoberthecompanyandethiconsettledthemultistate investigationwithotherstatesandthedistrictofcolumbiainaprilthecompanysettledthewestvirginiacase inoctoberthecompanysettledwiththeattorneygeneraloforegoninnovemberthecompanysettle withtheattorneygeneralofmississippitrialinthekentuckymatterisscheduledforjunethecaliforniacase startedtrialinjulyandconcludedinseptemberinjanuarythecourtincaliforniaissuedastatementof decisionfindinginfavorofthestateofcaliforniaandawardedcivilpenaltiesintheamountofmillioninapril thecourtincaliforniadeniedthecompanysmotionforanewtrialinaugustthecourtenteredjudgmentwith respecttothepenaltiesofmillionbutdeniedtheattorneygeneralsrequestforinjunctivereliefthecompany appealedthepenaltyjudgmentinaprilthecourtofappealsreducedthejudgmenttomillionbutotherwise deniedtheappealinjulythesupremecourtofcaliforniadeniedthecompanyspetitiontoreviewthecourtof appealsdecisionandthecompanyrecordedachargetoreflectthejudgmentinthesecondquarterofin novemberthecompanypetitionedtheunitedstatessupremecourtforreview injunethemississippiattorneygeneralfiledacomplaintinchancerycourtofthefirstjudicialdistrictofhind countymississippiagainstthecompanyandjohnsonjohnsonconsumercompaniesincnowknownasjohnson johnsonconsumerinccollectivelyjjcithecomplaintallegesthatjjciviolatedthemississippiconsumerprotection actbyfailingtodiscloseallegedhealthrisksassociatedwithfemaleconsumersuseoftalccontainedinjohnson babypowderandjohnsonsshowertoshoweraproductdivestedinandseeksinjunctiveandmonetaryrelief thecompanyandjjcimovedforsummaryjudgmentonthegroundsthatthestatesclaimwasbarredbypreemption whichthetrialcourtdeniedthemississippisupremecourtgrantedthecompanyandjjcisrequesttofilean interlocutoryappealofthedenialofthemotionforsummaryjudgmentinlatebriefingandoralargumentwere completedthereafterthecourtrejectedtheinterlocutoryappealinaprilandremandedthemattertothetrialcourt inaugustjjcifiledapetitionforwritofcertiorariintheunitedstatessupremecourtastothemississippi supremecourtsrulingofaprilindecembertheunitedstatessupremecourtdeniedthepetitionforwritof certiorariafterthemississippisupremecourtremandedthemattertothetrialcourtthestatemovedforatrialsette jjciobjectedtoanytrialsettingasbarredbythestayarisingfromtheltlbankruptcycasereferencedabovewhilethe statearguedthatthestaydidnotapplyinjanuarythecourtgrantedthestatesmotionfortrialsettingand directedthepartiestoconsultwiththecourtadministratortosecureatrialdateinfebruarythetrialcourtsetthe casefortrialtobegininfebruaryhowevergiventheeffortstoresolvetalcrelatedclaimsintheltlbankruptcy casethecompanyandthestateagreedtoatemporarystayofdiscoveryuntilmaythetemporarystayexpiredin mayltlthereaftermovedtoenjoinprosecutionofthecaseintheltlbankruptcycaseinoctoberthe bankruptcycourtissuedanorderstayingthecasethestatefiledanappealtothethirdcircuitconcerningthestayorder injanuarythestateofnewmexicofiledaconsumerprotectioncaseallegingthatthecompanydeceptively marketedandsolditstalcumpowderproductsbymakingmisrepresentationsaboutthesafetyoftheproductsandthe presenceofcarcinogensincludingasbestosthestateofnewmexicofiledanamendedcomplaintinmarchthe companymovedtodismisscertainoftheclaimsintheamendedcomplaintwhichwasgrantedthecompanythenfile amotionforpartialjudgmentonthepleadingsindecemberwhichwasdeniedinmarchthenewmexico courtdeniedthecompanysmotiontocompelthestateofnewmexicotoengageindiscoveryofstateagenciesand deniedthecompanysrequestforinterlocutoryappealofthatdecisionthecompanythenfiledapetitionforwritof superintendingcontrolandarequestforastaytothenewmexicosupremecourtontheissueofthestateof newmexicosdiscoveryobligationsinaprilinviewoftheeffortstoresolvetalcrelatedclaimsintheltl bankruptcycasethecompanyandthestateagreedtoadaystayofallmattersexceptforthependingwritbeforethe johnsonjohnsonannualreportnewmexicosupremecourtwhichexpiredinjunethereafterthecompanymovedtoenjoinprosecutionofthe caseintheltlbankruptcycaseinoctoberthebankruptcycourtissuedanorderstayingthecaseindecember thestatefiledanappealtothethirdcircuitconcerningthestayorderseparatelyinseptemberthe newmexicosupremecourtgrantedthecompanysrequestforastaypendingfurtherbriefingonthescopeofthestate ofnewmexicosdiscoveryobligation fortytwostatesandthedistrictofcolumbiahavecommencedajointinvestigationintothecompanysmarketingofit talcumpowderproductsatthistimethemultistategrouphasnotassertedanyclaimsagainstthecompanyfivestate haveissuedcivilinvestigativedemandsseekingdocumentsandotherinformationthecompanyhasproduce documentstoarizonanorthcarolinatexasandwashingtonandenteredintoconfidentialityagreementsthecompany hasnotreceivedanyfollowuprequestsfromthosestatesinmarcheachofthefortytwostatesinclude mississippiandnewmexicoagreedtomediationoftheirclaimsintheltlbankruptcycaseinjulynewmexico andmississippiindicatedtheywouldnolongervoluntarilysubmittofurthermediationintheltlbankruptcyandwould proceedwiththeirrespectivecasesinstatecourtltlmovedthenewjerseybankruptcycourtforanorderstaye furtherproceedingsinthosetwoactionswhichthebankruptcycourtgrantedinoctoberindecemberthe bankruptcycourtallowednewmexicoandmississippitofileadirectappealofitsstay injulythecompanyandjanssenproductslpwereservedwithaquitamcomplaintpursuanttothefalseclaim actfiledintheunitedstatesdistrictcourtforthedistrictofnewjerseyallegingtheofflabelpromotionoftwohiv productsprezistaandintelenceandantikickbackviolationsinconnectionwiththepromotionoftheseproduct thecomplaintwasfiledundersealindecemberthefederalandstategovernmentshavedeclinedtointerveneand thelawsuitisbeingprosecutedbytherelatorsthecourtdeniedsummaryjudgmentonallclaimsindecember daubertmotionsweregrantedinpartanddeniedinpartinjanuaryandthecaseisproceedingtotrial inmarchjanssenbiotechincjbireceivedacivilinvestigativedemandfromtheunitedstatesdepartmentof justiceregardingafalseclaimsactinvestigationconcerningmanagementandadvisoryservicesprovidedto rheumatologyandgastroenterologypracticesthatpurchasedremicadeorsimponiariainaugustthe unitedstatesdepartmentofjusticenotifiedjbithatitwasclosingtheinvestigationsubsequentlytheunitedstates districtcourtforthedistrictofmassachusettsunsealedaquitamfalseclaimsactcomplaintwhichwasservedonthe companythedepartmentofjusticehaddeclinedtointerveneinthequitamlawsuitinaugustthecompanyfile amotiontodismisswhichwasgrantedinpartanddeniedinpartdiscoveryisunderway inaprilandseptemberthecompanyreceivedsubpoenasfromtheunitedstatesattorneyforthedistrictof massachusettsseekingdocumentsbroadlyrelatingtopharmaceuticalcopaymentsupportprogramsfordarzalex olysioremicadesimponistelaraandzytigathesubpoenasalsoseekdocumentsrelatingtoaverage manufacturerpriceandbestpricereportingtothecenterformedicareandmedicaidservicesrelatedtothoseproduct aswellasrebatepaymentstostatemedicaidagenciesthecompanyhasprovideddocumentsinresponsetothe subpoena injunethecompanyreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekinginformationregardingpracticespertainingtothesterilizationofdepuysynthesincdepuyspinal implantsatthreehospitalsinbostonaswellasinteractionsofemployeesofcompanysubsidiarieswithphysiciansat thesehospitalsthecompanyanddepuyfullycooperatedwiththegovernmentsinvestigationinjanuarythe companydepuysynthesincanddepuysynthessalesincenteredintoasettlementagreementwiththeunitedstate resolvingthematterforanimmaterialamount injulythepublicprosecutionserviceinriodejaneiroandrepresentativesfromthebrazilianantitrustauthority cadeinspectedtheofficesofmorethancompaniesincludingjohnsonjohnsondobrasilindstriaecomrciode produtosparasadeltdatheauthoritiesappeartobeinvestigatingallegationsofpossibleanticompetitivebehaviorand possibleimproperpaymentsinthemedicaldeviceindustrythecompanycontinuestorespondtoinquiriesregardingthe foreigncorruptpracticesactfromtheunitedstatesdepartmentofjusticeandtheunitedstatessecuritiesand exchangecommission fromtimetotimethecompanyhasreceivedrequestsfromavarietyofunitedstatescongressionalcommitteesto produceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsontocooperatewith theseinquiriesbyproducingtherequestedinformation johnsonjohnsonannualreport generallitigation beginninginseptembermultiplepurportedclassactionswerefiledonbehalfofindirectpurchasersofremicade againstthecompanyandjanssenbiotechinccollectivelyjanssenallegingthatjanssenhasviolatedfederalantitrust lawsthroughitscontractingstrategiesforremicadethecaseswereconsolidatedforpretrialpurposesasinre remicadeantitrustlitigationinunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniathiscasewassettled infebruarythefinalapprovalhearingisscheduledforfebruary injunetheunitedstatesfederaltradecommissionftcissuedacivilinvestigativedemandtothecompany andjanssenbiotechinccollectivelyjansseninconnectionwithitsinvestigationofwhetherjanssensremicade contractingpracticesviolatefederalantitrustlawsthecompanyhasproduceddocumentsandinformationresponsiveto thecivilinvestigativedemandjanssenisinongoingdiscussionswiththeftcstaffregardingitsinquiry infebruarytheunitedstatesfederaltradecommissionftcissuedcivilinvestigativedemandstojohnson johnsonandjanssenbiotechinccollectivelyjansseninconnectionwithitsinvestigationofwhetheradvertise practicesforremicadeviolatefederallawjanssenhasproduceddocumentsandinformationresponsivetothecivil investigativedemandsjanssenisinongoingdiscussionswiththeftcstaffregardingtheinquiry injunegenmabasfiledanoticeforarbitrationwithinternationalinstituteforconflictpreventionandresolution cpragainstjanssenbiotechincseekingmilestonesandanextendedroyaltytermfordarzalexfasprojanssenfile itsnoticeofdefenseinjulygenmabandjanssenhavecrossmovedforearlydispositionofthearbitration argumentwashadinjanuary inoctobercertainunitedstatesservicemembersandtheirfamiliesbroughtacomplaintagainstanumberof pharmaceuticalandmedicaldevicescompaniesincludingjohnsonjohnsonandcertainofitssubsidiariesinunite statesdistrictcourtforthedistrictofcolumbiaallegingthatthedefendantsviolatedtheunitedstatesantiterrorism actthecomplaintallegesthatthedefendantsprovidedfundingforterroristorganizationsthroughtheirsalespractice pursuanttopharmaceuticalandmedicaldevicecontractswiththeiraqiministryofhealthinjulythedistrictcourt dismissedthecomplaintinjanuarytheunitedstatescourtofappealsforthedistrictofcolumbiacircuitreverse thedistrictcourtsdecisioninfebruarydefendantspetitionedforrehearingenbanc inoctobertwoseparateputativeclassactionswerefiledagainstactelionpharmaceuticalltdactelion pharmaceuticalsusincandactelionclinicalresearchinccollectivelyactelioninunitedstatesdistrictcourtforthe districtofmarylandandunitedstatesdistrictcourtforthedistrictofcolumbiathecomplaintsallegethatactelion violatedstateandfederalantitrustandunfaircompetitionlawsbyallegedlyrefusingtosupplygenericpharmaceutical manufacturerswithsamplesoftracleertracleerissubjecttoariskevaluationandmitigationstrategyrequiredby thefoodanddrugadministrationwhichimposesrestrictionsondistributionoftheproductinjanuarytheplaintiff dismissedthedistrictofcolumbiacaseandfiledaconsolidatedcomplaintintheunitedstatesdistrictcourtforthe districtofmarylandinoctoberthecourtgrantedactelionsmotiontodismisstheamendedcomplaintin apriltheunitedstatescourtofappealsforthefourthcircuitreversedandremandeddiscoveryisongoing inmayaclassactionantitrustcomplaintwasfiledagainstjanssenrdirelandjanssenandjohnsonjohnsonin theunitedstatesdistrictcourtforthenortherndistrictofcaliforniathecomplaintallegesthatjanssenviolatedfederal andstateantitrustandconsumerprotectionlawsbyagreeingtoexclusivityprovisionsinitsagreementswithgilead concerningthedevelopmentandmarketingofcombinationantiretroviraltherapiescarttotreathivthecomplaintalso allegesthatgileadenteredintosimilaragreementswithbristolmyerssquibbandjapantobaccoinmarchthe courtgrantedinpartanddeniedinpartdefendantsmotionstodismissplaintiffsfiledanamendedcomplaintin aprildefendantsmovedtodismisstheamendedcomplaintinjulythecourtgrantedinpartanddeniedin parttherenewedmotiontodismissindecemberseveralinsurancecompaniesandotherpayersfiledindividual optoutcomplaintscontainingallegationssimilartotheoriginalcomplaintinseptemberthecourtgrantedin partanddeniedinpartplaintiffsmotionforclasscertificationinjanuarythecourtgrantedinpartanddeniedin partdefendantsmotionforsummaryjudgmenttrialisscheduledformay inoctoberinnovativehealthllcfiledacomplaintagainstbiosensewebsterincbwiintheunitedstate districtcourtforthemiddledistrictofcaliforniathecomplaintallegesthatcertainofbwisbusinesspracticesand contractualtermsviolatetheantitrustlawsoftheunitedstatesandthestateofcaliforniabyrestrictingcompetitioninthe saleofhighdensitymappingcathetersandultrasoundcathetersinjanuarybwifiledamotiontodismissthe complaintinaugustthecourtgrantedinpartanddeniedinpartbwismotiontodismissindecember bwifiledamotionforsummaryjudgmentinmarchthecourtgrantedbwismotionforsummaryjudgmentin aprilinnovativeappealedthisrulingtotheunitedstatescourtofappealsfortheninthcircuit johnsonjohnsonannualreportinnovemberthecompanyreceivedademandforindemnificationfrompfizerincpfizerpursuanttothe stockandassetpurchaseagreementbetweenthecompanyandpfizeralsoinnovemberjohnsonjohnsoninc receivednoticereservingrightstoclaimindemnificationfromsanoficonsumerhealthincsanofipursuanttothe assetpurchaseagreementbetweenjohnsonjohnsonincandsanofiinjanuaryjohnsonjohnsonreceiveda demandforindemnificationfromboehringeringelheimpharmaceuticalsincboehringeringelheimpursuanttothe assetpurchaseagreementamongthecompanypfizerandboehringeringelheiminnovemberjohnson johnsonreceivedademandforindemnificationfromglaxosmithklinellcgskpursuanttothestockandasset purchaseagreementbetweenthecompanyandpfizerandcertainandagreementsbetweenglaxo wellcomeandwarnerlambertentitiesthenoticesseekindemnificationforlegalclaimsrelatedtooverthecounter zantacranitidineproductsplaintiffsintheunderlyingactionsallegethatzantacandotheroverthecounter ranitidinemedicationscontainunsafelevelsofndmannitrosodimethylamineandcancauseandorhavecausedvarious cancersinpatientsusingtheproductsandseekinjunctiveandmonetaryreliefthecompanyandjohnsonjohnsoninc havealsobeennamedinputativeclassactionsfiledincanadawithsimilarallegationsregardingzantacorranitidine usejohnsonjohnsonincwasalsonamedasadefendantalongwithothermanufacturersinvariouspersonalinjury actionsincanadarelatedtozantacproductsjohnsonjohnsoninchasprovidedsanofinoticereservingrightsto claimindemnificationpursuanttotheassetpurchaseagreementrelatedtotheclassactionsandpersonalinjury action inoctoberfortisadvisorsllcfortisinitscapacityasrepresentativeoftheformerstockholdersofaurishealth incaurisfiledacomplaintagainstthecompanyethiconincandcertainnamedofficersandemployeescollectively ethiconinthecourtofchanceryofthestateofdelawarethecomplaintallegesbreachofcontractfraudandother causesofactionagainstethiconinconnectionwithethiconsacquisitionofaurisinthecomplaintseeksdamage andotherreliefindecemberthecourtgrantedinpartanddeniedinpartdefendantsmotiontodismisscertain causesofactionallclaimsagainsttheindividualdefendantsweredismissedthetrialisscheduledforjanuary injunejanssenpharmaceuticalsincfiledademandforarbitrationagainstemergentbiosolutionsincetal ebsiwiththeamericanarbitrationassociationallegingthatebsibreachedthepartiesmanufacturingservice agreementforthecompanyscovidvaccineinjulyemergentfileditsansweringstatementand counterclaim inoctoberjanssenpharmaceuticalsincfiledademandforarbitrationagainstmercksharpdohmecorpwith theamericanarbitrationassociationpursuanttothepartiesagreementsrelatingtoproductionofdrugsubstanceand drugproductforthecompanyscovidvaccinealsoinoctobermerckfileditsanswerandcounterclaim beginninginmaymultipleputativeclassactionswerefiledinstateandfederalcourtscaliforniafloridanewyork andnewjerseyagainstvariousjohnsonjohnsonentitiesallegingviolationsofstateconsumerfraudstatutesbasedon nondisclosureofallegedbenzenecontaminationofcertainneutrogenaandaveenosunscreenproductsandthe affirmativepromotionofthoseproductsassafeandinatleastonecaseallegingastrictliabilitymanufacturingdefect andfailuretowarnclaimsassertingthatthenamedplaintiffssufferedunspecifiedinjuriesasaresultofallegedexposure tobenzenethejudicialpanelonmultidistrictlitigationhasconsolidatedallpendingactionsexceptoneproductliability caseandonecasependinginnewjerseystatecourtintheunitedstatesdistrictcourtforthesoutherndistrictof floridafortlauderdaledivisioninoctoberthecompanyreachedanagreementinprincipleforthesettlementofa nationwideclassencompassingtheclaimsoftheconsolidatedactionssubjecttoapprovalbythefloridafederalcourtin decemberplaintiffsintheconsolidatedactionsfiledamotionforpreliminaryapprovalofanationwideclass settlementthesettlementwaspreliminarilyapprovedbythecourtinmarch thecompanysubsequentlysubstitutedbyjohnsonjohnsonconsumerincjjcialongwithmorethanother companiesisadefendantinacostrecoveryandcontributionactionbroughtbyoccidentalchemicalcorporationin juneintheunitedstatesdistrictcourtforthedistrictofnewjerseyrelatedtothecleanupofasectionofthe lowerpassaicriverinnewjersey thecompanyoritssubsidiariesarealsopartiestovariousproceedingsbroughtunderthecomprehensiveenvironmental responsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalorforeignlawsin whichtheprimaryreliefsoughtisthecostofpastandorfutureremediation johnsonjohnsonannualreport restructure inthefiscalsecondquarterofthecompanyannouncedplanstoimplementaseriesofactionsacrossitsglobal supplychainthatareintendedtofocusresourcesandincreaseinvestmentsinthecriticalcapabilitiestechnologiesand solutionsnecessarytomanufactureandsupplyitsproductportfolioenhanceagilityanddrivegrowththeglobalsupply chainactionsincludeexpandingtheuseofstrategiccollaborationsandbolsteringinitiativestoreducecomplexityimprove costcompetitivenessenhancecapabilitiesandoptimizethesupplychainnetworkinfiscalyearthecompany recordedapretaxchargeofbillionwhichisincludedonthefollowinglinesoftheconsolidatedstatementof earningsbillioninrestructuringbillioninotherincomeexpenseandbillionincostofproductssoldtotal projectcostsofapproximatelybillionhavebeenrecordedsincetherestructuringwasannouncedtheprogramwas completedinthefiscalfourthquarterof thefollowingtablesummarizestheseverancechargesandtheassociatedspendingundertheseinitiativesthroughthe fiscalyearended dollarsinmillion severance assetwriteoffssale total reservebalancejanuary activity reservebalancejanuary currentyearactivity charge cashsettlement settlednoncash reservebalancejanuary althoughtherestructuringprogramhasbeencompletedinthefiscalyearthecompanyexpectsthatseverancechargeswill continuebeyondthatdatethereservebalanceasofjanuaryisrecordedintheemployeerelatedobligationaccountinthe consolidatedbalancesheet otherincludesprojectexpensesuchassalariesforemployeessupportingtheseinitiativesandconsultingexpense representsgainonsaleofasset johnsonjohnsonannualreportreport independent register public accounting firm totheboardofdirectorsandshareholdersofjohnsonjohnson opinionsonthefinancialstatementsandinternalcontroloverfinancialreporte wehaveauditedtheaccompanyingconsolidatedbalancesheetsofjohnsonjohnsonanditssubsidiariesthe companyasofjanuaryandjanuaryandtherelatedconsolidatedstatementsofearningsof comprehensiveincomeofequityandofcashflowsforeachofthethreefiscalyearsintheperiodendedjanuary includingtherelatednotescollectivelyreferredtoastheconsolidatedfinancialstatementswealsohaveauditedthe companysinternalcontroloverfinancialreportingasofjanuarybasedoncriteriaestablishedininternalcontrol integratedframeworkissuedbythecommitteeofsponsoringorganizationsofthetreadwaycommission coso inouropiniontheconsolidatedfinancialstatementsreferredtoabovepresentfairlyinallmaterialrespectsthefinancial positionofthecompanyasofjanuaryandjanuaryandtheresultsofitsoperationsanditscashflow foreachofthethreefiscalyearsintheperiodendedjanuaryinconformitywithaccountingprinciplesgenerally acceptedintheunitedstatesofamericaalsoinouropinionthecompanymaintainedinallmaterialrespectseffective internalcontroloverfinancialreportingasofjanuarybasedoncriteriaestablishedininternalcontrolintegrate frameworkissuedbythecoso basisforopinion thecompanysmanagementisresponsiblefortheseconsolidatedfinancialstatementsformaintainingeffectiveinternal controloverfinancialreportingandforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporte includedintheaccompanyingmanagementsreportoninternalcontroloverfinancialreportingourresponsibilityisto expressopinionsonthecompanysconsolidatedfinancialstatementsandonthecompanysinternalcontroloverfinancial reportingbasedonourauditsweareapublicaccountingfirmregisteredwiththepubliccompanyaccountingoversight boardunitedstatespcaobandarerequiredtobeindependentwithrespecttothecompanyinaccordancewiththe usfederalsecuritieslawsandtheapplicablerulesandregulationsofthesecuritiesandexchangecommissionandthe pcaob weconductedourauditsinaccordancewiththestandardsofthepcaobthosestandardsrequirethatweplanand performtheauditstoobtainreasonableassuranceaboutwhethertheconsolidatedfinancialstatementsarefreeofmaterial misstatementwhetherduetoerrororfraudandwhethereffectiveinternalcontroloverfinancialreportingwasmaintaine inallmaterialrespect ourauditsoftheconsolidatedfinancialstatementsincludedperformingprocedurestoassesstherisksofmaterial misstatementoftheconsolidatedfinancialstatementswhetherduetoerrororfraudandperformingproceduresthat respondtothoseriskssuchproceduresincludedexaminingonatestbasisevidenceregardingtheamountsand disclosuresintheconsolidatedfinancialstatementsourauditsalsoincludedevaluatingtheaccountingprinciplesused andsignificantestimatesmadebymanagementaswellasevaluatingtheoverallpresentationoftheconsolidatedfinancial statementsourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol overfinancialreportingassessingtheriskthatamaterialweaknessexistsandtestingandevaluatingthedesignand operatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalsoincludedperformingsuchother proceduresasweconsiderednecessaryinthecircumstanceswebelievethatourauditsprovideareasonablebasisfor ouropinion asdescribedinmanagementsreportoninternalcontroloverfinancialreportingmanagementhasexcludedabiome incabiomedfromitsassessmentofinternalcontroloverfinancialreportingasofjanuarybecauseitwas acquiredbythecompanyinabusinesscombinationduringwehavealsoexcludedabiomedfromourauditof internalcontroloverfinancialreportingabiomedisawhollyownedsubsidiarywhosetotalassetsandtotalsalesexclude frommanagementsassessmentandourauditofinternalcontroloverfinancialreportingrepresentlessthanofeachof therelatedconsolidatedfinancialstatementamountsasofandforthefiscalyearendedjanuary definitionandlimitationsofinternalcontroloverfinancialreporte acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith johnsonjohnsonannualreport generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounte principlesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statement becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate criticalauditmatter thecriticalauditmatterscommunicatedbelowaremattersarisingfromthecurrentperiodauditoftheconsolidate financialstatementsthatwerecommunicatedorrequiredtobecommunicatedtotheauditcommitteeandthatirelateto accountsordisclosuresthatarematerialtotheconsolidatedfinancialstatementsandiiinvolvedourespecially challengingsubjectiveorcomplexjudgmentsthecommunicationofcriticalauditmattersdoesnotalterinanywayour opinionontheconsolidatedfinancialstatementstakenasawholeandwearenotbycommunicatingthecriticalaudit mattersbelowprovidingseparateopinionsonthecriticalauditmattersorontheaccountsordisclosurestowhichthey relate uspharmaceuticalrebatereservesmanagedcaremedicareandmedicaid asdescribedinnotetotheconsolidatedfinancialstatementsthecompanyrecognizesrevenuefromproductsales whenobligationsunderthetermsofacontractwiththecustomeraresatisfiedrebatesanddiscountsprovidedto customersareaccountedforasvariableconsiderationandrecordedasareductioninsalestheliabilityforsuchrebates anddiscountsisrecognizedwithinaccruedrebatesreturnsandpromotionsontheconsolidatedbalancesheeta significantportionoftheliabilityrelatedtorebatesisfromthesaleofpharmaceuticalgoodswithintheusprimarilythe managedcaremedicareandmedicaidprogramswhichamountedtobillionasofjanuaryforsignificant rebateprogramswhichincludetheusmanagedcaremedicareandmedicaidrebateprogramsrebatesanddiscounts estimatedbymanagementarebasedoncontractualtermshistoricalexperiencepatientoutcomestrendanalysisand projectedmarketconditionsintheuspharmaceuticalmarket theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtouspharmaceuticalrebate reservesmanagedcaremedicareandmedicaidisacriticalauditmatterarethesignificantjudgmentbymanagement duetothesignificantmeasurementuncertaintyinvolvedindevelopingthesereservesandthehighdegreeofauditor judgmentsubjectivityandauditeffortinperformingproceduresandevaluatingtheassumptionsrelatedtocontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsintheuspharmaceutical market addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour overallopinionontheconsolidatedfinancialstatementstheseproceduresincludedtestingtheeffectivenessofcontrols relatingtouspharmaceuticalrebatereservesmanagedcaremedicareandmedicaidincludingcontrolsoverthe assumptionsusedtoestimatetheserebatestheseproceduresalsoincludedamongothersidevelopingan independentestimateoftherebatesbyutilizingthirdpartyinformationonpriceandmarketconditionsintheus pharmaceuticalmarketthetermsofthespecificrebateprogramsandthehistoricalexperienceandtrendanalysisof actualrebateclaimspaidiitestingrebateclaimsprocessedbythecompanyincludingevaluatingthoseclaimsfor consistencywiththecontractualandmandatedtermsofthecompanysrebatearrangementsandiiicomparingthe independentestimatestomanagementsestimate litigationcontingenciestalc asdescribedinnotesandtotheconsolidatedfinancialstatementsthecompanyrecordsaccrualsforloss contingenciesassociatedwithlegalmattersincludingtalcwhenitisprobablethataliabilitywillbeincurredandthe amountofthelosscanbereasonablyestimatedtotheextentadverseawardsjudgmentsorverdictshavebeenrendered againstthecompanymanagementdoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbe reasonablyestimatedforthesemattersmanagementisunabletoestimatethepossiblelossorrangeoflossbeyondthe johnsonjohnsonannualreportamountsaccruedamountsaccruedforlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfuture eventsanduncertaintiesthatrelyheavilyonestimatesandassumptionsincludingtimingofrelatedpaymentstheabilityto makesuchestimatesandjudgmentscanbeaffectedbyvariousfactorsincludingamongotherthingswhetherdamage soughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedoris notcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindispute proceduralorjurisdictionalissuestheuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachieve comprehensivemultipartysettlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerous partiesinvolvedmanagementcontinuestobelievethatthecompanyhasstronglegalgroundstocontestthetalcverdict ithasappealednotwithstandingmanagementsconfidenceinthesafetyofthecompanystalcproductsincertain circumstancesthecompanyhassettledcasesinoctoberjohnsonjohnsonconsumerincoldjjciawholly ownedsubsidiaryofjohnsonjohnsonimplementedacorporaterestructuringandcreatedasubsidiaryltl managementllcltlwhichbecamesolelyresponsibleforthetalcrelatedliabilitiesandanothersubsidiarynewjjci whichbecameresponsiblefortheremainingbusinessofoldjjciltlfiledavoluntarypetitionseekingreliefunder chapterofthebankruptcycodeasaresultoftheltlbankruptcycasethecourtenteredatemporaryrestraine orderstayingalllitigationagainstltlandoldjjcionnovemberthenorthcarolinabankruptcycourt confirmedthescopeofthestayissuingapreliminaryinjunctionpiprohibitingandenjoiningthecommencementand prosecutionoftalcrelatedclaimsagainstltloldjjcinewjjcijohnsonjohnsonotheroftheircorporateaffiliate identifiedretailersinsurancecompaniesandcertainotherpartiestheltlbankruptcycasewastransferredtothe unitedstatesbankruptcycourtforthedistrictofnewjerseyinnovemberandthatcourtextendedthepithrough theendoffebruaryclaimantsfiledmotionstodismisstheltlbankruptcycaseandfollowingamultipleday hearingthenewjerseybankruptcycourtdeniedthosemotionsbyorderissuedinmarchthenewjersey bankruptcycourtsimultaneouslyissuedanotherorderextendingthestayastotheprotectedpartiestheclaimant subsequentlyfilednoticesofappealastothedenialofthemotionstodismissandtheextensionofthestayinmay thethirdcircuitcourtofappealsgrantedthepetitionstoappealthebriefingandoralargumentontheappeal werecompletedinseptemberonjanuarythethirdcircuitreversedthebankruptcycourtsrulingand remandedtothebankruptcycourttodismisstheltlbankruptcyltlhasfiledapetitionforrehearingonthedecision theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtothetalclitigationisacriticalaudit matterarethesignificantjudgmentbymanagementwhenassessingthelikelihoodofalossbeingincurredandwhen determiningwhetherareasonableestimateofthelossorrangeoflossforthefutureandexistingtalcclaimscanbemade whichinturnledtoahighdegreeofauditorjudgmentsubjectivityandeffortinperformingproceduresandevaluate managementsassessmentofthelosscontingenciesassociatedwiththislitigation addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour overallopinionontheconsolidatedfinancialstatementstheseproceduresincludedtestingtheeffectivenessofcontrol relatingtomanagementsevaluationofthetalclitigationincludingcontrolsoverdeterminingwhetheralossisprobable andwhethertheamountoflosscanbereasonablyestimatedaswellasfinancialstatementdisclosuresthese proceduresalsoincludedamongothersigaininganunderstandingofthecompanysprocessaroundtheaccounting andreportingforthetalclitigationiidiscussingthestatusofsignificantknownactualandpotentiallitigationandthe ongoingltlbankruptcyproceedingswiththecompanysinhouselegalcounselaswellasexternalcounselwhen deemednecessaryiiiobtainingandevaluatingthelettersofauditinquirywithinternalandexternallegalcounselfor significantlitigationivevaluatingthereasonablenessofmanagementsassessmentregardingwhetheranunfavorable outcomeisreasonablypossibleorprobableandreasonablyestimableandvevaluatingthesufficiencyofthecompany litigationcontingenciesdisclosure spricewaterhousecoopersllp florhamparknewjersey february wehaveservedasthecompanysauditorsinceatleastwehavenotbeenabletodeterminethespecificyearwe beganservingasauditorofthecompany johnsonjohnsonannualreport management report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciple internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofjanuaryinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframework thesecriteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunication andmonitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignand operatingeffectivenessofitsinternalcontrolsoverfinancialreporting thecompanyacquiredabiomedincabiomedinabusinesscombinationindecemberabiomedstotalasset excludingintangibleassetsandgoodwillandtotalsalesrepresentedlessthanofeachoftherelatedconsolidate financialstatementamountsasofandforthefiscalyearendedjanuaryastheacquisitionoccurredinthefiscal yearthescopeofthecompanysassessmentofthedesignandeffectivenessofinternalcontroloverfinancial reportingforthefiscalyearexcludedtheabovementionedacquisitionthisexclusionisinaccordancewiththe secsgeneralguidancethatanassessmentofarecentlyacquiredbusinessmaybeomittedfromthescopeintheyearof acquisition basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof januarythecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofjanuaryhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappear sjduato sjosephjwolk joaquinduato josephjwolk chairmanboardofdirector executivevicepresident chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreportshareholder return performance graph setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingjanuaryagainstthecumulativetotalreturnofthestandardpoor stockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipmentindex thegraphsandtablesassumethatwasinvestedondecemberanddecemberineachofthe companyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexandthe standardpoorshealthcareequipmentindexandthatalldividendswerereinvested yearshareholderreturn performancejjvsindice johnson johnson index pharmaceucidcal index healthcare equipment index year cagr pharm equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex yearshareholderreturn performancejjvsindice johnson johnson index pharmaceucidcal index healthcare equipment index year cagr pharm equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreport item change disagreement accountant account financial disclosure notapplicable item control procedure disclosurecontrolsandproceduresattheendoftheperiodcoveredbythisreportthecompanyevaluatedthe effectivenessofthedesignandoperationofitsdisclosurecontrolsandproceduresthecompanysdisclosurecontrols andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatit filesorsubmitsundertheexchangeactisrecordedprocessedsummarizedandreportedwithinthetimeperiods specifiedinthesecsrulesandformsdisclosurecontrolsandproceduresincludewithoutlimitationcontrolsand proceduresdesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatitfilesor submitsundertheexchangeactisaccumulatedandcommunicatedtothecompanysmanagementincludingitsprincipal executiveandprincipalfinancialofficersorpersonsperformingsimilarfunctionsasappropriatetoallowtimelydecision regardingrequireddisclosurejoaquinduatochairmanandchiefexecutiveofficerandjosephjwolkexecutivevice presidentchieffinancialofficerreviewedandparticipatedinthisevaluationbasedonthisevaluationmessrsduato andwolkconcludedthatasoftheendoftheperiodcoveredbythisreportthecompanysdisclosurecontrolsand procedureswereeffective reportsoninternalcontroloverfinancialreportingtheinformationcalledforbythisitemisincorporatedhereinby referencetomanagementsreportoninternalcontroloverfinancialreportingandtheattestationregardinginternal controlsoverfinancialreportingincludedinthereportofindependentregisteredpublicaccountingfirmincludedin itemofthisreport changesininternalcontroloverfinancialreportingduringthefiscalquarterendedjanuarytherewereno changesinthecompanysinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequire underrulesaanddundertheexchangeactthathavemateriallyaffectedorarereasonablylikelyto materiallyaffectthecompanysinternalcontroloverfinancialreportingthecompanycontinuestomonitorandassess theeffectivenessofthedesignandoperationofitsdisclosurecontrolsandprocedure thecompanyisimplementingamultiyearenterprisewideinitiativetointegratesimplifyandstandardizeprocessesand systemsforthehumanresourcesinformationtechnologyprocurementsupplychainandfinancefunctionstheseare enhancementstosupportthegrowthofthecompanysfinancialsharedservicecapabilitiesandstandardizefinancial systemsthisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessinthecompanysinternalcontrolover financialreportinginresponsetothisinitiativethecompanyhasandwillcontinuetoalignandstreamlinethedesignand operationofitsfinancialcontrolenvironment item information notapplicable item disclosure foreign jurisdiction prevent inspection notapplicable johnsonjohnsonannualreportpart iii item director executive officer corporate governance theinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheauditcommitteeunder thecaptionitemelectionofdirectorsboardcommitteesandthematerialunderthecaptionsitemelectionof directorsandifapplicablestockownershipandsectioncompliancedelinquentsectionareportsinthe proxystatementandthematerialunderthecaptionexecutiveofficersoftheregistrantinpartiofthisreport thecompanyscodeofbusinessconductwhichcoversallemployeesincludingthechiefexecutiveofficerchief financialofficerandcontrollermeetstherequirementsofthesecrulespromulgatedundersectionofthe sarbanesoxleyactofthecodeofbusinessconductisavailableonthecompanyswebsiteatwwwjnjcom codeofbusinessconductandcopiesareavailabletoshareholderswithoutchargeuponwrittenrequesttothesecretary atthecompanysprincipalexecutiveofficesanysubstantiveamendmenttothecodeofbusinessconductoranywaiver ofthecodegrantedtothechiefexecutiveofficerthechieffinancialofficerorthecontrollerwillbepostedonthe companyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysandretainedonthewebsiteforatleastone year inadditionthecompanyhasadoptedacodeofbusinessconductethicsformembersoftheboardofdirectorsand executiveofficersthecodeofbusinessconductethicsformembersoftheboardofdirectorsandexecutiveofficer isavailableonthecompanyswebsiteatwwwinvestorjnjcomgovboardconductcfmandcopiesareavailableto shareholderswithoutchargeuponwrittenrequesttothesecretaryatthecompanysprincipalexecutiveofficesany substantiveamendmenttothecodeoranywaiverofthecodegrantedtoanymemberoftheboardofdirectorsorany executiveofficerwillbepostedonthecompanyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysand retainedonthewebsiteforatleastoneyear item executive compensation theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorcompensationanditemcompensationbenefitscommitteereport compensationdiscussionandanalysisandexecutivecompensationtablesintheproxystatement thematerialincorporatedhereinbyreferencetothematerialunderthecaptioncompensationbenefitscommittee reportintheproxystatementshallbedeemedfurnishedandnotfiledinthisreportandshallnotbedeeme incorporatedbyreferenceintoanyfilingunderthesecuritiesactofasamendedorthesecuritiesexchangeactof asamendedasaresultofthisfurnishingexcepttotheextentthatthecompanyspecificallyincorporatesitby reference item security ownership certain beneficial owner management relate stockholder matter theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitem stockownershipandsectioncomplianceintheproxystatementandnotecommonstockstockoptionplan andstockcompensationagreementsofthenotestoconsolidatedfinancialstatementsinitemofthisreport johnsonjohnsonannualreport equity compensation plan information thefollowingtableprovidescertaininformationasofjanuaryconcerningthesharesofthecompanyscommon stockthatmaybeissuedunderexistingequitycompensationplans numberof securitiesto beissuedupon weightedaverage numberofsecuritie exerciseof exercisepriceof remainingavailablefor outstanding outstanding futureissuanceunderequity plancategory optionsandright optionsandright compensationplan equitycompensationplansapprovedbysecurity holder equitycompensationplansnotapprovedbysecurity holder total includedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbythecompanysshareholder longtermincentiveplanandlongtermincentiveplan thiscolumnexcludessharesreflectedunderthecolumnnumberofsecuritiestobeissueduponexerciseofoutstandingoption andright thelongtermincentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewere underthelongtermincentiveplan item certain relationship relate transaction director independence theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorindependenceandrelatedpersontransactionsintheproxystatement item principal accountant fee service theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitem ratificationofappointmentofindependentregisteredpublicaccountingfirmintheproxystatement johnsonjohnsonannualreportpart item exhibit financial statement schedule thefollowingdocumentsarefiledaspartofthisreport financialstatement consolidatedbalancesheetsatendoffiscalyearsand consolidatedstatementsofearningsforfiscalyearsand consolidatedstatementsofcomprehensiveincomeforfiscalyearsand consolidatedstatementsofequityforfiscalyearsand consolidatedstatementsofcashflowsforfiscalyearsand notestoconsolidatedfinancialstatement reportofindependentregisteredpublicaccountingfirm allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial statementsornote exhibitsrequiredtobefiledbyitemlofregulationsk theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheexhibitindexinthisreport item summary registrantsmayvoluntarilyincludeasummaryofinformationrequiredbyformkunderthisitemthecompanyha electednottoincludesuchsummaryinformation johnsonjohnsonannualreport signature pursuanttotherequirementsofsectionofthesecuritiesexchangeactoftheregistranthasdulycausedthis reporttobesignedonitsbehalfbytheundersignedthereuntodulyauthorize datefebruary johnsonjohnson registrant sjduato jduatochairmanoftheboard andchiefexecutiveofficer pursuanttotherequirementsofthesecuritiesexchangeactofthisreporthasbeensignedbelowbythefollowe personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicate signature title date sjduato chairmanoftheboard february jduato chiefexecutiveofficer principalexecutiveofficer sjjwolk chieffinancialofficer february jjwolk principalfinancialofficer srjdeckerjr controllerandchiefaccountingofficer february rjdeckerjr principalaccountingofficer sdadamczyk director february dadamczyk smcbeckerle director february mcbeckerle sdsdavis director february dsdavis sieldavis director february ieldavis sjadoudna director february jadoudna smahewson director february mahewson shjoly director february hjoly smbmcclellan director february mbmcclellan johnsonjohnsonannualreportsignature title date sammulcahy director february ammulcahy saewashington director february aewashington smaweinberger director february maweinberger snywest director february nywest johnsonjohnsonannualreport exhibit index regsk exhibittable itemno descriptionofexhibit agreementandplanofmergerdatedasofoctoberbyandamongjohnsonjohnsonathosmergersubincand abiomedincincorporatedhereinbyreferencetoexhibitoftheregistrantsformkcurrentreportfilednovember restatedcertificateofincorporationeffectivefebruaryincorporatedhereinbyreferencetoexhibitiofthe registrantsformkannualreportforthefiscalyearendedjanuary certificateofamendmenttothecertificateofincorporationofjohnsonjohnsoneffectiveaprilincorporatedherein byreferencetoexhibitoftheregistrantsformkcurrentreportfiledapril iii bylawsofthecompanyasamendedeffectivejuneincorporatedhereinbyreferencetoexhibitofthe registrantsformkcurrentreportfiledjune upontherequestofthesecuritiesandexchangecommissiontheregistrantwillfurnishacopyofallinstrumentsdefiningthe rightsofholdersoflongtermdebtoftheregistrant descriptionofsecuritiesregisteredpursuanttosectionofthesecuritiesexchangeactofincorporatedhereinby referencetoexhibitoftheregistrantsformkcurrentreportfiledaugust longtermincentiveplanincorporatedhereinbyreferencetoexhibitoftheregistrantssregistrationstatement filedonmayfileno formofstockoptioncertificateunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibitof theregistrantsformkcurrentreportfiledjanuary longtermincentiveplanincorporatedhereinbyreferencetoappendixaoftheregistrantsproxystatementfiledon march formofstockoptioncertificaterestrictedshareunitcertificateandperformanceshareunitcertificateunderthe longtermincentiveplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformq quarterlyreportforthequarterendedapril globalnonqualifiedstockoptionawardagreementglobalrestrictedshareunitawardagreementandglobalperformance shareunitawardagreementunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibits andoftheregistrantsformqquarterlyreportforthequarterendedapril johnsonjohnsonexecutiveincentiveplanamendedasofnovemberincorporatedhereinbyreferenceto exhibitaoftheregistrantsformqquarterlyreportforthequarterendedmarch domesticdeferredcompensationcertificateofextracompensationplanincorporatedhereinbyreferencetoexhibitg oftheregistrantsformkannualreportfortheyearendeddecember amendmentstothecertificateofextracompensationplaneffectiveasofjanuaryincorporatedhereinbyreferenceto exhibitjoftheregistrantsformkannualreportfortheyearendeddecember certificatesoflongtermperformanceplanincorporatedhereinbyreferencetoexhibitoftheregistrant formqquarterlyreportforthequarterendedseptember amendedandrestateddeferredfeeplanfordirectorsamendedasofjanuaryincorporatedhereinbyreference toexhibitkoftheregistrantsformkannualreportforthefiscalyearendedjanuary thejohnsonjohnsonexecutiveincomedeferralplanamendedandrestatedeffectivejanuaryincorporatedherein byreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterendedseptember thejohnsonjohnsonexcesssavingsplanamendedandrestatedasofjanuaryfiledwiththisdocument excessbenefitplanofjohnsonjohnsonandaffiliatedcompaniesamendedandrestatedasofjanuary incorporatedbyreferencetoexhibitnoftheregistrantsformkannualreportforthefiscalyearendedjanuary executivelifeplanagreementincorporatedhereinbyreferencetoexhibitioftheregistrantsformkannualreport forthefiscalyearendedjanuary executivelifeplanagreementclosureletterincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedmarch longtermincentiveplanincorporatedbyreferencetoappendixaoftheregistrantsproxystatementfiledon march severancepayplanofjohnsonjohnsonandusaffiliatedcompaniesamendedandrestatedasofoctober incorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterende september johnsonjohnsonannualreportregsk exhibittable itemno descriptionofexhibit firstamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestate effectiveoctoberincorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreport forthequarterendedjune secondamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestate effectiveoctoberincorporatedhereinbyreferencetoexhibitxoftheregistrantsformkannualreportfor thefiscalyearendedjanuary contingentvaluerightsagreementdatedasofdecemberbyandbetweenjohnsonjohnsonandamericanstock transfertrustcompanyllcincorporatedhereinbyreferencetoexhibitoftheregistrantsformkcurrentreport fileddecember subsidiariesfiledwiththisdocument consentofindependentregisteredpublicaccountingfirmfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument exhibit exin instancedocumenttheinstancedocumentdoesnotappearintheinteractivedatafilebecauseitsxbrltagsareembedde withintheinlinexbrldocument exsch inlinexbrltaxonomyextensionschema excal inlinexbrltaxonomyextensioncalculationlinkbase exlab inlinexbrltaxonomyextensionlabellinkbase expre inlinexbrltaxonomyextensionpresentationlinkbase exdef inlinexbrltaxonomyextensiondefinitiondocument exhibit coverpageinteractivedatafilethecoverpageinteractivedatafiledoesnotappearintheinteractivedatafilebecauseit xbrltagsareembeddedwithintheinlinexbrldocument managementcontractorcompensatoryplan paperfile certainexhibitsandscheduleshavebeenomittedpursuanttoitembiiorbivofregulationskasapplicable acopyofanyoftheexhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequ specifyingthedesiredexhibitstothesecretaryattheprincipalexecutiveofficesofthecompanypursuantto itembiiiaofregulationskthecompanyhasnotfiledasexhibitstothisformkcertainlongtermdebt instrumentsincludingindenturesunderwhichthetotalamountofsecuritiesauthorizeddoesnotexceedofthetotal assetsofthecompanyanditssubsidiariesonaconsolidatedbasisthecompanyherebyagreestofurnishacopyofany suchinstrumenttothesecuponrequ thefollowingexhibitsindicatedasbeingfiledwiththisdocumentareomittedfromtheprintedversionofthis annualreport exhibitl exhibit exhibit johnsonjohnsonannualreport thispageintentionallyleftblankexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact ijoaquinduatocertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportofjohnson johnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostateamaterial factnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementsweremadenot misleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairlypresentin allmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofandfortheperiod presentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrolsand proceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancialreportingas definedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandproceduresto bedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingit consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodinwhich thisreportisbeingprepare bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityoffinancial reportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerallyaccepte accountingprinciple cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendoftheperiod coveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthatoccurre duringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofanannualreport thathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontroloverfinancial reportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternalcontrol overfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardofdirectorsor personsperformingtheequivalentfunction aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocesssummarize andreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificantrole inthecompanysinternalcontroloverfinancialreporte sjoaquinduato joaquinduato chiefexecutiveofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact ijosephjwolkcertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportofjohnson johnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostateamaterial factnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementsweremadenot misleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairlypresentin allmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofandfortheperiod presentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrolsand proceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancialreportingas definedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandproceduresto bedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingit consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodinwhich thisreportisbeingprepare bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityoffinancial reportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerallyaccepte accountingprinciple cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendoftheperiod coveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthatoccurre duringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofanannualreport thathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontroloverfinancial reportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternalcontrol overfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardofdirectorsor personsperformingtheequivalentfunction aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocesssummarize andreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificantrole inthecompanysinternalcontroloverfinancialreporte sjosephjwolk josephjwolk chieffinancialofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact theundersignedjoaquinduatothechiefexecutiveofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfullycomplie withtherequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionandresultsof operationsofthecompany sjoaquinduato joaquinduato chiefexecutiveofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthesarbane oxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompanyforpurpose ofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityofthatsection johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact theundersignedjosephjwolkthechieffinancialofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfullycomplie withtherequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionandresultsof operationsofthecompany sjosephjwolk josephjwolk chieffinancialofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthesarbane oxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompanyforpurpose ofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityofthatsection johnsonjohnsonannualreportthispageintentionallyleftblankthispageintentionallyleftblankthetablesbelowareprovidedtoreconcilecertainnongaapfinancialdisclosuresinthe chairmansletter reconciliationofnongaapfinancialmeasure dollarsinmillionsexceptpersharedata change netearningsaftertaxasreporte pretaxadjustment intangibleassetamortizationexpense litigationrelate iprd restructuringrelate acquisitionintegrationanddivestiturerelate gainslossesonsecuritie medicaldeviceregulation covidvaccinerelatedcost consumerhealthseparationcost taxadjustment taximpactonspecialitemadjustments consumerhealthseparationtaxrelatedcost taxlegislationandothertaxrelate adjustednetearningsaftertax averagesharesoutstandingdilute adjustednetearningspersharedilute operationaladjustednetearningspersharediluted growth inc salesgrowthvs dec wwtotalasreporte operational currency board director senior management joaquinduato joaquinduato chairmanboardofdirector chiefexecutiveofficer chairmanexecutivecommittee dariusadamczyk chairmanandchiefexecutiveofficer vanessabroadhurst honeywellinternational executivevicepresidentglobalcorporateaffair marycbeckerle robertjdeckerjr chiefexecutiveofficerhuntsmancancerinstitute corporatecontrollerchiefaccountingofficer attheuniversityofutah distinguishedprofessorofbiology petermfasolo collegeofscienceuniversityofutah executivevicepresidentchiefhumanresourcesofficer dscottdavis formerchairmanandchiefexecutiveofficer elizabethforminard unitedparcelserviceinc executivevicepresidentgeneralcounsel ianeldavis williamnhait formernonexecutivechairman executivevicepresidentchiefexternalinnovationand rollsroyceholdingsplc medicalsafetyofficerinterimheadjanssenrd formerchairmanandworldwidemanagingdirector mckinseycompany marclarkin corporatesecretary jenniferadoudna worldwidevicepresidentcorporategovernance professorofchemistryprofessorofbiochemistry molecularbiology ashleymcevoy likashingchancellorsprofessorinbiomedical executivevicepresidentworldwidechairman andhealthuniversityofcaliforniaberkeley medtech marillynahewson thibautmongon formerchairandchiefexecutiveofficer executivevicepresidentworldwidechairman lockheedmartincorporation consumerhealthceodesignatetheplanne paulaajohnson newconsumerhealthcompany presidentwellesleycollege jamesswanson hubertjoly executivevicepresidentchiefinformationofficer formerchairmanandchiefexecutiveofficer bestbuycoinc jennifertaubert markbmcclellan executivevicepresidentworldwidechairman directordukerobertjmargolismd pharmaceutical centerforhealthpolicydukeuniversity duanevanarsdale annemmulcahy treasurer formerchairmanandchiefexecutiveofficer xeroxcorporation kathrynewengel executivevicepresidentchieftechnicaloperations aeugenewashington riskofficer dukeuniversityschancellorforhealthaffair presidentandchiefexecutiveofficer josephjwolk dukeuniversityhealthsystem executivevicepresidentchieffinancialofficer markaweinberger formerchairmanandchiefexecutiveofficer memberexecutivecommittee ernstyoung nadjaywest formerlieutenantgeneralusarmy johnsonjohnsonannualreportprincipaloffice stockliste johnsonjohnsononline onejohnsonjohnsonplaza johnsonjohnsoncommonstock newbrunswicknewjersey listedonnewyorkstockexchange ourwebsitewwwjnjcom stocksymboljnj httpwwwjnjcommediacenter annualmeetingofshareholder shareholderrelationscontact thursdayapril marclarkin corporatesecretary wwwfacebookcomjnj ameasternstandardtime meetingheldvirtuallyat wwwtwittercomjnjnews wwwtwittercomjnjcare wwwvirtualshareholdermeetingcomjnj investorrelationscontact allshareholdersasoftherecorddateof jessicamoore wwwyoutubecomjnj februaryareinvitedtoattend vicepresidentinvestorrelation aformalnoticeofannualmeete investorrelationsitsjnjcom httpwwwlinkedincomcompany proxystatementandproxyhavebeen johnsonjohnson madeavailabletoshareholders stocktransferagentandregistrar annualreportonformkand questionsregardingstockholding proxystatement certificatereplacementtransferdividend johnsonjohnsonsannualreportonformk andaddresschangesshouldbedirectedto forthefiscalyearendedjanuaryis ourstocktransferagentandregistrarat thelatestnewsconferenceannouncement includedinthisannualreportinitsentiretywith computersharetrustcompanyna pressreleasesandcompanyperformance theexceptionofcertainexhibitstheformk pobox completewithallofitsexhibitsisavailableonour providenceri informationcanbefoundatinvestorjnjcom websiteatwwwinvestorjnjcomseccfmandthe overnightmail theinformationonthesewebsitesshouldnot secswebsiteatwwwsecgov computersharetrustcompanyna bedeemedtobepartofthisannualreport royalstreetsuite shareholdersmayalsoobtaincopiesofthe cantonma exhibitsourannualreporton formkandourproxystatement withoutchargeuponwrittenrequesttothe shareholderwebsite wwwcomputersharecominvestor officeofthecorporatesecretaryatour principalofficeaddressorbycalle dividendreinvestmentplan theplanallowsforfullorpartialdividend electronicdeliverynotification reinvestmentandadditionalcash investmentsuptoperyearin theproxystatementandourannual johnsonjohnsoncommonstockwithout reportareavailableonourwebsite pershareorservicechargesonstock investorjnjcomasmshareholderswhoreceive purchasesifyouareinterestedin papercopiesofourproxystatementandannual participatingintheplanandneedan reportbymailcanelecttoreceiveinsteadane enrollmentformandormoreinformation mailmessagewithalinktothosedocumentsonthe pleasecalltheplanadministrator internetregisteredshareholdersmayenrollin computersharetrustcompanynaat electronicdeliveryatwwwcomputersharenacom greenbeneficialshareholderswhoholdsharesof outsidetheusoraccessonlineat johnsonjohnsoncommonstockthroughabank wwwcomputersharecominvestor brokerorotherholderofrecordgenerallycan enrollforelectronicdeliveryat hearingimpaire johnsonjohnsonallright enrollicsdeliverycomjnj shareholderswhohaveinquiriesregarde reserve stockrelatedmatterscancommunicate directlywithcomputersharetrustcompany naviaatelecommunicationsdevicetdd thetelephonenumberforthisserviceis outsidetheus